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Roswell Park Memorial Institute-l 640 Medium 
Reverse-transcriptase Polymerase Chain Reaction 
Streptavidin 
Severe Combined Immunodeficiency 
Side Scatter 
Signal Transducers and Activators of Transcription 
Central Memory T cell 
T Cell Receptor 
Effector Memory T cell 
12-0-tetradecanoylphorbol I3-acetate 
T Helper 1 
T Helper 2 
T Helper 17 
Toll Like Receptor(s) 
Regulatory T cell 
Tumour Necrosis Factor 
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VEGF 
WT 
XCL 
XCR 
Vascular Endothelial Growth Factor 
Wild type 
XC-chemokine ligand 
XC-chemokine receptor 
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SUMMARY 
D6 is a novel chemokine receptor, homologous to other members of the CC-chemokine 
receptor family, which recognises a number of inflammatory CC-chemokines with high 
affinity. Unusually, D6 fails to induce any detectable intracellular signal in response to its 
ligands, but has been demonstrated to traffic constitutively to and from the cell surface, 
targeting any bound ligand for intracellular degradation. Due to this atypical behaviour, it 
has been suggested that 06 may serve as a decoy receptor for inflammatory CC-
chemokines and, moreover, recent work on skin inflammation in 06 KO mice indicates that 
06 may serve an important role in the resolution of inflammatory responses. However, the 
vast majority of evidence to support this claim has arisen from data derived in vitro: the 
true biological function of 06 remains unclear. 
The aims of this thesis therefore, were to further our understanding of the biology of 06, 
chiefly through characterisation of immune responses in 06-deficient animals. Firstly, as 
described in Chapter 3, I analysed the cellular composition of lymphoid tissues of 06 KO 
mice. These studies revealed higher proportions ofCOllc+ and F4/80+ cells in the 06 KO 
spleen compared with WT controls, suggesting that increased accumulation of myeloid 
lineage cells was occurring at this site. No other alterations in lymphoid populations were 
seen, but lymphocytes from 06 KO mice demonstrated higher levels of proliferation in 
response to mitogen, in vitro. In the same chapter I examined the induction of antigen-
specific immune responses by immunising 06 KO animals with OV AlCF A. These results 
were variable, with 06 KO animals demonstrating both reduced and enhanced antigen-
specific responses depending on the particular time-point analysed. This suggested that 06 
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may have a temporal affect on the development of antigen-specific immune responses, 
although this will need substantiated by further experimentation. 
In Chapter 4, I examined the role of D6 in myeloid cell responses, by comparing monocyte 
recruitment to the inflamed peritoneum and dendritic cell development from bone-marrow 
(BM) cultures. I found that while the accumulation of inflammatory 
monocytes/macrophages appeared quantitatively similar in WT and D6 KO animals, 06 
KO cells expressed greater levels of CD 11 c, suggesting preferential accumulation of OC-
like cells in the inflamed peritoneum. Functional comparison of inflammatory PEC between 
WT and D6 KO mice showed reduced generation of pro-inflammatory cytokines by KO 
cells following ex vivo stimulation. OC generated from GM-CSF supplemented 06 KO BM 
cultures displayed higher levels of CD 11 c and of the CC-chemokine receptors, CCR2 and 
CCR5 compared with their WT counterparts. BM-derived DC from D6 KO mice showed 
no differences in endocytosis or in the upregulation of costimulatory molecules following 
LPS-induced activation. However, KO OC were less efficient in generating a mixed 
leukocyte reaction, and also demonstrated higher production of TNFa, VEGF and the CC-
chemokines CCL3, CCL4 and CCL5 in response to LPS-stimulation. These data suggest 
that 06 may influence the development and function of myeloid lineage cells. 
As D6 is expressed at high levels in the small and large intestine, I next investigated both 
tolerogenic and inflammatory intestinal responses in 06 KO animals. As detailed in 
Chapter 5 of this thesis, the induction of oral tolerance in response to a high dose feeding 
protocol was normal in 06 KO mice. However, 06 KO mice showed increased resistance 
to experimental colitis induced by the administration of dextran sulphate sodium (OSS) in 
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their drinking water. The reduced susceptibility to DSS colitis was found to correlate with 
increased ex vivo secretion of several pro-inflammatory type cytokines, including IFNy and 
IL-17. There were also differences in basal epithelial proliferation rate between WT and 
06-deficient animals, indicating, that altered inflammatory cytokine production and barrier 
function may be involved in protecting KO mice from OSS-induced disease. 
Finally, as I had detected several differences in the expression of CCR2 and CCRS by 06 
KO leukocytes in the inflamed peritoneum and colon, I undertook a more thorough 
examination of the expression of these receptors by 06 KO leukocyte populations. As 
described in Chapter 6, various 06 KO populations displayed differential chemokine 
receptor profiles compared with their WT counterparts, the most significant of which was 
strikingly enhanced expression of CCR5 by 06 KO B cells: this increased CCR5 
expression was seen by B cells isolated from all lymphoid tissues, as well as from the 
resting peritoneal cavity and colonic lamina propria. In addition, altered CCR5 expression 
was detected on B cells from the bone marrow of 06-deficient animals, suggesting that 
aberrant B cell differentiation may be occurring in the absence of 06. Purified B cells from 
06 KO mice showed enhanced migration to CCL4 in chemotaxis assays, but responded 
comparably to WT B cells in response to in vitro mitogens. These results suggest a role for 
06 in the nonnal development of leukocytes popUlations, with absence of this atypical 
receptor leading to the dysregulated expression of other chemokine receptors. 
Taken together, my data suggest that the biological functions of 06 may be more 
complicated than previously appreciated. Indeed, I found no evidence for a decoy role of 
06 in vivo, but 06-deficient animals were characterised by altered leukocyte development, 
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aberrant chemokine receptor expression and increased resistance to experimental colitis 
induction. Further study of these animals will hopefully identify the mechanisms leading to 
these phenotypical differences. 
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Chapter 1 
General Introduction 
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Introduction 
The innate and adaptive arms of the immune system have evolved in partnership over 
countless millennia, ensuring our protection from the hordes of potentially menacing agents 
that lurk in our air, food and water. Beyond the physical barriers of the skin and mucosal 
surfaces, a vast array of chemical mediators and a highly coordinated force of leukocytes 
defend us. In response to dangerous stimuli, these versatile cells mobilise to inflammatory 
sites, where they can attack and evict troublesome agents. However, as well as possessing 
potent pro-inflammatory mechanisms, the immune system must also be able to become 
tolerant to ensure that essential foodstuffs, commensal organisms and our own bodily 
tissues are not caught in the crossfire. 
Be they of a tolerogenic or pro-inflammatory nature, the generation of effective immune 
responses requires the temporal and spatial coordination of leukocyte popUlations within 
tissues. The cells of the immune system are in constant motion, navigating between blood, 
lymphoid organs and non-lymphoid tissues. Multiple adhesion molecules, such as members 
of the selectin, integrin and immunoglobulin families, and chemotactic factors, including 
complement metabolites, lipid mediators and pathogen-derived products themselves, 
integrate to successfully guide immune populations (1-7). However, many of the most 
important mediators of motility belong to the chemokine superfamily. 
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CXC Family 
Systematic Name Human Ligand 
CXCl1 GROa 
CXCl2 GROfl 
CXCl3 GROy 
CXCl4 PF4 
CXCl5 ENA-78 
CXClS GCP-2 
hCXCl7 NAP-2 
hCXCl8 Il-8 
CXCl9 Mig 
CXCl10 IP-10 
CXCl11 I-TAC 
CXCl12 SOF-1 
CXCl13 BCA-1 
CXCl14 BRAKlbolekine 
mCXCl15 
CXCl1S 
CC Family 
CCl1 1-309 
CCl2 MCP-1 
CCl3 MIP-1a 
CCl4 MIP-1fl 
CCl5 RANTES 
mCCl6 
CCl7 MCP-3 
CCl8 MCP-2 
mCCl9 
mCCl10 
CCl11 Eotaxin 
mCCl12 
hCCl13 MCP-4 
hCCl14 HCC-1 
hCCl15 HCC-2 
hCCl16 HCC-4 
CCl17 TARC 
hCCl18 OC-CK1/PARC 
CCl19 ElCIMIP-3~/exodus3 
CCl20 MIP3a /lARC/exodus1 
CCl21 SlC/SCkine/exodus2 
CCl22 MOC 
hCCl23 MPIF-1 
CCl24 Eotaxin-2/MPIF-2 
CCl25 TECK 
hCCl2S Eotaxin-3 
CCl27 C-TACK 
CCl28 MEC 
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Mouse Ligand 
GRO/MIP-2/KC 
GRO/MIP-2/KC 
GRO/MIP-2/KC 
PF4 
GCP-21LIX 
GCP-2 
? 
? 
Mig 
IP-10 
I-TAC 
SOF-1 
BlC 
BRAK 
lungkinelWECHE 
TCA-3 
JE 
C10 
MIP-1y 
MIP-1 y 
Eotaxin 
MCP-5 
TARC 
ElC/MIP-3~/exodus3 
MIP3a /lARC/exodus1 
SlC/SCkine/exodus2 
ABCO-1 
Eotaxin-2IMPIF-2 
TECK 
CTACKlEskine 
Chemokine 
Receptor(s) 
CXCR1, CXCR2 
CXCR2 
CXCR2 
CXCR3B 
CXCR2 
CXCR1 , CXCR2 
CXCR2 
CXCR1 , CXCR2 
CXCR3 
CXCR3 
CXCR3 , CXCR7 
CXCR4, CXCR7 
CXCR5 
? 
? 
CXCRS 
CCR8 
CCR2 
CCR1 , CCR5 
CCR5 
CCR1, CCR3, CCR5 
CCR1 
CCR1 , CCR2, CCR3 
CCR3 
CCR1 
CCR1 
CCR3 
CCR2 
CCR2, CCR3 
CCR1 
CCR1 , CCR3 
CCR1 , CCR2, CCR5 
CCR4 
? 
CCR7 
CCRS 
CCR7 
CCR4 
CCR1 
CCR3 
CCR9 
CCR3 
CCR10 
CCR10 
C Family 
Systematic Name Human Ligand 
XCL1 Lyphotactin/SCM-1 a 
hXCL2 SCM-1~ 
CX3C Family 
I CX3CL1 I Fractalkine 
Table 1.1 
The Chemokine Superfamily 
Mouse Ligand 
Lymphotactin 
Chemokine 
Receptor(s) 
XCR1 
XCR1 
I Fractalkine/Neurotactin I CX3CR1 
The systematic nomenclature for the chemokine family is shown, along with the 
previously used common names for human and mouse ligands. The far right column 
indicates the receptor(s) to which each chemokine normally binds. Chemokines that are 
present only in human or mouse are denoted with "h" or "m", respectively . This 
systematic nomenclature was adopted in the late nineties to clarify confusion in the 
literature, arising from the existence of multiple common names for singular chemokines. 
Four sub-families of chemokines have been identified, based on the configuration of a 
conserved N-terminal tetra-cysteine motif. CXC chemokines have a single amino acid 
between the first two cysteines of this conserved motif, while the initial cysteine residues 
are directly juxtaposed in members of the CC-chemokine sub-family. The sole member of 
the CX3C family, CXC3CLl/fractalkine, has three intervening amino acid residues 
between the first two cysteines, while members of the C family lack these initial cysteine 
residues altogether. 
22 
1.1 The Chemokine Family 
Best known and named for their ability to induce chemotaxis, chemokines are small (6-
IlkDa), basic proteins that mediate their functions via G-protein coupled serpentine 
receptors (8, 9). Membership of the chemokine family is defined structurally rather than 
functionally, with all chemokines (with the exception of XCL 1, XCL2) possessing a 
conserved tetra-cysteine motif. Although chemokines demonstrate relatively low homology 
at the primary sequence level (15-50%) (10), disulphide bonding between the cysteine 
residues results in a distinctive conserved three-dimensional structure. 
To date, around 50 chemokines have been identified and classified into four major families 
(CXC, CC, XC and CX3C) according to the precise positioning of the first two cysteine 
residues in the aforementioned motif (Table 1.1) (8, 9, 11). For the most part, chemokines 
are secreted as soluble proteins and are produced by many different cell types, including 
leukocyte, epithelial, endothelial and stromal cell populations. However, CXCL 16 and 
CX3CL 1 can exist in transmembrane forms, with the chemokine domain associated with a 
mucin-like stalk (12, 13). 
In addition to the systematic classification based on structure, chemokines can also be 
divided into two different functional categories, homeostatic and inducible, based upon 
their pattern of expression (14). Typically, homeostatic chemokines are expressed 
constitutively and are involved in processes such as lymphorganogenesis, immune 
surveillance and tissue-specific trafficking (15, 16). The inducible chemokines, on the other 
hand, tend to be upregulated during inflammation and are important for recruiting immune 
effectors to inflammatory sites (14). 
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However, the distinction between homeostatic and inducible chemokine classes is 
becoming increasingly unclear (17, 18). It is now apparent that many so-called inducible 
chemokines are constitutively expressed and participate in important homeostatic responses 
(19, 20). Conversely, homeostatic chemokines can be upregulated in inflamed tissues and 
perpetuate inflammatory responses (18, 21,22). 
1.2 Chemokine Receptors 
Chemokines signal via 7-transmembrane spanning, G-protein coupled receptors, which 
have been classified in such a way as to parallel the systematic nomenclature of their 
ligands (See Table 1.1) (11). Thus CCR, CXCR, XCR and CX3CR chemokine receptors 
recognise members of the CC, CXC, C and CX3C chemokine subfamilies, respectively. As 
a general rule, members of each chemokine sub-family are recognised only by members of 
their corresponding receptor family. For example, CC-chemokines will bind only CC-
chemokine receptors. However, there are some notable exceptions to this doctrine and these 
will be discussed further below (see section 1.17) (23-30). 
Chemokine receptors are around 40 kDa in size and typically 340-370 amino acids long. 
The general chemokine receptor structure is highly conserved at the primary level «80%) 
and chemokine receptors also share identity with other G-protein-coupling receptors, such 
as dopamine and beta-adrenergic receptors. The receptor molecule consists of an acidic 
extracellular amino terminus, 7 hydrophobic transmembrane domains, 3 intra- and extra-
cellular loops and an intracellular tail at the carboxy terminus (Figure 1.1). Each of the 
extracellular loops contains a cysteine residue, and these enable formation of disulphide 
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bridges essential to maintain the 3-dimensional structure of the receptor. Additionally, the 
second intracellular loop contains a canonical DRYLAIV amino acid motif, which mediates 
coupling of the activated receptor to G-proteins and so is necessary for chemokine receptor 
signalling. With a few important exceptions, which will be discussed later in this chapter, 
ligand binding to chemokine receptors leads to the activation of several well-characterised 
signalling pathways. Although the complexities of chemokine receptor signalling cascades 
are beyond the scope of this thesis, the following section and Figure 1.1 give a brief 
overview of the best-known chemokine receptor signalling pathways (31-33). 
Chemokine Receptor Signal Transduction 
Upon activation, chemokine receptors act as GDP exchange factors (GEF) for receptor-
coupled G-proteins. This leads to dissociation of the heterotrimeric G-protein into Gil and 
Gfly subunits, both of which subsequently initiate a variety of signalling cascades (See 
Figure 1.1) (31-33). The response is terminated by Gu hydrolysis of bound GTP to GDP, 
leading to reassociation of the Gapy heterotrimer. Gfly subunits derived from G j complexes 
are principally responsible for initiating the downstream signalling pathways that lead to 
chemotaxis. GIIY activates the phosphoinositide specific phospholipase C (PLC), which 
catalyses the cleavage of cell membrane phosphatidyl inositol biphosphate (PIP2) into two 
parts, inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 interacts with receptors on 
the endoplasmic reticulum (ER), causing the release of ER-stored Ca2+ into the cytosol, thus 
raising intracellular Ca2+ levels several-fold. Such increases in Ca2+ intracellular levels are 
commonly used to determine the ability of a particular chemokine to act as an agonist for a 
chemokine receptor. DAG and the released Ca2+ cooperate in the activation of the protein 
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Figure 1.1: 
Schematic Representation of Chemokine Receptor Signalling 
The figure overleaf gives an overview of some of the major signalling 
pathways initiated following chemokine receptor activation. Arrows indicate 
downstream targets. 
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kinase C (PKC) family of serine/threonine kinases. PKC generated signals are important for 
responses such as integrin activation, through activation of the GTPase Rho, as well as for 
phosphorylation of the activated chemokine receptor promoting its desensitisation and 
internalisation (see below). 
The GPy subunits also activate phosphatidylinositol 3-kinasey (PI3Ky), and this enzyme 
rapidly generates phosphatidylinositol 3,4,5-triphosphate (PIP3) from the membrane lipid 
phosphatidylinositol (34). PIP3 acts as a high-affinity docking site for proteins containing 
pleckstrin-homology (PH) domains, enabling their localisation to the cell membrane. 
Recruitment and activation of protein kinase B (PKB) leads to the activation of a number of 
downstream signalling pathways, many of which promote cell survival. In addition, PI3K is 
thought to regulate the activity of the Rho family GTPases, Rac and Cdc42. Activation of 
Rac is required for actin polymerisation, which is essential for pseudopod extension and 
leukocyte migration. Cdc42 meanwhile, enables the establishment of orientation machinery 
at the pseudopod, and without this GTPase cells display random movement rather than 
directed migration in response to a chemotactic gradient (33). 
As well as their actions discussed above, second messenger protein kinases, such as PKB 
and PKC, promote phosphorylation of serine and threonine residues on the C-terminus of 
chemokine receptors, both directly and also indirectly, through their activation of specific 
G-protein coupled receptor kinases (GRKs) (35). C-terminus phosphorylation leads to 
steric inhibition of G-protein coupling and receptor desensitisation (36). The 
phosphorylated receptors also provide binding sites for multifunctional intracellular adaptor 
and scaffold proteins, the p-arrestins. p-arrestins link the chemokine receptor complex to 
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the endocytic machinery, promoting receptor internalisation and can also act as a scaffold 
for downstream signal transduction (35, 36). 
In addition to activation of membrane lipids, chemokine receptors trigger other intracellular 
signalling cascades. G'l subunits can target Src family kinases leading to the activation of 
proteins, such as focal adhesion kinase (F AK), that are important for regulating cytoskeletal 
adhesion to the extracellular matrix. Mitogen-activated protein kinase (MAPK) cascades 
are initiated in response to chemokine signalling, and this is suggested to be critical for T 
cell proliferation and the transcription of cytokine genes (37). There are also reports that 
chemokine receptors can act in a G-protein independent manner through janus-family 
tyrosine kinases (JAKs) and signal transducers and activators of transcription (STA Ts) (38-
40). However, this issue remains controversial as others have found no involvement of the 
JAKISTAT pathway in chemokine receptor signalling (41). 
1.3 Chemokine Receptor and Ligand Interactions 
A key feature of the chemokine system is the highly promiscuous nature of the interactions 
between ligands and receptors. Many chemokines interact with two or more receptors, and 
most receptors can recognise multiple chemokines (11). This characteristic has led to 
suggestions of high redundancy in chemokine biology (42). However, it is more probable 
that as yet undetermined intricacies exist in the chemokine network, and that complexity 
ensures robust responses to a broad array of pathogens that may be attempting to 
manipulate the chemokine system (see section 1.19) (33). Chemokines show heterogeneous 
binding affinities and potencies for the same receptor and, consequently, triggering of a 
single receptor can lead to a different functional outcome depending on the ligand involved 
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(43-45). For instance, while both CCL 19 and CCL21 act as agonists for CCR 7, only 
CCL 19 induces a reduction in surface receptor levels (46). Moreover, studies in genetically 
manipulated animals have revealed that deletion of a single ligand or receptor can lead to 
phenotypic changes in experimental models of infection or disease (19, 47-58). For 
example, during the induction of experimental autoimmune encephalitis (EAE), CCL2-
deficient mice do not upregulate other CCR2 ligands in compensation and these animals are 
resistant to disease development (57). Such studies argue against the existence of a system 
where multiple ligands and receptors can be mere substitutes for one another. 
Single chemokine and receptor partnerships do appear to exist in the chemokine system, 
usually involving homeostatic chemokines. Examples of these include the B-cell 
chemoattractant, CXCL13, recognised solely by CXCR5, and CCL25/CCR9, whose 
interactions are important in thymocyte development and intestinal homing (59, 60). 
However, it remains possible that additional receptors or ligands will be identified for such 
pairs. Indeed, the long thought monogamous relationship of CXCR4 and CXCL 12 was 
recently challenged by the discovery of CXCR 7 as a novel receptor for both CXCL 12 and 
CXCLII(61). 
Functional Outcomes of Chemokine Receptor Activation 
1.4 Chemotaxis 
The cardinal response of chemokine receptor activation is the induction of chemotaxis, the 
process by which cells show directed migration along a chemically imposed gradient. 
Almost all chemokines can induce chemotaxis in vitro and indeed, they were named for 
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their ability to induce this response: chemotactic cytokines (62). Directed leukocyte motion 
requires a number of cellular responses to occur, including cytoskeletal rearrangements and 
changes in integrin affinity. Migrating cells assume a polarised morphology, characterised 
by a pseudopod at the leading edge of the cell, and a trailing uropod at the rear. These 
changes are mediated by activation of G proteins coupled to chemokine receptors and 
initiation of downstream signalling cascades (See Figure 1.1) (31). 
It has been argued however, that genuine chemotaxis may be an entirely in vitro 
phenomenon and it has been suggested that it may not be feasible to maintain true 
chemokine gradients in living tissues (63). Instead, it is proposed that in vivo leukocytes 
may be guided by chemokines immobilised on vascular or stromal cells (haptotaxis), or that 
chemokine receptor activation may increase the overall motility of cells in a gradient-
independent manner (chemokinesis). In support of the latter, imaging of intact lymph nodes 
using two-photon microscopy has revealed apparently random migratory patterns for Band 
T lymphocytes despite the presence of substantial amounts of chemokines and known 
restriction of lymphocytes to specific anatomical niches (64-66). However, a recent report 
by Takada et al. provided evidence for the in vivo existence of chemokine gradients, 
demonstrating CCR7-dependent haptotaxis of activated B cells towards the B-zone/T-zone 
boundary in the lymph node (67). It is possible therefore that the ability of chemokines to 
guide cell trafficking involves a combination of chemotaxis, haptotaxis and chemokinesis. 
Originally, CXC and CC chemokine receptors were proposed to mediate migration of 
neutrophils and monocytes, respectively. Although now realised to be a gross over-
simplification, leukocyte subsets can exhibit differential chemokine receptor profiles, and 
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variations in chemokine receptor expression determine the migratory pathway undertaken 
by a particular leukocyte. This fine control of leukocyte trafficking is essential for the 
proper development of immune responses, as will be discussed later. 
1.5 More Than Movers 
While their synonymous function may be the activation of leukocyte locomotion, the scope 
of chemokine activity greatly exceeds this (8, 68). Chemokines upregulate integrin 
expression by blood-borne leukocytes, enabling their arrest at venular endothelium and 
subsequent tissue entry (Figure 1.2) (69). At the inflammatory site, triggering of chemokine 
receptors can induce leukocyte degranulation, phagocytosis and activation of the 
respiratory burst (70-78). Chemokines have also been shown to promote leukocyte 
proliferation, influence T-cell differentiation and to exert both positive and negative effects 
on apoptosis (61, 79-90). In addition, expression of CX3CRI by DC has been shown to 
mediate their protrusion of transepithelial dendrites into the intestinal lumen, which may 
facilitate the sampling and uptake of intestinal contents (91). 
Chemokine receptors are also expressed by non-leukocyte populations, including 
epithelium, endothelium, smooth muscle cells, fibroblasts and neurons (57,58). As a result, 
chemokines can directly influence many important physiological processes, such as 
angiogenesis, epithelial turnover, and wound healing (53, 92, 93) Additionally, the 
chemokine receptor CXCR4 has been demonstrated to play an essential role in the 
development of nervous, circulatory and immune networks (94-96). 
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Interestingly, the activity of chemokines is not just restricted to interactions with 
endogenous chemokine receptors. Chemokines share close structural similarity to cationic 
antimicrobial peptides, such as the defensins, and several chemokines have been found to 
kill a broad spectrum of micro-organisms in vitro (97-99). Thus chemokines not only 
promote immune responses through the recruitment and activation of leukocytes, but may 
also be directly employed to attack microbes. Interestingly, defensins can also induce 
chemotaxis via chemokine receptors and it has been shown that human ~-defensins attract 
immature DC and memory T cells via CCR6 (100). 
With such a comprehensive range of activities, it is hardly surprising that chemokines are 
involved at all stages of leukocyte life. The following sections aim to give an overview of 
the various ways in which chemokines coordinate leukocyte development and function to 
enable the generation of productive immune responses. 
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Role of Chemokines in Lymphocyte Extravasation 
DIAPEDESIS 
Through their ability to induce rapid integrin activation, chemokines play an 
important role in leukocyte extravasation. For example, during the recruitment 
of naive T cells to peripheral lymph nodes, weak affinity interactions between 
L-selectin and PNAd lead to the tethering and rolling of lymphocytes along the 
endothelium. Rolling cells are activated by endothelial-bound chemokines, 
leading to the conformational change ofLFA-I to its high-affinity state and the 
clustering ofLFA-1 molecules. This increases both the affinity and avidity of 
LF A-I and rCAM interactions, resulting in the arrest of T cells at the 
endothelium and subsequent extravasation to the lymph node. The induction of 
high-affinity LF A-I is dependent on the downstream activation of the small 
GTPase, RhoA, while both RhoA and PKCt are involved in controlling the 
lateral mobility of integrins. 
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Chemokines: The Leukocyte's Guide to The Galaxy 
1.6 Chemokines and Haematopoiesis 
The leukocytes of the immune system originate from self-renewing haematopoietic 
progenitor cells, which are able, by asymmetric division, to produce more differentiated, 
non-renewing multipotent progenitors. These progenitors in turn give rise to committed 
lineages of progenitor cells known as common lymphoid progenitors (CLP) and common 
myeloid progenitors (CMP). CLP generate B cells, T cells and NK cells, while CMP 
produce granulocytes, monocytes, erythrocytes and megakaryocytes. Both CLP and CMP 
appear to be able to differentiate into different dendritic cell subsets. Lineage commitment 
and generation of mature functional immune cells is mediated by activation of transcription 
factors under the influence of cytokines and growth factors present in the surrounding 
stromal environment (101). This occurs in the specialised niches of the bone marrow for all 
lineages except T cells, which are generated in the thymus from bone marrow-derived 
immigrants. 
For all these lineages, spatial positioning of precursors must be effectively controlled to 
ensure contact with supportive stroma and the other cell populations involved in the 
developmental process. Fittingly, a variety of chemokine ligands and receptors have been 
implicated in haematopoiesis, most notably CXCR4 and its ligand, CXCL 12 (94, 96, 102-
Ill). Mice deficient in either receptor or ligand exhibit gross abnormalities in B-
lymphopoeisis and myelopoiesis, as well as in vascular, neuronal and cardiac development, 
and these animals die perinatally. It has been suggested that CXCR4-mediated signals 
induce retention of cells in the bone marrow, preventing the premature release of myeloid 
35 
and B-cell precursors during development (103, 109). In addition, in a comprehensive study 
of the chemotactic responses of B lineage cells, Bowman and coworkers revealed efficient 
migration of very early progenitor B cells to the CC-chemokines CCLS, CCL2 and CCL2S 
(l12). The authors speculated that these chemokines may attract progenitor B cells to 
supportive bone marrow niches during development or, alternatively, may have direct 
effects on the growth or survival of these cells. Consistent with their ability to migrate to 
CCL2S, pre-pro B cells were shown to express CCR9 and CCR9-deficient mice have 
reduced numbers of pre-pro B cells in the bone marrow (113). In spite of this, the 
peripheral B cell compartment appears normal in CCR9-deficient mice (1l3). To the best of 
my knowledge, B cell development has not been thoroughly assessed in CCR2- and CCRS-
deficient animals. However, it has been reported that signalling via CCR5 on human 
progenitor B cells leads to heterologous desensitisation of CXCR4, allowing immature B 
cells to escape from the BM into the bloodstream (114). 
Signalling via CXCR4 is additionally critical during generation of T cells in the thymus, 
with CXCR4-deficient progenitors showing complete arrest at the DN 1 stage of 
development (115). The chemokine receptors CCR7 and CCR9 are also expressed at 
specific stages of T cell development and are thought to be important for the proper 
guidance and positioning of progenitor T cells throughout the thymus (116). While T cell 
development is not blocked in animals lacking these receptors, deficiency of CCR 7 results 
in abnormal early progenitor development, characterised by accumulation of CD25+CD44+ 
thymocytes at the corti co-medullary junction and disruption of the thymic architecture 
(1l3, 117). In addition, a recent study has shown that CCR7 expression may be essential 
for establishment of central tolerance in the thymus (118). Kurobe et al. reported that the 
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failure of CCR7-deficient thymocytes to migrate from the thymic cortex to the medulla 
prevents their acquisition of tolerance to lachrymal and salivary glands. CCR9 KG BM 
precursors meanwhile, were shown by competitive transplantation experiments to 
repopulate the thymus of lethally irradiated Rag KG mice less efficiently than BM cells 
from WT animals (119). 
Various other chemokines are expressed in primary lymphoid organs, including CCLS, 
CCL 17 and CCL22, and the receptors for these ligands are found on progenitor lymphocyte 
populations. However, the exact role of these molecules in haematopoiesis remains to be 
defined. It should also be noted that the influence exerted by chemokines on cell 
development extends beyond precursor navigation: members of the chemokine family can 
suppress haematopoiesis or promote precursor survival (120) (102, 108, 121, 122). 
1.7 Mobilisation and Circulation Of Haematopoietic Cells 
In the absence of inflammation, constitutively produced chemokines can facilitate the 
steady-state release of haematopoietic cells into the bloodstream and their subsequent 
circulation throughout the body. However, the role of chemokines in this steady state traffic 
of myeloid populations remains poorly defined. The homeostatic-type chemokines 
CXCL 14 and CX3CL 1 have been proposed to be involved in baseline trafficking of 
monocyte populations (123, 124). Geissmann and coworkers have described the existence 
of two distinct functional murine monocyte subsets one of which, the CX3CR I hiCCR2-Gr 1-
subset, is recruited to noninflamed sites and is thought to represent the precursor of tissue 
resident macrophages and DC (124). The complementary CX3CRI IOCCR2+0rl + subset, on 
the other hand, is preferentially recruited to inflamed tissues. 
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Low-level production of inflammatory-type chemokines may also be involved in 
constitutive cell trafficking. For example, eotaxin enables the baseline recruitment of 
eosinophils to the small intestine and signals via CXCR2 mediate the homing of mast cell 
precursors to this same site (125, 126). Additionally, CCR2 promotes the release of a subset 
of monocytes from the bone marrow into the circulation in the absence of inflammation 
(127). 
Constitutive recirculation of naIve lymphocyte populations between and within secondary 
lymphoid tissues is dependent on leukocyte expression of CCR7 and CXCR5. CCR7 is 
present on naive T cells and enables their entry to lymph nodes in response to CCL 19 and 
CCL21 presented on HEVs (128). Recruitment of dendritic cells from peripheral tissues to 
the draining lymph node also depends on CCR7, and it has been suggested that low-level 
CCR7-mediated traffic of DC may contribute to the development and maintenance of 
peripheral tolerance (129, 130). In addition, CCR7-dependent trafficking of DC from the 
intestinal lamina propria to mesenteric lymph nodes (MLN) has recently been shown to be 
essential for the induction of oral tolerance following antigen feeding (131). 
Akin to their T cell counterparts, naive B cells also recirculate between the blood and 
secondary lymphoid tissues in search of their specific antigens. Intravital microscopy 
imaging of chemokine-desensitised cells has revealed that CCR7 and CXCR4 are important 
for the arrest and extravasation of B cells at HEV (132). CXCR5 meanwhile, enables 
follicular homing of B cells within lymph nodes and spleen in response to CXCL 13 (132, 
133). In addition, CXCR5 and CXCL13 interactions are involved in B cell recruitment to 
small intestinal Peyer's patches (132). 
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This chemokine-controlled recirculation of lymphocyte populations is important as, 
although collectively the TCR and BCR repertoires are of enormous magnitude, only a 
relatively small proportion of naIve T and B cells will recognize any specific antigen. Thus 
by guiding naIve lymphocytes to sites at which tissue-derived antigen concentrate, 
chemokines help optimise the generation of productive adaptive immune responses. 
1.8 Chemokines in Innate Immunity 
In contrast to the relative paucity of information regarding steady-state leukocyte 
trafficking, an extensive body of work has focussed on the importance of chemokines for 
leukocyte infiltration to inflamed tissues (134). Typically, the ligands of CXCR2, CXCR3, 
CCRl, CCR2, CCR3 and CCR5 collaborate to bring granulocytes, monocytes, dendritic 
cells, NK cells and effector lymphocytes to the epic entre of inflammation (Figure 1.3) (11, 
47, 48, 52, 135-149). Activation of chemokine receptors on endothelial cells can also 
augment leukocyte recruitment by increasing endothelial permeability (150, 151). 
Animals deficient in the aforementioned chemokine receptors, or their ligands, have been 
shown to have reduced or delayed cellular infiltration following acute inflammatory 
challenge and several display increased susceptibility to infectious agents (48, 52, 137, 142, 
144, 152-154). CCR2 KO mice, for instance, show impaired monocyte recruitment to 
inflamed tissues, are incapable of clearing Listeria monocytogenes infection and have 
reduced granuloma formation in response to yeast or Mycobacterium extracts (47, 48, 136-
139, 155). Conversely, over-expression of inflammatory chemokine ligands can enhance 
immunity to pathogens (156, 157). 
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Acute inflammation typically occurs following triggering of pattern-recognition receptors 
(PRR), such as members of the toll-like receptor family (TLR) or the nucleotide-binding 
site leucine-rich repeat (NOD) proteins (158, 159). These receptors recognise highly 
conserved microbial products, such as LPS and flagellin, and thus represent an effective 
intruder alert system. Activation of PRR leads to the production of chemokines as well as 
inflammatory cytokines, such as IL-l, IL-6 and TNFa, which in turn stimulate further 
chemokine secretion (158). 
Different PRR elicit distinct patterns of cytokine and chemokine expression and since 
leukocyte populations display distinct chemokine receptor profiles (Figure 1.3), such 
differential chemokine generation enables the immune system to tailor the cellular infiltrate 
to suit the precise nature of the challenge at hand (158). 
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1.9 Chemokines in the Generation of Adaptive Immunity 
Chemokine-mediated recruitment of innate leukocyte populations is essential for a swift 
response to infection. Moreover, the escalating inflammatory cascade triggered by the 
innate immune system is critical for the generation of adaptive immune responses. DC, 
attracted to inflammatory CC-chemokines generated at the affected site, mature in response 
to microbial products and endogenous cytokines (160-162). Consequently, these cells lose 
expression of CCR1, CCR5 and CCR6, and instead up-regulate CCR7 (163-165). This 
switch in chemokine receptor expression allows the DC to exit the inflamed tissue and 
passage via afferent lymphatics to draining lymphoid tissues. Pro-inflammatory cytokines 
derived from the infected tissue increase expression of CCL21 by lymphatic endothelial 
cells, thus amplifying the rate of DC traffic (128, 129). On route to the lymph node CCR 7 
signals induce further maturation of DC, upregulating their expression of costimulatory 
molecules and production of pro-inflammatory cytokines, ensuring they arrive optimally 
prepared to prime antigen-specific T cells (78). 
Passage along afferent lymphatics is not the only channel by which DC gain access to the 
lymph node: monocytes and DC can directly enter lymph nodes from the blood. Such 
recruitment is mediated by presentation of peripheral tissue-derived inflammatory 
chemokines at HEV following their drainage via the lymph (166). This phenomenon, 
initially described by Palframan and colleagues, has been termed a "remote control" 
mechanism for leukocyte recruitment to lymphoid tissues draining sites of inflammation. 
The rate of T cell entry to lymph nodes neighbouring inflamed tissue also increases in 
response to the higher levels of CCL21 and CCL 19 present on HEV. Simultaneously, 
lymphoid organ "shutdown", induced by cytokines such as type 1 IFN or TNF, prevents 
42 
egress of lymphocytes from lymphoid tissue thus increasing the precursor frequency of 
antigen-specific T cells (167, 168). 
The interactions that occur between antigen-loaded DC and antigen-specific T cells in the 
LN are vital for initiation of adaptive immune responses as well as for determining the 
nature of the ensuing response. Recent elegant studies utilising twin-photon microscopy 
have revealed apparently random migratory behaviour of T cells within the lymph node 
(66). However, chemokines within the lymph node will also influence the dynamics of T 
cells and DC interactions. For instance, encounters between T cells and DC are promoted 
by CCL21 and CCL 19, expressed by stromal cells in the T cell dependent area of secondary 
lymphoid tissues as well as by a subset of DC at this location (169-171). Mature DC can 
directly attract activated T cells via generation of CCL22, which may increase the 
frequency of activated DC and antigen-specific T cells encounters (172). Additionally, it 
was shown recently that inflammation-induced upregulation of CCR5 guides naive CD8+ 
cells to clusters of CD4+ T cells and DCs in response to CCL3 and CCL4 produced at these 
sites, with these interactions being important for the development of CD8+ T cell memory 
(173). 
Mature DC displaying peptide-MHC complexes engage antigen-specific T cells, forming a 
specialised site at which signalling molecules are compartmentalised, known as the 
immunological synapse (174). The multiple signals integrated at this site lead to activation 
and proliferation of antigen-specific T cells. Interestingly, the chemokine receptors CCR5 
and CXCR4 are recruited into the immunological synapse where, by either promoting 
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stability of the IS or having direct activatory effects, they enhance T-cell proliferation and 
cytokine production (81, 175-177). 
Following activation, naIve T cells acquire new chemokine receptor profiles that dictate 
their subsequent role in the immune response (Table 1.2). Some activated T cells can 
upregulate CXCR5 and migrate towards CXCL I3-rich LN follicles (178). Here, they 
colocalise with antigen-specific B cells at the follicle boundary and providing help for 
antibody production (133, 178, 179). As B cells differentiate, they downregulate CXCR5 
and instead express new chemokine receptors that enable them to localise to peripheral 
sites. Upregulation ofCXCR4, for example, facilitates plasma cell homing to the bone 
marrow, while CCR9 and CCRI0 enable IgA-secreting plasma cells to enter the lamina 
propria of the small and large intestine (180). 
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Subset Chemokine Receptor Profile Function 
TNAIVE CCR7, CXCR4 Recirculate throughout secondary 
lymphoid tissue in search of specific 
antigen. 
TFH CXCR5 Locate to follicles and provide help to 
B cells for antibody production. 
TH1 CCR5, CXCR3 Defence against intracellular 
pathogen, induction of cell-mediated 
immunity. 
TH2 CCR3, CCR4, CCRa Defence against extra-cellular 
pathogens, induction of humoral 
immunity. 
TH17 Not yet defined. Defence against acute infection, 
promote upregulation of pro-
inflammatory cytokines and 
neutrophil recruitment. 
TREG Many, including CCR2, CCR4, CCR5, Down-regulation of pro-inflammatory 
CCRa, CCR5, CXCR4, CXCR5 responses. 
Large repertoire of chemokine 
receptors may allow access to all 
sites at which effector cells can 
locate. 
TCUTANEOUS CCR4, CCR10 Induced by DC from peripheral LN 
and home preferentially to the skin. 
TINTESTINE CCR9 Induced by small intestinal DC and 
preferentially home to this site. 
TCM CCR7 Traffic throughout secondary 
lymphoid tissue, involved in long-
term protection. 
TEM Negative for CCR7, express Rapidly recruited to inflamed tissues 
inflammatory chemokine receptors and mount immediate effector 
response. 
Table 1.2 
Chemokine Receptor Profiles of Various Helper T Cell Subsets 
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1.10 Chemokine Receptor Expression By Effector T Cell Subsets 
Newly generated effector T cells upregulate chemokine receptors that facilitate homing to 
peripheral sites of inflammation. The particular class of pathogen faced in the inflamed 
tissue will dictate the type of adaptive immune response generated. T HI cells produce IFNy 
and promote macrophage activation and immunity against intracellular pathogens, whilst 
T H2 cells characteristically secrete IL-4, IL-5 and IL-13 and are key to the development of 
humoral immune responses involving IgE, eosinophils and basophils. These subsets have 
been found to differ in their chemokine receptor profiles with T HI effectors predominantly 
expressing CCR5 and CXCR3, while T H2 cells primarily display CCR3, CCR4 and CCR8 
(181, 182). Distinct chemokines may themselves promote T H I and T H 2 development, with 
CCL3 and CCL2 reported to drive expression of IFNy and IL-4, respectively, during T cell 
activation (86-90). 
The distinctive chemokine receptor profiles of helper T cells may allow preferential 
recruitment of one subset over another according to the particular pattern of chemokines 
present at an inflamed site. Moreover, such particular patterns of chemokine receptor 
expression could enable co-localisation of effector T cells with those innate cells most 
suited to deal with the challenge at hand. However, a problem with a number of these 
studies is that analyses were performed on T HI and T H2 cells derived from in vitro 
differentiation protocols. Indeed, analysis of peripheral CD4+ memory T cells by a single 
cell RT-PCR method did not reveal any correlation between cytokine and chemokine 
receptor expression (183). Thus whether chemokine receptor expression actually differs 
between T HI and T H2 subsets remains a controversial issue. 
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1.11 Chemokine Receptor Profile of the T "17 Subset 
It has recently become evident that a separate effector T cell lineage, distinct from both TH 1 
and TH2 exists (184). This T-cell population secretes high levels ofIL-17A, IL-17F, TNFa 
and IL-6, but not the signature cytokines typically associated with T HI or T H2 responses. 
These cells, which have been termed T H17, are characterised by the expression of distinct 
transcription factors, and the development of T HI, T H2 and T H 17 cells appears to be 
mutually exclusive (185-187). TGFj3, in conjunction with the inflammatory cytokines IL-l , 
IL-6 and TNFa, drives the development of T H 17 from naIve T cells, while IL-23 appears to 
be important for their expansion and maintenance, in vivo (188-190) 
The T H 17 subset has been shown to be vital in protection against a number of infectious 
agents (191-193). This is due to their capacity to rapidly mobilise, recruit and activate 
neutrophils. However, it is now apparent that the IL-23/IL-17 pathway is also a major 
mediator of tissue inflammation in autoimmune disease models previously believed to be 
driven by an IL-12 induced T HI response (194, 195). As yet, no study has determined any 
particular chemokine receptor associations with these cells. However, this will be an 
important goal for future studies, as a better understanding of the trafficking properties of 
T H17 cells may enable the development of therapeutics for the various diseases in which 
they have been implicated. 
1.12 Chemokine Receptor Expression By Regulatory T cells 
An important class of T -lymphocytes are regulatory T cells, commonly termed T REG. 
Regulatory T cells secrete immunosuppressive cytokines such as IL-tO and TGF-beta and 
are important for preventing immunopathology through their control of both the innate and 
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the adaptive arms of the immune system (196, 197). Development of regulatory T cells is 
dependent on the expression of the forkhead family transcription factor FoxP3, and humans 
with null mutations in the gene encoding FoxP3 succumb to a severe and fatal autoimmune 
syndrome known as IPEX (lmmunodysregulation, poly endocrinopathy , enteropathy, X-
linked) syndrome (198). 
A variety of chemokine receptors have been associated with T REG; these include CCR1, 
CCR2, CCR4, CCR5, CCR8 and CXCR4 (199-201). During collagen-induced arthritis, it 
has been demonstrated that CCR2+ T REG playa protective role with blockade of CCR2 
resulting in worse disease (202). Several studies have linked CCRS and its ligands to T REG 
biology, and CCRS KO mice were recently shown to have enhanced clearance of 
Leishmania infection due to reduced T REG recruitment (203-206). In addition, it has been 
shown that regulatory T cells can migrate to follicles via CXCR5 expression and suppress 
GC-B cell reactions (207). 
However, perhaps logic dictates that T REG should be able to locate to all sites to which pro-
inflammatory cells traffic. In agreement with this supposition, Lim and colleagues recently 
reported the expression of a wide array of chemokine receptors by human regulatory T 
cells, with the exact receptor repertoire of the T REG being determined by its state of 
activation and differentiation (208). 
1.13 Chemokine Receptor Expression By Memory T cells 
An important feature of adaptive immunity is the capacity to mount swifter and more 
effective responses following re-exposure to a previously encountered pathogen. This is 
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due to the maintenance of pools of antigen-specific T cells that mediate rapid secondary 
immune responses. It has been suggested that memory T cells can be divided into two 
different subsets, central memory (T CM) and effector memory cells (T EM), based upon their 
differential expression of CCR 7 (209-211). T EM are CCR 7 -negative, but display receptors 
for inflammatory chemokines and localise in non-lymphoid tissues where they can mount a 
rapid tissue response upon re-challenge. T CM on the other hand, express CCR 7 and 
recirculate throughout lymphoid tissue, where they proliferate and provide a source of fresh 
effector cells upon antigenic-stimulation. The presence of these two distinctly routed 
memory populations may enhance immunological memory by providing T cells that mount 
an immediate effector response (T EM), as well as a subset that are involved in the secondary 
response and long-term protection (T eM) (212). 
1.14 Chemokines and the Control of Tissue Specific Migration 
Subsets of memory and effector T -lymphocytes re-circulate through tissues associated with 
their initial site of antigen encounter. Evidence for such compartmentalisation of T cell 
responses came from early studies showing that cells collected from lymph draining the gut 
or the skin demonstrated a preference of at least two-fold to recirculate to the type of organ 
from whence they came (213). This phenomenon was observed in adult animals but not in 
neonates, suggesting that priming by a specific antigen in a particular environment leads to 
the acquisition of specific surface receptors that dictate the particular recirculatory route 
undertaken by a lymphocyte. 
The molecular mechanisms behind tissue-specific trafficking are beginning to be 
unravelled, and have been shown to involve the acquisition of distinct adhesion molecules 
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and chemokine receptors by effector cells primed at different tissue sites (214, 215). 
Acquisition of such specific tissue homing phenotypes by effector T cells is due to 
"imprinting" by dendritic cells in the associated lymphoid tissues. T cells that are activated 
by DC in lymphoid tissue draining cutaneous sites acquire expression of CCR4 and CCR 10 
(216). Ligands of these receptors, CCL 17 and CCL27, respectively, are expressed on 
dermal postcapillary venules and thus enable the specific homing of cutaneous effector T 
cells to the skin (216-218). On the other hand, effector T cells stimulated by DC in gut-
associated lymphoid tissues upregulate CCR9 and are targeted to the lamina propria of the 
small intestine in response to CCL25, which is constitutively expressed at this site (219-
223). The ability of GALT DC to upregulate lymphocyte expression of CCR9 and a4~7, 
the mucosal homing integrin, was found to be due to their generation of retinoic acid, a 
vitamin A metabolite (223, 224). On the other hand, vitamin D3 metabolites appear to 
promote lymphocyte upregulation of the cutaneous-homing receptor, CCRI0 (225). 
Such compartmentalisation of immune responses is likely to increase the efficiency of 
immune responses, as effector T cells are targeted to the sites at which they are actually 
needed. Additionally, it may allow containment of inflammatory responses so as to reduce 
the risk of immunopathological damage at distant sites. Indeed, the extra-intestinal 
expression of gut-homing molecules has been associated with disease (226, 227) 
1.15 Chemokine Receptor Expression By B Cells 
Akin to T cells, B cells demonstrate differential patterns of chemokine receptor expression 
at distinct developmental stages. CXCR4 is expressed universally by B cells and, as already 
described in Section 1.7, signals via this receptor are thought to retain developing pre and 
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pro B cells in the supportive environs of the bone marrow. Expression ofCCR5 and CCR9 
has also been described on progenitor B cells, although the roles of these particular 
receptors in B cell development are less well understood (see Section 1.7) (112,113,228). 
Immature B cells exiting the bone marrow retain expression of CXCR4, and this receptor 
has been proposed to cooperate with CXCR5 and CCR7 to enable B cell homing to 
peripheral lymph nodes and Peyer's patches, as well as the peritoneal cavity (229-231). 
CCR6 meanwhile enables accumulation ofB cells within Peyer's patches and isolated 
lymphoid follicles of the intestine (232). 
Within the LN, CXCR5 expression enables the localisation of B cells to the follicles (233). 
During an immune response, follicular B cells activated by their specific antigen will 
proliferate, giving rise to low affinity IgM-producing plasma cells or, alternatively, forming 
a germinal centre. In the germinal centre, B cell-derived centroblasts proliferate extensively 
and undergo somatic hypermutation, affinity maturation and class switching. This process 
leads to the generation of high affinity centrocytes, which are positively selected to become 
class-switched memory and plasma cells. Proliferation of centro blasts occurs within the so-
called "dark zone" of the germinal centre, and CXCR4 is required for the accumulation of 
centroblasts at this particular anatomical location (234). CXCR5 meanwhile, may be 
involved in guiding centrocytes from the dark to the light zone to interact with follicular 
helper T cells (234). 
Subsets of memory B cells and plasma cells acquire distinct chemokine receptor profiles 
that, in combination with various adhesion molecules, contribute to the particular 
trafficking pathways these cells subsequently undertake. Class switched memory B cells 
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express CCR7, CXCR4, CXCR5 and CCR6, and may use these receptors to recirculate via 
secondary lymphoid organs (229). CXCR4 has also been shown to be involved in the 
accumulation of long-lived plasma cells in the bone marrow, a process thought to be 
important for the maintenance of serum antibody levels (235). IgO-secreting cells traffic 
mainly to the bone marrow or inflamed tissue, whereas IgA-producing cells are generated 
in mucosa- associated lymphoid tissues and targeted to mucosal sites (229). CXCR3 is 
upregulated by activated B cells and may enable accumulation of plasma cells at inflamed 
sites in response to the IFNy-inducible chemokines, CXCL9, CXCL 1 0 and CXCL 11. 
However, ligands of CXCR3 are expressed constitutively in spleen and lymph nodes, 
raising the possibility that this receptor also contributes to homing to these sites. 
IgA-secreting plasma cells, but not IgO- or IgM-secreting plasma cells express high levels 
ofCCR9 and are recruited to the small intestine in response to CCL25 (236,237). CCR9 
KO mice have reduced number oflgA+ plasma cells in the small intestinal lamina propria 
and show a defective generation oflgA in response to orally administered antigen (237). It 
has recently been demonstrated that intestinal DC, as well as inducing T cell expression of 
CCR9 and n4j37, can similarly imprint B cells with these gut-homing receptors (224). The 
chemokine CCL28 and its receptor CCRI 0 are also involved in targeting IgA-plasmablasts 
to diverse mucosal surfaces, including the salivary glands, tonsils and both the small and 
large intestine (180). 
This section has given an overview of the most well characterised roles of chemokine 
receptors and their ligands in B cell biology. However, in addition to the receptors 
described above, B cells have been shown to express various other chemokine receptors. 
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For example, CCRI to CCR5 as well as CXCR6 have been reported to be expressed by 
human memory B cells or plasma cells, although the biological significance of this remains 
to be established (238, 239). 
Regulation of The Chemokine System 
The preceding passages have provided an overview of the role of chemokines in the 
development of immune responses. With such potent effects, it is imperative that 
appropriate methods exist to regulate chemokine responses. That increased chemokine 
levels are associated with a number of chronic inflammatory and autoimmune diseases 
stresses the importance of controlling these powerful mediators (22, 240, 241). A number 
of mechanisms have evolved to regulate the chemokine network and these are discussed in 
the following sections. 
1.16 Chemokine Regulation by the Glycosaminoglycan Family 
The glycosaminoglycan (GAG) family comprises long, sulphated polysaccharides, such as 
heparan sulphate and chondroitin sulfate, which are capable of binding soluble chemokines. 
GAGs are thought to be essential for the proper presentation of chemokines on activated 
endothelial cells and for creating haptotactic gradients to guide leukocytes (242, 243). In 
support of this, leukocytes have been shown to exhibit swifter integrin activation and arrest 
in response to immobilised and endothelium-bound chemokines as opposed to soluble 
chemokines (244). 
While all chemokines bind GAGs, they do not do so uniformly. Chemokines differ in their 
affinity for various GAGs, which are themselves highly heterogeneous molecules, and they 
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can also interact with GAGs by diverse functional domains (245). Thus differential 
anatomical expression of GAGs can facilitate site-specific patterns of chemokine 
expression, enabling control of cellular recruitment and activation at these locations. In 
addition, chemokine binding to GAGs can mediate outside-in signalling and GAGs are also 
likely to facilitate the presentation of chemokines to modifying proteases (246). 
1.17 Proteolytic Regulation of The Chemokine System 
Enzymatic alteration of chemokines can alter their agonistic potential. A number of 
proteases have been identified that digest chemokines: these include the cell surface 
dipeptidyl-peptidase CD26, elastase, chymotrypsin, cathepsins and matrix 
metalloproteinases (MMPs). Chemokine editing by proteases can enhance or diminish their 
potency. Truncated CCL2 family members still bind, but cannot activate their respective 
receptors (247, 248). Conversely, chemokines with weak affinity for CCR 1 can be 
converted into potent agonists following N-terminal truncation (249). 
1.18 Chemokine Receptor Antagonism 
Even in the absence of proteolytic modification some chemokines can act as receptor 
antagonists. CCL 7 has been shown to act as a natural antagonist for CCR5 (23) , while 
CCL 11 and CCL26 antagonise CCR2 (24-26). Additionally, CCR3 ligands antagonise 
CXCR3, and the ligands of CXCR3 antagonise CCR3 (25, 27-29). As CXCR3 and CCR3 
are associated with T HI and T H2 type responses respectively, their ability to act as 
functional antagonists may allow them to promote one arm of immunity while 
simultaneously suppressing the another. 
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1.19 Regulation of Chemokine Receptor Signalling 
Cytokines can regulate chemokine-induced activities by altering receptor expression or 
coupling of receptors to downstream signalling pathways. Additionally, signalling via 
chemokine receptors may be modulated by homodimerisation or heterodimerisation. CCR2, 
CCR5, CXCR2 and CXCR4 have been shown to oligomerise. Also, CCR2 forms 
heterodimers with CCR5 and CXCR4 (250). However, controversy shrouds the functional 
consequences of this phenomenon, and both increased and decreased chemokine responses 
have been reported following CCR2/CCR5 heterodimerisation (251). 
Chemokine receptor activation leads to exchange of GDP for GTP and the dissociation of 
Ga and G~y subunits, with each proceeding to trigger distinct signalling cascades. The 
response is terminated due to the intrinsic GTPase activity of the Ga subunits, which 
trigger hydrolysis of GTP, allowing the heterotrimeric G-protein units to reunite. A group 
of molecules called regulators of G-protein signalling (RGS proteins) can enhance or limit 
the rate of hydrolysis by the Ga subunits (252). Chemokine signalling can also be 
terminated by desensitisation and intemalisation of the chemokine receptor, which typically 
occurs following ligand binding (33). 
1.20 Microbial Regulation of The Chemokine System 
Given the importance of the chemokine system in the development of protective immunity, 
it is not surprising that microbes have come to possess a remarkable array of proteins that 
interfere with chemokine networks (253). Although such molecules are not endogenous to 
the host, the pressures these pathogen-derived products have placed upon our immune 
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system is likely to have heavily influenced the evolution of the chemokine network, 
contributing to its complexity. 
Herpes VIruses generate chemokine analogues that can antagonise host chemokine 
receptors, allowing these pathogens to keep the cells of the immune system at bay. For 
example, Kaposi's sarcoma associated herpesvirus (HHV-8) encodes the vMIP-II 
chemokine, which binds with high affinity to a number of CC and CXC- chemokine 
receptors and prevents their activation by endogenous chemokines (254). Conversely, 
viruses also produce agonistic chemokine molecules and such tactics may facilitate viral 
dissemination by attracting cellular targets of infection, or by favouring the induction of 
non-protective host responses over anti-viral T H I-type immunity. Murine cytomegalovirus 
(MCMV) for instance, attracts target monocyte populations by generating the CC-
chemokine homologues MCK-I and MCK-2, while the HHV-8-derived vMIP-I chemokine 
agonises CCR8, a chemokine receptor associated with Th2 and regulatory T cell 
populations (199, 255-258). 
Pox and herpes viruses are able to induce the expression of virally encoded chemokine 
receptors in infected cells. Ligation of such receptors can result in increased cell 
proliferation, providing additional targets for viral replication (259). Viruses can also 
secrete chemokine-binding proteins and encode "decoy" receptors, enabling broad-
spectrum chemokine neutralisation. For example, human cytomegalovirus induces infected 
cells to express a viral chemokine receptor, US28, which can internalise and facilitate 
destruction of a number of host CC-chemokines (260-262). The egg stage of the parasite 
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Schistosoma mansoni was also recently found to produce a chemokine-neutralising protein 
(263). 
1.21 Regulation of the Chemokine Network by Decoy Receptors 
It is well established that decoy receptors can play a role in preventing excessive 
accumulation of cytokines. Non-signalling decoy receptors have been identified for 
members of the IL-I/IL-IS, TNF, IL-IO and IL-13 cytokine receptor families (264, 265). 
Recently, it has become apparent that decoy receptors may play an analogous role in 
maintaining homeostasis within the chemokine system. 
Exposure of DC to IL-IO in combination with LPS can uncouple chemokine receptors from 
intracellular signalling pathways, effectively resulting in the generation of decoy receptors. 
These receptors may then "clean up" sites of inflammation by scavenging chemokines from 
the surrounding environment (266). Ariel and co-workers recently demonstrated 
upregulation of CCR5 by apoptotic leukocytes and showed that these receptors were not 
functional with regard to migration, but instead acted to sequester and clear CCL3 and 
CCL5 at inflammatory sites (267). In addition, it appears that a number of dedicated decoy 
receptors may regulate chemokine responses. To date, three chemokine binding receptors 
of this kind have been proposed: these are DARC (26S, 269), D6 (270,271) and CCX-CKR 
(272,273). 
DARC, D6 and CCX-CKR are capable of recognising multiple ligands with high affinity, 
but all appear unable to couple to major signalling pathways or to induce any functional 
response following ligand binding (274). In addition, unlike conventional chemokine 
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receptors, these atypical receptors appear to be predominantly expressed outwith the 
haematopoietic system, where they have been suggested to playa role in neutralisation or 
transport of chemokines (275). Ineligible for membership to the chemokine receptor super-
family, due to their lack of signalling capabilities, it has been suggested that these 
molecules be classified into a separate family of "interceptors", abbreviated to CIPR 1-3 
(Chemokine Intemalising PseudoReceptors) (275). 
1.22 The Duffy Antigen Receptor For Chemokines (DARe) 
The Duffy blood group antigen was first identified in 1950 but attracted interest in the mid-
1970s when it was found to act as an erythrocyte receptor for the malarial parasites 
Plasmodium vivax and Plasmodium knowlesi. Absence of Duffy expression by red blood 
cells provides resistance to these parasites, and the high prevalence of Duffy-negative 
individuals seen among black African populations suggests that this trait may have emerged 
due to evolutionary selection pressure. Later, it became apparent that Duffy could also bind 
a large variety of inflammatory CXC and CC chemokines and Duffy was re-christened 
DARC (Duffy Antigen/Receptor for Chemokines). In addition to erythrocytes, vascular 
endothelial cells were shown to express DARC and interestingly, Duffy-negative 
individuals were found to maintain venular DARC expression. 
DARC completely lacks the DRYLAIV motif, which is found on the second intracellular 
loop of most chemokine receptors and required for coupling to G-proteins, and appears 
unable to transduce any detectable signal upon ligand binding (268, 276). Instead, it has 
been proposed to serve as a chemokine transporter or neutraliser at vascular endothelial 
barriers (277, 278). In favour of a transporter role, Lee et al. found that DARC could traffic 
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CXCL8 across endothelial cell mono layers in vitro, and DARC-deficient animals showed 
diminished neutrophil recruitment in response to CXCL8 or LPS administration (278, 279). 
On the other hand, when Dawson et al. administered high doses of LPS, DARC KO mice 
were found to have increased neutrophil infiltration, suggesting an anti-inflammatory 
function for DARC (280). Also, transgenic mice that over-express venular DARe 
demonstrate reduced angiogenesis following administration of pro-angiogenic exe 
chemokines (281). These conflicting data may be reconciled by the fact that when lower 
levels of chemokine are present, chemokine trancytosis by DARC may promote neutrophil 
influx while, when chemokine levels become excessive, DARC may act to sequester its 
ligands, thus down-regulating the inflammatory response. 
Similar to this dual-purpose on vascular endothelial cells, erythrocyte DARC might not 
only act to sequester its ligands, but may also help to maintain sufficient levels of 
chemokines in the circulation. Injected chemokines disappear more rapidly from the plasma 
of DARC-deficient mice compared to WT animals, and Duffy-negative individuals have 
lower plasma levels of CCL2 compared with their Duffy-positive counterparts (282, 283). 
Therefore the true physiological importance of DARC may be as a chemokine "buffer" to 
maintain homeostatic levels of chemokines in the circulation. 
1.23 CCX-CKR: A Regulator of Homeostatic Chemokines? 
The most recently discovered of the three proposed interceptors, CCX-CKR 
(ChemoCentryx chemokine receptor) binds three constitutive ce chemokines, CCL 19, 
CCL21 and CCL25, as well as showing weak affinity for CXCL13 (272, 273). As with 
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DARC, CCX-CKR appears unable to connect to major signalling pathways following 
ligand recognition. 
A recent report by Comerford et al. has suggested that, at least in vitro, CCX-CKR might 
function as a chemokine scavenger (284). Transfection of HEK293 cell lines with either 
CCX-CKR or the structurally related CCR7, a functional receptor for CCL19 and CCL21, 
revealed that both receptors could internalise CCL19, but uptake by CCX-CKR led to 
enhanced degradation of the chemokine. Moreover, while recognition of CCL 19 led to 
desensitisation of CCR7, ligation of CCX-CKR led to even greater uptake of CCL 19. 
Little else is currently known regarding this receptor. However, ongoing studies in the 
recently generated CCX-CKR-deficient animals should help us to decipher its real 
biological relevance (284). 
1.24 D6: Regulation of Inflammatory CC-Chemokines 
D6, the final of these three atypical chemokine receptors, has the capacity to bind multiple 
inflammatory CC-chemokines (270, 271, 285, 286). The ligands of D6 are agonists of 
CCRl, CCR2, CCR3, CCR4 or CCR5; Figure 1.4 depicts the interactions between D6 
ligands and CCRI-CCRS and describes the leukocyte populations that typically express 
these chemokine receptors. The predominant site of D6 expression appears to be on 
lymphatic endothelial cells, with D6-positive lymphatics particularly abundant in barrier 
tissues, such as the skin, lung and intestine (270, 287). Additionally, 06 is highly expressed 
by placental trophoblasts and there is some evidence for leukocyte expression (270, 271). 
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The above diagram represents the chemokine receptors which are 
conventionally activated (i .e. induce productive signalling) in response to 
ligands of D6. The leukocytes on which these receptors are typically found are 
listed in the associated boxes. 
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Despite high structural homology to other chemokine receptors, D6, akin to DARC, fails to 
initiate intracellular signalling following ligand recognition. This may be due to alteration 
of the highly conserved intracellular DRYLAIV motif to DKYLEIV instead. In support of 
this, introduction of DKYLEIV into the CCR5 sequence in place of DR YLAIV has been 
found to block signalling by this receptor (275). Conversely, mutation of the DKYLEIV in 
the D6 sequence to DKYLAIV, enables weak signal transduction by the receptor (275). 
Although lacking signalling capabilities, D6 has been shown in vitro to internalise its 
chemokine ligands efficiently and target them for intracellular degradation (285, 288). This 
process can occur in the absence of signal transduction due to constitutive phosphorylation 
of D6, which drives continuous, ligand-independent internalisation and recycling of the 
receptor (285, 288-291) (See Figure 1.5). As a consequence, the majority of D6 protein is 
found intracellularly, with < 5% on the cell surface at anyone time (288). Within the cell, 
D6 associates with early and recycling endosomes, where the acidic conditions facilitate 
dissociation of internalised chemokines from the recycling receptor. These unique 
properties explain why D6, unlike other chemokine receptors, is not desensitised by 
repeated exposure to ligand. This capacity for inflammatory chemokine intemalisation and 
degradation in the absence of any functional response has suggested a role for D6 as a 
"scavenging" or "decoy" receptor (275, 285). 
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D6 is an atypical chemokine receptor that binds inflammatory CC-
chemokines but fails to initiate classical intracellular signalling 
pathways. Instead, D6 traffics constitutively to and from the cell 
surface, targeting it ligands for degradation. It has been proposed that 
through this capacity to effectively scavenge CC-chemokines, D6 may 
play an important role in the resolution of inflammation. 
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The recent generation of D6-deficient mice lends further support to the "decoy" hypothesis. 
Compared to wild-type controls, D6-knockout animals show enhanced pathology in a 
model of skin inflammation induced by repeated application of phorbol ester (292). While 
dennal inflammation subsides in WT animals a few days following phorbol ester 
application, inflammatory responses are prolonged in D6-deficient animals. These mice are 
characterised by increased leukocyte infiltration and epidennal hyperproliferation, 
associated with high levels of chemokines within the inflamed dennal tissue. In an 
additional study, D6-null mice demonstrated an exaggerated response following 
subcutaneous challenge with complete Freund's adjuvant (291). Compared to WT mice, the 
draining lymph nodes of06-null mice demonstrated increased cellularity and contained 
higher levels of inflammatory chemokines (291). These studies indicate that, in vivo, 06 
may be important for neutralising excess chemokine levels and facilitating resolution of 
inflammatory responses. 
1.25 Examining The Function of D6 In Vivo 
On the strength of the above experiments, it has been proposed that D6 is a "decoy" 
receptor that serves to down-regulate tissue inflammation. However, as detailed in this 
introductory chapter, the scope of CC-chemokine function extends beyond the recruitment 
of innate effector cells. Members of the CC-chemokine family can affect the development 
of adaptive immune responses, for example, by inducing DC maturation, promoting 
interactions at the immunological synapse and determining the developmental pathway 
undertaken by naive T cells; therefore 06 may influence such responses. In addition, 06 
could affect immune responses independent of active infection and inflammation. 
Regulation of CC-chemokines in primary lymphoid tissue may be essential for proper 
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lymphocyte development, for instance, by controlling T and B cell precursors localisation 
with stromal cells in the thymus and bone marrow. Levels of 06 ligands in the blood could 
also impinge upon steady-state leukocyte mobilisation, as has been shown for the release of 
Ly6Chi monocytes into the bloodstream (127). Indeed, as expression of 06 is constitutive at 
many sites, it is likely that its function may extend beyond the elimination of its ligands 
during inflammation. Thus, theoretically, the function of 06 may impact upon multiple 
aspects of immunity. However, these particular facets of 06 biology have not been 
investigated, and it will be important to thoroughly examine the role of 06 in homeostatic 
immune interactions, as well as this atypical receptor's role in the generation of adaptive 
immune responses. 
1.26 Exploring the Function of D6 in the Intestine 
As already mentioned above, expression of D6 is particularly abundant in the intestinal 
mucosa, but its function at these sites remains unexplored (287). The mucosal surfaces are 
continuously exposed to a vast array of antigens from the external milieu and at such sites 
the immune system faces a particularly delicate challenge in managing pro- and anti-
inflammatory type responses (293). Mucosal infections are the major killer before the age 
of five, emphasising the need for strong effector immune responses to deal with potentially 
deadly pathogens (294). On the other hand, it is vital that the immune system is tolerant 
towards foodstuffs and commensals, which are essential for life (295). Breakdown in these 
tolerance mechanisms in the gut can lead to the development of intestinal pathology. 
Coeliac disease is caused by an aberrant immune response against dietary gluten, whilst 
Crohn's disease and ulcerative colitis are believed be driven by T cell dependent attacks 
directed against the intestinal flora (296). 
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The CC-chemokine ligands of D6 have been implicated in both inflammatory and 
tolerogenic intestinal immune responses, suggesting that this atypical receptor could playa 
role in immune homeostasis in the intestine. For example, Karpus and coworkers have 
described a role for both CCR5 and CCR2 in oral tolerance, the process by which the 
immune system becomes systemically tolerant towards fed antigens (19, 20, 297). By 
regulating levels of the CC-chemokine ligands of these receptors, D6 could contribute to 
this essential physiological phenomenon. 
On the other hand, it is possible that chronic immunopathology could ensue from excessive 
chemokine accumulation in the gut. In support of this, increased levels of CCL2, CCL3, 
CCL4, CCL5, CCL 7 and CCL8 are detected in the colonic mucosa of patients with 
ulcerative colitis and Crohn's disease (298-300), with a strong correlation seen between 
CCL 7 expression and the extent of epithelial destruction in biopsies from patients with IBD 
(300). Additionally, mice with deletion of the CCR5 or CCR2 receptors are protected from 
experimental colitis induced by dextran sulphate sodium (DSS) administration (301). 
Studies such as these have led to increasing interest in targeting chemokines as a possible 
therapy for IBD (302). However, our limited understanding of chemokine networks within 
the intestine hampers this goal. 
Accordingly, a better appreciation of the role of D6 will be important for extending our 
knowledge of chemokine responses in the intestine. With its potential capacity to scavenge 
CC-chemokines, D6 may serve to limit excessive inflammation developing in the intestine, 
in an analogous manner to that described for cutaneous inflammation. Moreover, as the 
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intestine is faced with the greatest antigenic load in the entire body, the role of D6 may be 
particularly important at this site. 
One chief aim of this thesis therefore, was to characterise the role of D6 in intestinal 
tolerance and inflammation, by examining the induction of oral tolerance and colitis in D6-
deficient animals. It was planned to adopt a model of experimental colitis induced by the 
oral administration of dextran-sulphate sodium (DSS) (303). Mice subjected to DSS 
develop inflammation of the colon, characterised by diarrhoea, rectal bleeding, weight loss 
and significant shortening of colon length (303,304). Histologically, epithelial erosion and 
ulceration, a marked infiltration of inflammatory cells, and destruction of crypt architecture 
are seen (303, 304). DSS has been shown to be directly toxic to intestinal epithelial cells 
and its administration leads to disruption of the colonic epithelium (305). Following 
breakdown of the epithelial barrier, colonic microflora may gain access to the underlying 
lamina propria and drive the colitic response. It was anticipated that, due to increased levels 
of inflammatory CC-chemokines, D6 KO mice might display increased susceptibility to 
this model of colitis. 
Importantly though, despite the current belief that D6 is a chemokine scavenger, its true 
biological function remains to be established. It is possible that D6 may exert pro-
inflammatory effects or may even signal through as yet unidentified pathways. Dissecting 
the intricacies of D6 action and of the chemokine network as a whole is an important goal; 
such knowledge may enable manipulation of the chemokine system to either enhance 
efficacy of vaccines or curtail immunopathological responses. 
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THESIS AIMS 
Regulation of the chemokine family is essential for proper immune homeostasis and the 
CC-chemokine system has a role at each stage of leukocyte life, not merely during 
inflammation. Thus, with its ability to recognise multiple inflammatory CC-chemokines. 
D6 could potentially influence numerous stages of immune development and function. 
Initial experimental data suggested an anti-inflammatory "scavenging" role for D6; 
however the vast majority of these studies had been conducted in vitro. 
The aims of this thesis therefore, were to conduct a thorough characterisation of the 
immune system of D6 KO mice. As described in this introductory chapter, chemokines 
facilitate the development and baseline trafficking of haematopoietic cells. Thus, I first 
explored a possible homeostatic role for D6 by analysing lymphoid tissues of resting D6-
null animals. Subsequently, utilising appropriate experimental models, I sought to examine 
the influence of 06 on both tolerogenic and inflammatory-type immune responses. Oue to 
the abundant expression of 06 in the intestine, I planned to place significant emphasis on 
exploring the role of D6 at this site. It was anticipated that my studies would either fortify 
the decoy hypothesis or shed light on as yet unappreciated functions of 06, thus aiding a 
more complete understanding of this atypical chemokine receptor. 
Chapter 3 of this thesis chronicles my preliminary studies in which I assessed the cellular 
composition of various lymphoid tissues from resting 06 KO animals and examined the 
ability of the 06 KO animals to respond to specific immunisation with antigen and 
adjuvant. These early data suggested differences in the myeloid cell compartment of the 06 
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KO mice, and Chapter 4 describes how I explored myeloid cell responses in D6 KO mice, 
by examining monocyte and macrophage recruitment to the inflamed peritoneum and by 
characterising D6 KO dendritic cells derived from bone marrow cultures. In chapter 5, I 
detail the impact of D6 in intestinal immunity, by describing the induction of oral tolerance 
and experimental colitis in D6-deficient mice. Finally, Chapter 6 follows up on unexpected 
observations from the preceding chapter, in which I found that intestinal leukocytes, most 
notably B cells, from D6 KO animals show aberrant chemokine receptor expression, and I 
describe how I uncovered this to be a universal feature of leukocytes in D6-deficient mice. 
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Chapter 2 
Materials and Methods 
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2.1 Animals 
D6 knock out (KO) and wild-type (WT) mice were originally obtained from the Beatson 
Institute for Cancer Research, Glasgow and subsequently bred and maintained on a 129 x 
C57Bl/6 background under specific pathogen free conditions in the Central Research 
Facility, University of Glasgow. For some experiments, D6 KO animals and WT controls 
on a DBA/2 background, also obtained from the Beatson Research for Cancer Institute 
were used. BALB/c mice were obtained from Harlan Olac, Bicester, U.K. 
All mice used in experiments were male and first used between 6-12 weeks of age. All 
procedures were performed in accordance with United Kingdom Home Office regulations. 
2.2 Preparation of Genomic DNA from Tailtips for Genotyping 
Tailtips were removed and incubated in 1.5ml screwcap tubes at 55°C overnight in 100",,1 
lysis buffer (lOOmM Tris.HCI pH 8.5, 5mM EDT A, 0.2% SDS, 200mM NaCl, 0.1 mg/ml 
Proteinase K). Tubes were heated to 96°C on a heating block for 5 min before 500",,1 of 
distilled H20 was added. Tubes were then spun in a microcentrifuge at 13,000 rpm for 5 
min and samples stored at 4°C. 
2.3 Isolation of RNA 
Mouse MLN, PP, small intestinal and large intestinal tissue were dissected out, rinsed in 
PBS, snap frozen in liquid nitrogen and stored at -70°C. Tissue was ground up whilst 
frozen using a mortar and pestle under liquid nitrogen. Ground tissue was collected in a 
sterile RNAse free microcentrifuge tube and homogenised in lOml ofTRIZOL (Invitrogen) 
by pi petting vigorously up and down. RNA was then isolated from cell extracts according 
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to the manufacturer's instructions. Briefly, samples were incubated at room temperature for 
5 min, spun at 3000g for 5 min at 4°C, and the supernatant collected in fresh tubes. Next, 
chloroform (O.2ml per ml of TRIZOL) was added to each sample and the samples were 
shaken vigorously for 15 sec and incubated at room temperature for 2 min. Samples were 
then spun in a microcentrifuge at 3000g at 4°C for 15 min before the aqueous phase was 
removed and placed in a fresh tube. Propan-2-01 (O.5ml per Iml of TRIZOL) was added to 
each sample and the samples were incubated at RT for 10 min to enable RNA precipitation. 
Samples were then centrifuged at 3000g for 10 min at 4°C and the pellets of RNA were 
washed in 75% EtOH, air-dried and resuspended in distilled water. The optical absorbance 
at 260nm and 280nm were measured using a Beckman DU 650 spectrophotometer and the 
readings used to determine the RNA concentration. Purity was estimated from the 
OD26OI'OD280• 
2.4 Removal of DNA from RNA samples 
RNA samples were DNAase treated using the DNA:free kit (Ambion) according to the 
manufacturer's instructions. In brief, 10~g of each RNA sample was diluted in 1 x 
DNAaseI buffer containing 1 ~l of DNAaseI with the total volume made up to 50~1 with 
diethylpyrocarbonate (DEPC) treated water. Samples were mixed and incubated at 37°C for 
30min. 5~1 of DNAase Inactivation Reagent was then added and samples mixed thoroughly 
and incubated at RT for 2min. Samples were centrifuged at 1O,000g for 1.5 min and the 
supernatant, containing the DNAase treated RNA, placed in a fresh tube. 
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2.5 Synthesis of eDNA from RNA 
cDNA was reverse transcribed from DNAase-treated RNA using the Superscript First-
Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's 
instructions. Briefly, 5~g of each RNA sample was mixed with l~g/ml of random 
hexamers, 25~g/ml Oligo(dT)12_18, ImM dNTP mix, and the volume made up to 1O~1 with 
DEPC treated water. Samples were incubated at 65°C for 5 min and then placed on ice for 
> 1 minute. 9~1 of a mixture containing the following components was added to each 
sample: 1 x RT-buffer, 5mM MgC12, IOnmDTT and 40 units of RNase OUT Recombinant 
RNase Inhibitor. Samples were incubated at 42°C for 2 min and then 1 ~l (50 units) of 
Superscript II Reverse Transcriptase added to each sample, or 1 ~l of DETC-treated water 
added to -RT controls. Samples were incubated at room temperature for 10 min, and then 
heated to 42°C for 50 min before termination of the reaction by heating samples at 70°C for 
15 mins. Samples were collected by centrifugation and 1 ~l of RNAaseH added to each of 
the samples, which were then incubated at 37°C for 20 min and stored at -20°C prior to 
PCR amplification. 
2.6 Polymerase Chain Reaction (PCR) 
PCR was performed using Reddymix PCR Master Mix Tubes according to the 
manufacturer's instructions. Briefly, 2~1 of an oligonucleotide primer mixture comprising 
1 ~g of forward and 1 ~g of reverse primers (all purchased from Sigma, see Table 2.1 for 
sequences) was added to each of the tubes along with 3~1 of cDNA sample. Tubes were 
then incubated in a thermocycler under the following conditions: 94°C for 2 mins, 35 
cycles of 94°C for 20 seconds + 57°C for 1 min + 72°C for I min, then 72°C for 10 min 
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and 4°C until end. PCR products were analysed by agarose gel electrophoresis and 
visualised with ethidium bromide under UV illumination. 
2.7 Isolation of Leukocytes from Lymphoid Tissue 
Single cell suspensions from spleen, peripheral lymph node (PLN), mesenteric lymph node 
(MLN), Peyer's Patch (PP) and thymus were prepared in sterile RPMI 1640 medium 
(Gibco BRL) by homogenisation of organs through Nitex mesh (Cadisch, London, UK). 
Cells were washed by centrifugation in RPMI 1640 at 400g for 5 minutes, resuspended in 
fresh RPMI 1640 and viable cell counts were performed in a Neubauer haemocytometer 
using a phase contrast microscope (Nikon Labophot, UK). Cells were stored on ice until 
required. 
2.8 Proliferative Responses of Lymphocytes 
The proliferative capacity of lymphocytes was assessed by culturing 2 x 105 cells in 200l-li 
of complete RPMI (RPMI containing 2mM L-glutamine (Gibco), 100 Ulml penicillin 
(Gibeo), 100 Ulml streptomycin (Gibco), 1.25 I-lg/ml fungizone (Gibco) and 10% foetal calf 
serum) in the presence or absence of 1-10 I-lg/ml concanavalin-A (ConA), 1 I-lg/ml E. Coli 
LPS (Sigma) or anti-CD3 (2I-lglml). Cells were cultured for 48-120h in triplicate in flat-
bottomed 96-well tissue culture plates (Costar) at 37°C in 5% C02. The cells were pulsed 
with IJ.tCi/weU thymidine CH-TdR) (West of Scotland Radionucleotide Dispensary) for the 
last 18-24 hours of culture and cell bound DNA was harvested onto glass-fibre filter mats 
(Wallac). 3H-TdR uptake was measured by a Betaplate counter (Wallac). 
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2.9 Staining of Leukocytes for Analysis by Flow Cytometry 
Aliquots of cells « 1 x 106) were added to 5ml conical, round-bottomed tubes (Becton 
Dickinson, UK) and washed by adding ice cold F ACS buffer (PBS, 2% FCS) and 
centrifuging at 400g for 5 min at 4°C. Cells were incubated with anti-C016/C032 (BD 
Pharmingen) for 15 min at 4°C to prevent binding of antibody to cells via Fc regions. 
Subsequently, cells were stained for 45 min with fluorescein isothiocyanate (FITC)-, 
phycoerythrin (PE)-, allophycoerythrin (APC)-, or biotin-conjugated antibodies specific 
for the surface markers of interest (see Table 2.1 for antibody clones used). Biotinylated 
antibodies were recognised by streptavidin (SA)-APC (BO Pharmingen). All antibodies 
were purchased from BD Pharmingen, except anti-F4/80-PE and anti-F4/80-bio, which 
were obtained from Caltag. 
2.10 Chemokine Receptor Staining 
For flow cytometric analysis of chemokine receptor expression, monoclonal antibodies 
against CCR2 (MC-21) and CCR5 (MC-68), were generously provided by Prof M. Mack 
(Department of Internal Medicine, Ludwig-Maximilians University, Munich, Germany). 
Monoclonal antibodies specific for CCR9 (7E7), CXCR4 (2Bll) and CXCR5 (2F18) were 
a kind gift of Dr Oliver Pabst (Institute of Immunology, Hannover Medical School, 
Hannover, Germany). Cells were incubated in PBS/ 2% FCS/ 10% mouse serum for lh at 
4°C, washed in 2% FCSIPBS three times and then stained with 5~g/ml of anti-chemokine 
receptor antibody or isotype control antibody (purified rat IgG2b) for 1 h at 4°C. Cells were 
washed three times in 2% FCS/ PBS and stained with biotinylated polyclonal anti-rat IgG 
(BD Pharmingen) for 30 min at 4°C. Following a further set of washes, cells were stained 
with SA-APC for 15 min at 4°C and then washed again. Expression of cell surface markers 
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was assessed as described in the previous section, except that the anti-CD 16/C032 
blocking step was omitted. 
2.11 Intracellular Cytokine Staining 
To assess expression of IFNy and IL-17, leukocytes were stimulated for 4-5 hours with 50 
ngiml PMA, 500 ng/ml ionomycin and 10!!giml Brefeldin A or with IO!-lg/ml Brefeldin A 
alone, in complete RPM!. Cells were washed in ice-cold F ACS buffer as described above 
and stained with F4/80-bio for 30 min at 4°C and, following a further wash, were stained 
with SA-FITC for 15 min at 4°C. The cells were then washed twice in FACS buffer and 
resuspended in 200!!1 Cytofix/Cytoperm (BD Pharmingen) for 30 min at 4°C before 
washing twice with Perm Wash (BO Pharmingen). Permeabilised cells were next stained in 
50!!1 Perm wash containing FITC- or PE-Iabelled cytokine specific antibody (BD 
Pharmingen), or isotype control antibody, for 30 min at 4°C. Following cytokine staining, 
the cells were washed with Perm wash and then with F ACS buffer before being 
resuspended and analysed for intracellular cytokine staining by flow cytometry. 
2.12 Analysis of Stained Cells By Flow Cytometry 
Cellular fluorescence data was acquired using a dual-laser (488-nm argon laser, 635-nm red 
diode laser) Becton Dickinson F ACSCalibur flow cytometer and CELLQuest software (BO 
Biosciences). Dead cells were excluded by addition of 9!!1 of a 50!!g/ml propidium iodide 
solution (Sigma-Aldrich) to each tube immediately before analysis. Following acquisition, 
data files were analysed using FlowJo software (Tree Star Inc, OR, USA). 
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2.13 Measurement of Cytokine and Chemokines by ELISA 
To detect IL-I, IL-6 and TNFa, Immulon-4 plates (Coming-Costar) were coated with anti-
lL-I (4~g/ml, R&D systems), anti-IL-6 (l~g/ml, BO Biosciences) or anti-TNFa (2!-lg/ml, 
BD Biosciences) detection antibodies overnight at 4°C. Plates were washed at least three 
times with PBS/0.05% Tween (Sigma) before being blocked with PBS/ 10% FCS for I h at 
room temperature. The plates were washed and incubated with serially diluted recombinant 
cytokine standards (BD Pharmingen) and samples for 2 h before being again washed and 
incubated with biotinylated-detection antibody (300ng/ml IL-I (R&D Systems), I ~g/ml IL-
6 (BD Pharmingen), 21-lglml TNFa (BD Pharmingen» for I h. Plates were then washed and 
incubated with Extravidin-Peroxidase (111000 dilution, Sigma) for I h. Following a final 
series of washes, plates were developed using tetramethylbenzidine (TMB) substrate (KPL) 
and read at 630 nm on a MRX II microplate reader (Dynex). 
MCP-I and IL-23 supernatant levels were assessed by ELISA using commercial kits (from 
R&D Systems and E-Biosciences, respectively) according to the manufacturer's 
instructions. 
2.14 Measurement of Cytokine and Chemokine Levels by Luminex 
The following cytokines and chemokines were analysed simultaneously using Multiplex 
Bead Assay (BioSource, UK) according to the manufacturer's instructions: CCL2, CCL3, 
CCL4, CCL5, CCL19, CXCLIO, FGF, GM-CSF, IFNy, IL-Ia, IL-I~, IL-2, IL-4, IL-5, IL-
6, IL-IO, IL-I2 (p40 and p70), IL-l3, IL-17, KC, MIG and TNFa. The principle of the 
method is a sandwich immunoassay where specific antibodies for the cytokines/chemokines 
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of interest have been coated onto the surface of fluorescently encoded microspheres. Each 
microsphere is labelled with a distinguishable fluorophore that enables its assignment to a 
particular region by the scanner. Cytokine capture microspheres were incubated in a 96 
well Luminex plate with test samples or cytokine standards and, following washing of the 
plate, biotinylated detection antibody added. At the end of the incubation period, the plate 
was washed and samples incubated with Streptavidin-PE. After a final wash, the 
fluorescence bound to the micro spheres was analysed using a Luminex XMAP system with 
the intensity of the fluorescence being directly proportional to the concentration of cytokine 
present. 
2.15 Antigens 
Ovalbumin (OVA, Grade V) was obtained from Sigma (Poole, Dorset, UK) as a lyophilised 
powder and stored at 4°C until required. Heat-aggregated OVA (HAO) was prepared by 
heating a 2% solution of OV A in sterile saline at 70°C for 60 minutes in a waterbath. The 
precipitated OVA was then centrifuged for 10 minutes at 450g, 4°C and the supernatant 
removed. The pelleted HAO was resuspended in sterile saline at a concentration of 
20mg/ml and stored in aliquots at -20°C until required. For use as an in vivo challenge, 
HAO was resuspended in sterile saline at a concentration of 2mg/ml and sonicated for 20 
minutes until a colloidal suspension was obtained. 
2.16 Assessment of Oral Tolerance 
Oral tolerance was induced by feeding mice 25mg of OVA dissolved in 0.2 ml of saline 
using a rigid steel gavage tube. Control mice received oral saline alone. One week later, 
mice were challenged by subcutaneous injection in the hind footpad with 100"",g OVA 
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dissolved in saline and emulsified at a 1: 1 ratio in Complete Freund's Adjuvant (Sigma-
Aldrich) in a total volume of 50f-t1. 
2.17 Induction and Measurement of antigen-specific proliferation in vitro 
Single cell suspensions of draining popliteal lymph node cells were prepared in sterile 
RPMI 1640 medium by homogenisation of organs through nitex mesh as described above 
and cultured in complete RPMI alone or in complete RPMI containing 1 mg/ml OVA or 
5f-tglml con A (Sigma) at 37°C in 5% C02 for 120h. Culture supernatants were collected at 
48h, centrifuged at 13000g and stored at -20°C until use for cytokine analysis by ELISA 
(see above). Proliferation was assessed by addition of 1 f-tCi/well thymidine for the last 18-
24 hours of culture as described above. 
2.18 Measurement of Antigen-specific DTH Responses 
Systemic OVA-specific DTH responses were assessed 21 days after OV A/CF A footpad 
challenge by using callipers (Kroplin Ltd, Kingston-upon-Thames, Surrey, UK) to measure 
the increment in footpad thickness 24 hours after subcutaneous challenge of the previously 
unimmunised hind footpad with IOOf-tg heat-aggregated OVA. Antigen-specific DTH 
responses were calculated by subtracting the footpad increments found after challenge of 
naIve mice. 
2.19 Measurement of Antigen-specific Antibodies 
Serum levels of OVA-specific total IgG were measured by ELISA 21 days after 
immunisation with OV AlCF A. Briefly. plates were coated overnight at 4°C with 1 Oftg/ml 
OV A in 50mM carbonate buffer. The plates were washed 3 times with PBS/O.05% Tween 
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and blocked with 10%FCSIPBS to prevent non-specific binding. Following 3 washes with 
PBS/Tween, aliquots of test sera in doubling dilutions in 10%FSC/PBS were added to the 
plates and incubated overnight at 4°C. Following a further series of washes, peroxidase 
conjugated anti-IgG antibody (Sigma) diluted 1: 1 000 in 10%FCS/PBS was added to the 
plates and incubated for Ih at 37°C. The plates were washed 5 times before addition of 
TMB substrate to each well. Plates were read at 630nm on a MRXII microplate reader 
(Dynex). 
OV A-specific IgG 1 and IgG2a antibody levels in serum were measured as described above, 
except that following incubation of test samples, plates were washed in PBS/Tween and 
either biotinylated-anti-IgGI (111000) or biotinylated-anti-IgG2 (112000) added to the plate 
for Ih. Subsequently, plates were washed 3 times and incubated with Extravidin-Peroxidase 
(1/1000 dilution, Sigma) for 1 h. Plates were developed and read as described above for 
total IgG. 
2.20 Measurement of Total Serum Antibodies 
Total serum levels oflgG and IgM were measured by ELISA. Briefly, plates were coated 
overnight at 4°C with 1 00~1 of 1 ~g/ml capture anti-IgG (Sigma) or 1001-l1 of 2 ~g/ml 
capture anti-IgM (Sigma) in 50mM carbonate buffer. The plates were washed 3 times with 
PBS/0.05% Tween and blocked with 200~1 of 10%FCS/PBS to prevent non-specific 
binding. Following 3 washes with PBS/Tween, 1 00 ~l of test sera, serially diluted in 
lO%FSCIPBS, were added to the plates and incubated overnight at 4°C. Following a further 
series of washes, biotin-conjugated anti-IgG antibody diluted 1 :200,000 in 10%FCS/PBS 
(Sigma) or 100~1 of2~g/ml anti-IgM (Sigma) diluted in 10%FCS/PBS was added to the 
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plates and incubated for Ih at 37°C. Plates were washed 3 times and incubated with 
Extravidin-Peroxidase (diluted 1: 1 000 in 10% FCSIPBS) for 1 h. The plates were washed 5 
times before addition of TMB substrate to each well. Plates were read at 630nm on a 
MRXII microplate reader (Dynex). 
2.21 Induction of Peritonitis by Injection of Thioglycollate 
Mice were injected intraperitoneally with 2ml of 4% Thioglycollate broth (Sigma) and, at 
the time-points indicated, mice were euthanised by C02 inhalation. To obtain peritoneal 
exudate cells (PEC), sacrificed mice were injected with 6 ml of PBS/lmM EOTA, the 
abdomen was gently massaged and the fluid withdrawn using a 21-gauge needle. Cells 
were washed by centrifugation in RPMI 1640 at 400g for 5 minutes, resuspended in fresh 
RPMI 1640 and counted before being stored on ice until required. The lavage fluids were 
stored at -20°C until use. 
To analyse PEC in cytospins, aliquots of 1-5 x 105 cells were spun onto glass microscope 
slides at 600 RPM for 4 min using a cyto-centrifuge (Shandon, Runcom, UK) and fixed in 
acetone for 5-10 min. The slides were allowed to air dry and washed in PBS before 
immersion in 1: 1 0 Geimsa stain (Sigma) for 30 minutes. Next, the slides were rinsed in 
distilled water, allowed to air dry and then mounted in OPX mountant (BOH, UK) under 
glass. Slides were sealed using clear nail varnish (Rimmel, Boots The Chemist, UK) and 
the stained cells assessed histologically at 400x magnification using a Nikon Labophot 
microscope. To perform analysis of cell numbers, 10 fields per cytospin were assessed and 
the average calculated. 
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2.22 Measurement of Nitric Oxide Production 
Isolated PEC were resuspended in complete RPMI -1640 and 1 x 1 05 cells were stimulated 
with IFNy (25U/ml, Biosource) and/or LPS (ll-'g/ml) for 48h. The concentration of nitric 
oxide (NO) present in culture supernatants was determined by detection of nitrite, a stable 
metabolite of NO, using the Griess reaction. Supernatants from cultured cells (501-'1) or 
standard dilutions of sodium nitrite were added to 96-well Immulon 4 plates in triplicate 
and then 501-'1 of Griess reagent A (1 % sulphanilamidel 5% H3P04) and 50 1-'1 of Griess 
reagent B (0.1 % napthyethylenediamine/ 5% H3P04) added. Plates were read at 570nm 
using a microplate reader. 
2.23 Induction of Intestinal Inflammation by Administration of Indomethacin 
Stock solution was prepared by dissolving 100mg of indomethacin (Sigma) in 1001-'1 
DMSO + 9001-'1 of absolute ethanol. The solution was then diluted in pre-warmed PBS and 
mice received an intraperitoneal dose of2.5mglkg daily for 14 days. Control mice received 
PBS injections. At the end of the experiment, animals were sacrificed and the small and 
large intestines of each mouse removed for histological analysis. 
2.24 Analysis of Intestinal Architecture 
The method of Clarke was used to assess intestinal architecture. 1 cm2 pieces of duodenum, 
jejunum, ileum and colon were opened longitudinally and fixed for 6-24h in Clarke's 
Fixative (75% ethanol, 25% glacial acetic acid) before being stored in 75% alcohol. After 
hydrolysis in 1 N HCl at 60°C, the tissues were stained with Schiff reagent (Sigma). Using 
a dissecting microscope, the muscularis mucosae was removed and sections one villus/crypt 
unit thick were cut using a cataract knife (Weiss). The sections were placed on a 
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microscope slide in 30% acetic acid and villus and crypt lengths measured. The tissues 
were then gently squashed under the coverslip and the number of mitotic bodies per crypt 
determined. 
2.25 Assessment of Epithelial Cell Turnover by Uptake of Bromodeoxyuridine 
Mice were injected intraperitoneally with 1 mg bromodeoxyuridine (BD Pharmingen) 
diluted in PBS and sacrificed 24 hours later. Excised colons were frozen with liquid 
nitrogen in cryomoulds containing OCT embedding medium (Bayer, Newbury, Berkshire, 
England) and stored at -70°C. Tissue sections 6~m thick were cut on a cryostat 
(ThermoShandon, Chesire, UK) and stored at -20°C. Brd-U incorporation was assessed 
immunohistochemically using a commercial kit (BD biosciences) in accordance with the 
manufacturer's instructions. 
2.26 Induction and Assessment of Dextran Sodium Sulphate Colitis 
Mice received dextran sodium sulphate (molecular weight 36-50 kDa, ICN Biomedicals) 
dissolved in sterile drinking water, ad libitum, for up to 14 days. Control mice received 
water without DSS. Animals were monitored daily for clinical signs of colitis, namely 
weight loss, diarrhoea, rectal bleeding and general morbidity. Weight change was 
calculated as percent change in weight compared with body weight at start of experiment. 
Any animal that lost > 20% of its original body weight was immediately sacrificed by 
cervical dislocation. At the end of the experiment, colons were excised and their length 
recorded. 
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Histological scoring of colitis was performed on samples of colon, which were fixed in 
10% formalin, embedded in paraffin and stained with haematoxylin and eosin. Scoring was 
performed in a blinded fashion utilising a combined score of inflammatory cell infiltration 
(0-5) and tissue pathology (0-5) (see table 2.3). 
2.27 Colon Organ Culture 
Colons were opened longitudinally and washed in sterile PBS (Gibco BRL, Paisley) 
supplemented with 1 % penicillin/streptomycin (Gibco BRL, Paisley). Three segments from 
the distal colon of approximately 1 cm in length were placed in 24 flat-bottom well culture 
plates (Costar) containing fresh RPMI 1640 (Gibco BRL, Paisley) supplemented with 1% 
penicillin/streptomycin and incubated at 37°C for 24 h. Culture supernatants were then 
harvested, centrifuged at 13,000g and stored at -20°C before measurement of cytokines and 
chemokines by ELISA and Luminex. 
2.28 Isolation of Colonic Lamina Propria Cells 
Whole colons were washed in CMF-HBSS (Gibco), opened longitudinally and cut into 
segments of - 1 cm. Epithelial cells were removed by incubating the colon segments in 
2mM EDTAI CMF-HBSS for 15 minutes at 37°C with shaking. The tissue was then 
washed in CMF-HBSS, the supernatant discarded and fresh EDTAI CMF-HBSS added. A 
total of three EDT AlHBSS incubations were performed, after which the tissue was washed 
thoroughly in sterile PBS and digested in 20% FCSI eMF-HBSS containing 100 Vlml 
collagenase-A (Sigma) and 30llg/ml DNase (Roche) for 3 x 45 minute incubations at 
37°C. Liberated cells were harvested by shaking, washed in fresh CMF-HBSS, counted and 
stained for analysis by flow cytometry. 
84 
2.29 Generation of Bone Marrow Dendritic Cells 
To obtain dendritic cells (DC), mouse femurs were washed out with RPM! 1640 using a 
syringe and a 21g needle. Aliquots of 3 x 106 bone marrow cells were seeded into 90cm 
low-adherence Petri dishes (Bibby Sterilin, UK) and grown in complete RPMI at 37°C in 
5% CO2• On days 0, 3 and 6 of culture, the medium was supplemented with 10% sterile, 
filtered supernatant from X-63, a GM-CSF-transfected fibroblast cell line. Non-adherent 
DC were harvested by gentle washing of the Petri dishes after 5-12 days of culture. 
2.30 Activation of DC in vitro 
BM-DC (1 x 106) were cultured overnight in ultra low adherence 24-well flat-bottom plates 
(Coming, NY) either in complete medium alone, or with 1-2!lg/ml Escherichia Coli LPS 
(Sigma). Non-adherent cells were analysed by flow cytometry and supernatants harvested 
for analysis of cytokine production. 
2.31 Assessment of Antigen Presenting Cell (APC) Activity of DC 
The ability of WT and D6 KO DC to stimulate allogeneic T-cell responses was assessed by 
culturing 1-2 x lOs BM derived DC, pre-treated with 50 !lg/ml mitomycin C (Sigma) at 
37°C for 40 min, with 1-2 x lOS BALB/c lymphocytes in V-bottom well plates (Corning) 
for 48-72 hours. The cells were pulsed with 1 !lCi/well thymidine for the last 18-24 hours of 
culture. 
2.32 Assessment of Endocytic Activity of DC 
BM-derived DC were cultured with complete RPMI 1640 containing 1 mg/ml FITC-
dextran (Sigma) in ultra low adherence 24-well flat-bottom plates at 4°C or 37°C. Cells 
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were then washed twice in ice-cold F ACS buffer (2% FCS/PBS) and stained for 30 min 
with anti-CDllc-PE (BD Pharmingen). Cells were analysed by flow cytometry and the 
uptake of FITC-dextran (~ MFI) was calculated by subtracting the FITC-channel Mean 
Fluorescence Intensity (MFI) of cells cultured with FITC-dextran at 4°C from the FITC-
channel MFI of cells cultured at 37°C. 
2.33 Negative Selection of Naive B Cells 
Naive B cells were purified from the spleen by negative selection. Single cell suspensions 
were prepared and red blood cells lysed by addition of 5ml Red Blood Cell Lysis Solution 
(Sigma) for 5 minutes at room temperature. The remaining cells were washed in MACS 
medium (2% FCSI PBS), resuspended and counted. Following centrifugation, cells were 
resuspended at a concentration of 107 cell/l00t-t1 MACS medium before the addition of 
1Ot-tlllx107 cells anti-CD43 (Ly-48) coated microbeads (Miltenyi Biotech, UK) for 15 min 
at 4°C. After washing, a maximum of 2 xI08 cells in Iml MACS medium were applied 
through Nitex to a CS column (Miltenyi Biotec, UK), which had previously been 
equilibrated with 8 column volumes of cold MACS medium. To elute naive B-cells, a 
further 5 column volumes of cold MACS medium were passed through the CS column and 
the eluent collected. All solutions and cells were kept at 4°C throughout the procedure. B 
cell purity was assessed by F ACS analysis of B220 expression and was in the range of 90-
94%. 
2.34 Assessment of B cell Activation in vitro 
A total of 2 x 106 MACS-purified B cells were cultured in 24-well plates (Costar) in 
complete RPMI alone or complete RPMI containing anti-IgM (10t-tg/ml) ± anti-CD40 
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(lOJ.tg/ml), dextran sulphate sodium (DSS) (50J.tg/ml) or LPS (lJ.tg/ml) at 3rC in 5% CO2 . 
Cells were harvested 48h later and stained for expression of costimulatory molecules and 
chemokine receptors as described above. Proliferative responses were assessed by pulsing 
with 3H-TdR as described previously. 
2.35 RNA-isolation from Purified B cells 
Following MACS purification, 7x106 B cells were added to eppendorfs and lysed by 
vortexing in 350J.tl of RNA lysis buffer (provide by Dr Clive McKimmie, University of 
Glasgow). Samples were then added to QIAshredder Mini Columns (Qiagen) and 
centrifuged at top speed on a microcentrifuge for 2 min at room temperature. The spin 
through was kept and stored at -80°C. 
2.36 Statistical Analysis 
The results are represented as the mean ± I SD unless otherwise stated. Normally 
distributed data were analyzed using Student's t test, whereas other datasets were compared 
using a Mann-Whitney U test. Values of p < 0.05 were considered to be statistically 
significant. Statistically significant differences between data sets are indicated throughout 
this thesis using the following key: 
* Statistically significant with a p value < 0.05 
** Statistically significant with a p value < 0.01 
*** Highly significant with a value ofp < 0.001 
87 
Table 2.1: Primers Used For peR 
eDNA Forward Primer (5'-3') Reverse Primer (5'-3') 
CCL2 TGATCCCAATGAGTAGGCTGG AGAAGTGCTTGAGGTGGTTGTG 
CCL3 CTGCCCTTGCTGTTCTTCTCTG TCAGGCATTCAGTTCCAGGTC 
CCL4 GCTGTTTCTCTTACACCTCCCG AGCAAGGACGCTTCTCAGTGAG 
CCL5 CTCACCATCATCCTCACTGCAG TGCAAGATTGGAGCACTTGC 
CCL7 TTCTCCACCATGAGGATCTCTG TATAGCCTCCTCGACCCACTTC 
CCLS TGCTCATAGCTGTCCCTGTCAG TCAAGGCTGCAGAATTTGAGAC 
CCLII CCCCAACACACTACTGAAGAGC TTCCCTCAGAGCACGTCTTAGG 
CCL12 TCCACACTTCTATGCCTCCTGC TGGCTGCTTGTGATTCTCCTG 
CCL19n CTGCCTCAGATTATCTGCCATG TGGAGGTGCACAGAGCTGATAG 
CCL19p TGCCTCAGATCGTCTGCCAC TGGAGGTGCACAGAGCTGATAG 
CCL21 TCCCTACAGTATTGTCCGAGGC TCAGTTCTCTTGCAGCCCTTG 
CCL22 CACCCTCTGCCATCACGTTTAG GTGAGTAAAGGTGGCGTCGTTG 
CCL25 CTTTTTGCCTGCCTGGTTG GCTGTCAAGATTCTCATCGCC 
D6 AGCTTTAGCTGCTGAACCTGG AAGAAGATCATCGCCAAGAGTG 
~-actin TCCATCATGAAGTGTGACGT TACTCCTGCTTGCTGATCCA 
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Table 2.2: Antibodies used to detect Cell Surface Markers by Flow Cytometry 
ANTIBODY CLONE SUPPLIER ISOTYPE CELLS+ve NOTES LIGANDS 
CD3e 145- BD HamIgGl T cells TCR-signalling 
2CII Biosciences NK-Tcells complex, Ig SF 
CD4 RM4-5 BD RatIgG2b T cell subset T CR co-receptor, MHC II 
Biosciences DC subset Ig SF 
CD5 53-7.3 BD RatlgG2a T cells cysteine-rich con 
Biosciences NK-T cells scavenger-R 
BI B cells 
CD8a 53-6.7 BD Rat IgG2b T cell subset T CR co-receptor MHCI 
Biosciences DC subset Ig SF 
IEL 
CDllb MI170 BD Rat IgG2b Granulocytes aM integrin C3bi 
Biosciences Macrophages adhesion molecule CD54 
DC 
NK cells 
B-1 cells 
COlIc HL3 BD Ham IgGI DC Integrin ax iC3b 
Biosciences IEL 
Macrophages 
CDl9 103 BD RatIg2a B cells BCR co-receptor 
Biosciences Ig SF 
CD25 704 BD Rat IgMK Activated T Low affinity IL- IL-2 
Biosciences cells, activated 2Ra chain 
B cells, 
macrophages, 
Treg 
CD40 3/23 BD Rat IgG2b APCs Costimulatory CD40L 
Biosciences molecule 
TNF-R SF 
CD80 16-IOAI BD Ham IgG2 DC Costimulatory CD28 
Biosciences Monocytes molecule COl52 
Macrophages Ig SF 
B cells 
CD86 GLl BD Rat IgG2a DC Costimulatory CD28 
Biosciences Monocytes molecule CDl52 
Macrophages Ig SF 
B cells 
Tcells 
IAIIE 2G9 BD Rat IgG2a APCs Antibody reacts TCR 
Biosciences with following class 
II MHC: I_Ab, I_Ad, 
CD4 
I-A q I_Ed I_Ek , , 
89 
ANTIBODY CLONE SUPPLIER ISOTYPE CELLS+ve NOTES LIGANDS 
Ly6G lAS BD Rat IgG2a Granulocytes, GPI-anchored 
Biosciences predom inantly protein 
neutrophils 
Ly6C AL-21 BD Rat IgM Monocytes GPI-linked cell 
Biosciences Macrophages surface protein 
CD8 T cells Promotes 
NK cells endothelial 
Plasma cells adhesion via LF A-I 
clustering 
Grl R86-8C5 BD Rat IgG2b Neutrophils Recognises a 
Biosciences Eosinophils common epitope on 
monocytes Ly6C and Ly6G 
ybTCR V65 BD Mouse IgGI yb T cells TCR 
Biosciences IEL 
DETC 
NKl.l PK136 BD Mouse NK cells Recognises killer 
Biosciences IgG2a NK T cells cell lectin-like Rs: 
NKR-PIC 
(activatory) on 
C57B16, FVB and 
NZB and NKR-PIB 
(inhibitory) on 
Swiss NIH and SJL 
B220 (CD45) RA3- BD Rat IgG2a B cells Protein Tyrosine 
6B2 Biosciences T cell subset Phosphatase 
NK cells Regulation of 
TCRlBCR 
signalling 
F4/80 BM8 Caltag(Now Rat IgG2a Monocytesl EGF-TM7 family 
Invitrogen) Macrophages member 
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Chapter 3 
Characterisation of the Immune System in D6 KO Mice 
91 
Introduction 
Chemokines are of fundamental importance for the trafficking and positioning of leukocyte 
populations (9). The atypical chemokine receptor D6 has been shown to act as a scavenger 
for a number of inflammatory-type CC-chemokines, in vitro, (see Figure 1.4) and, 
interestingly, immunohistochemical studies have identified lymphatic endothelial cells as a 
prominent site of D6 expression (271,286-288). These data pointed to a potential role for 
D6 in controlling leukocyte recruitment to lymphoid tissues, possibly through regulating 
bioavailable levels of CC-chemokines at these sites. To explore this idea, I first compared 
the composition of various lymphoid tissues from resting WT and D6 KO animals (292) by 
flow cytometry, and assessed lymphocyte functions. Then, I immunised mice with specific 
antigen in adjuvant and induced inflammation in skin. 
3.1 Analysis of Lymphoid Tissue Composition in D6 KO Mice 
Cells isolated from primary lymphoid tissue (thymus) and secondary lymphoid tissue 
(peripheral lymph nodes, mesenteric lymph nodes and spleen) were stained with antibodies 
specific for CD4, CD8, B220, F4/80 and CDllc to identify CD4 T cells, CD8 T cells, B 
cells, macrophages and dendritic cells, respectively (Figures 3.1 - 3.2). As shown in Figure 
3.1, there were no differences between WT and D6 KO mice in the proportions of CD4+, 
CD8+ or B220+ cells found in any of the tissues analysed. Additionally, the percentages of 
F4/80+ and CDllc+ cells retrieved from PLN, MLN and thymuses of WT and KO mice 
were similar (Figures 3.2 A-B). 
However, analysis of spleen revealed small, but significant increases in the proportions of 
F4/80+ and CDllc+ cells in D6 KO animals compared with WT controls (Figures 3.2 C-D). 
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Thus the absence of the D6 chemokine receptor could affect population of the spleen by 
myeloid lineage cells. 
3.2 Mitogen-Induced Proliferative Responses of D6 KO Cells 
I next compared the functional responses of WT and D6 KO cells when stimulated with 
mitogen in vitro. Cells isolated from peripheral LN or spleen were cultured in complete 
medium supplemented with 5f..tg/ml concanavalin A (Con A) or 1 f..\,g/ml LPS and 
proliferative responses measured by 3H-Tdr incorporation 48, 72, 96 and 120 hours later. 
As shown in Figure 3.3, cells harvested from peripheral LN of D6 KO mice demonstrated 
higher proliferation responses in vitro to Con A compared with WT controls at all time-
points examined. A similar effect was also seen at 48 and 72 hours of culture when spleen 
cells were stimulated with Con A (Figures 3.4 A-B). By 96h there were no statistically 
significant differences in the Con A responses between the groups, although the 
proliferative response of the KO spleen cells still exceeded that of WT cells at this time 
(Figure 3.4 C). 
The proliferative responses of KO LN cells in response to LPS also exceeded those of WT 
at each time point assessed, but the differences were not statistically significant and the 
responses, in general, were relatively low. Spleen cells responded better to LPS stimulation 
and there was a significant enhancement of the KO response compared with that of WT 
cells at 48 and 72 hours of culture. 
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To confirm the increased responsiveness ofD6 KO cells to Con A, I stimulated PLN, MLN 
and spleen cells from WT and KO mice with different concentrations of Con A for 48-96h. 
As shown in Figures 3.5, 3.6 and 3.7, markedly higher proliferation rates were observed in 
the cultures of lymphoid tissues at each time-point and at all Con A concentrations 
investigated. 
3.3 Antigen Specific Immunisation of D6 KO Mice 
These initial experiments suggested that there were few differences in the 
compartmentalisation of lymphoid tissue in D6 KO mice under steady-state conditions. 
However, due to the great complexity of the chemokine system and the redundant nature of 
interactions between its family members, the effects of deficiency in an individual receptor 
are often only apparent when KO animals are subjected to specific immunological stimuli 
(11, 306). Therefore I next explored a role for D6 in the generation of antigen-specific 
immune responses and inflammation. 
D6 KO and WT mice were immunised in the footpad with OVA emulsified in complete 
Freund's adjuvant (CFA) and their ability to respond to this challenge was compared 1-6 
weeks later by measuring the antigen-specific proliferation and cytokine production of cells 
isolated from the draining popliteal lymph nodes. Serum levels of OVA-specific IgG 
antibody, IgG 1 IIgG2a isotypes, and specific delayed-type hypersensitivity responses 
following challenge with heat-aggregated OV A were also assessed. 
Initial experiments showed that both WT and D6 KO mice on the 129/B6 background 
developed effective antigen-specific immunity, in vivo and in vitro, in response to 
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OVAJCFA, which was maximal at 2-3 weeks (Figures 3.8 - 3.11). At weeks 1 and 6 post 
immunisation, primed WT cells appeared to proliferate better than cells from KO mice 
upon culture with OVA in vitro, but these differences were not statistically significant (Figs 
3.8 A and D). Conversely, cells harvested from KO mice at 2 and 3 weeks after priming, 
displayed increased proliferative responses and produced significantly greater levels of 
IFNy upon re-exposure to antigen compared with their WT counterparts (Figs 3.8 Band C 
and 3.9). 
D6 KO animals generally had higher DTH responses than WT controls when assessed 2 or 
3 weeks after immunisation (Figures 3.10 A and B). However, these changes did not reach 
statistical significance and there were no differences between the DTH responses 6 weeks 
after immunisation (Fig 3.10 C). Measurement of specific antibody responses at weeks 2 
and 3 post immunisation showed that WT and D6 KO mice had similar levels of OVA-
specific IgG, and there were also no statistically significant differences found between 
IgG I and IgG2a antibody subclasses (Figure 3.11). 
In view of the variability of these findings depending on the time of assessment, I decided 
to repeat the experiment and measured responses at one and two weeks following 
immunisation. On this occasion, there were no significant differences between the strains in 
terms of OVA-specific proliferation or IFNy production, in vitro (Figure 3.12) at both time 
points examined. Specific DTH responses were also comparable between WT and KO 
mice (Figures 3.13 A and 3.14 A). At week one, similar levels of OVA-specific IgG, IgGl 
and IgG2a were measured in serum from immunised WT and KO mice (Figures 3.13 B -
D). However, at two weeks after immunisation, D6 KO mice had significantly lower levels 
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of serum OVA-specific IgG compared with WT animals, and this appeared to be due to a 
specific reduction in the IgG 1 subclass (Figures 3.14 B - 0). 
As my data were variable, I decided to examine the contribution of 06 to the generation of 
antigen specific immune responses on a different genetic background, and therefore 
conducted similar experiments using mice on a OBAl2 background. In these mice, lymph 
node cells isolated from 06 KO mice showed significantly reduced antigen-specific 
responses in vitro compared with WT cells at one week after immunisation with OV NCF A 
(Fig 3.15 A and B). However, at two weeks post-challenge this phenotype had reversed, 
with the KO cells responding better upon re-exposure to OVA (Fig 3.15 C and D). DTH 
responses were comparable between WT and KO DBAl2 mice when measured at 1 or 2 
weeks (Figures 3.16 A and 3.17 A), although OVA-specific antibody levels were lower in 
KO mice one week after immunisation, with a striking defect in OVA-specific IgG2a in 
KO mice at this time point (Figures 3.16 B and 0). By two weeks post challenge, however, 
there were no differences between WT and KO animals in terms of OV A-specific antibody 
production (Fig 3.17 C and 0). 
Taken together, these data suggested that, whilst not necessary for the generation of 
effective antigen-specific immune responses, the D6 chemokine receptor might influence 
the kinetics of such immune responses, although the exact nature of this control needs to be 
defined. Unfortunately, due to time limitations and a shortage of animals, I was unable to 
follow up these experiments. 
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3.4 Analysis of Lymphoid Tissue Draining Inflamed Skin 
To assess further how D6 might regulate immune responses, I examined the draining lymph 
nodes ofB6/129 WT and D6 KO mice subjected to application of the phorbol ester, 12-0-
tetradecanoylphorbol 13-acetate (TPA). TPA treatment evokes an inflammatory response 
characterised by epidermal hyperplasia, hyperkeratosis, the development of rete ridges and 
increased cellular recruitment to the dermis of the skin. Recent work in the laboratory had 
shown that D6 knockout mice display increased epidermal thickening, excessive dermal 
infiltration and failure to resolve the inflammatory response generated by mUltiple TP A 
application (292). I therefore compared draining lymph nodes from TP A-painted WT and 
KO mice for absolute cell numbers, composition of leukocyte subsets, and for the 
proliferative capacity of isolated LN cells in vitro. 
In the first experiment, I examined lymph nodes from WT and D6 KO mice which had 
been given 3 doses of TP A at 4S-hour intervals. TP A treatment led to a marked increase in 
the cellularity of the draining inguinal nodes of both WT and KO mice when compared 
with controls treated with acetone alone (Figure 3.18). This peaked at four days after the 
last application, but at all times from day 1-6, more cells were obtained from the nodes of 
TP A-treated KO mice than from their WT counterparts, with the differences reaching 
statistical significance at both 2 and 6 days (Fig 3.18). There were no differences in the 
numbers of cells obtained from WT and KO control nodes (Fig 3.1S). 
To determine which particular leukocyte population(s) accounted for the increased 
cellularity of the nodes, the cells were analysed by flow cytometry for expression of CD4, 
CD8, CD25, B220, CDllc, MHCII and F4/S0. Overall, there were no consistent 
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differences between the individual subsets in the lymph nodes of TPA-treated KO and WT 
mice (Figure 3.19) suggesting that the increased total cellularity noted in the KO nodes was 
not due to selective expansion of anyone individual cell type. 
To explore further the increased cellularity in D6 KO nodes, I measured the proliferative 
responses of cells harvested from TP A-painted WT and KO mice when stimulated with 
Con A, anti-CD3 or LPS (Fig. 3.20). Cells from KO mice proliferated better in response to 
anti-CD3 stimulation compared with WT cells 4 days post TPA application (Fig. 3.20 A), 
although the differences were not statistically significant. There were no differences in 
proliferation between WT and KO cells following culture in medium alone or with LPS, 
but KO cells showed significantly higher proliferative responses to Con A than their WT 
counterparts at both 4 and 6 days following TPA-treatment (Figures 3.20 A and 8). These 
effects were most marked in TPA-treated mice, although they were also seen in acetone 
treated control mice. The data thus correlated with my earlier experiments examining 
mitogen responses, in which I found D6 KO lymphocytes to be more responsive to Con-A 
induced proliferation (Section 3.2, Figures 3.3 - 3.7). 
In conclusion, TPA-treated D6-deficient mice showed a tendency to have intense 
lymphadenopathy compared to WT counterparts. This did not appear to be due to the 
selective expansion of any particular cell type, but was associated with increased 
proliferation rates in vitro following stimulation with mitogen. 
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Summary 
In this chapter, I conducted an initial characterisation of the immune system of D6 KO 
animals, comparing the leukocyte composition of lymphoid tissues from WT and D6-
deficient mice and the ability of cells isolated from these tissues to respond to mitogen. 
Higher proportions ofF4/80+ and CDllc+ cells were retrieved from the spleens ofD6 KO 
animals compared with WT, suggesting a possible role for D6 in controlling myeloid cell 
population of this site. While the absence of D6 did not appear to alter the lymphocyte 
composition of spleen or lymph nodes, compared with WT counterparts, D6 KO 
lymphocytes showed increased proliferative responses following culture with Con A or 
LPS. Immunisation of WT and KO mice with OV A/CF A revealed a reduction or 
enhancement of in vitro responses and serum antibody production, depending on the 
particular time-point analysed, suggesting that these animals might differ kinetically in their 
ability to generate antigen-specific immune responses. Finally, TPA-induced skin 
inflammation was found to be associated with increased cellularity of draining lymph nodes 
in D6 KO mice, as well as elevated proliferative responses of KO lymph node cells in 
response to mitogen. Taken together, these data provided preliminary evidence that D6 
may be involved in the steady state popUlation of lymphoid tissues and in regulating the 
amplitude of inflammatory immune responses. 
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Figure 3.1 
Cellular Composition of D6 KO Lymphoid Tissues 
c:::JWT 
IIIKO 
Single cell suspensions obtained from MLN, PLN, spleen and thymus ofWT 
and D6 KO animals were analysed by flow cytometry for the relative proportions 
of (A) CD4+, (B) CD8+ and (C) B220+ cells. Dead cells were excluded by 
PI-staining. Results represent 3 animals per group and are presented as means + 
1 SD. Similar results were obtained from two additional experiments. 
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Figure 3.2 
Cellular Composition ofD6 KO Lymphoid Tissues 
Single cell suspensions obtained from MLN, PLN, and thymus (A, B) and spleen 
(C, D) of WT and D6 KO animals were analysed by flow cytometry for the relative 
proportions of CD 11 c+ and F 4/80+ cells. Dead cells were excluded by PI-staining. 
Results represent 3 animals per group and are presented as means + 1 SD. Similar 
results were obtained from two additional experiments. 
* p < 0.05 
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Proliferative Responses of D6 KO Lymph Node Cells 
72h 
120h 
* 
Single cell suspensions from peripheral lymph nodes ofWT and 06 KO animals 
were cultured in medium :t 5 ~g/ml Con A or 1 ~g/ml LPS for 48-120 hr and 
levels of proliferation determined by 3H_ TdR incorporation. Similar results 
were obtained from two experiments. Results represent the mean of 3 animals 
per group + 1 SD. 
* p < 0.05 
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Proliferative Responses of D6 KO Splenocytes 
72h 
•• 
Single cell suspensions from spleens ofWT and D6 KO animals were cultured in 
medium ± 5 ~glml Con A or 1 ~g/ml LPS for 48-96 hr and levels of proliferation 
determined by 3H-TdR incorporation. Similar results were obtained from two 
experiments. The data represent the mean of 3 animals per group + 1 SD. 
* p < 0.05, ** p < 0.001 , NS = not significant 
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Figure 3.5 
[Con A] 
Dose Response of Peripheral LN Cells Stimulated With Con A 
Single cell suspensions obtained from peripheral lymph nodes of a single WT 
mouse and a single D6 KO animal were cultured in medium ± 1, 2 or 5 I-tg/ml of 
Con A for 48-96 hr and levels of proliferation determined by 3H_ TdR 
incorporation. 
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Figure 3.6 
__ WT 
- .. - KO 
Dose Response of MLN CeUs Stimulated With Con A 
[Con A] 
Single cell suspensions obtained from mesenteric lymph nodes of a single 
WT mouse and a single D6 KO animal were cultured in medium ± 1,2 or 5 
""glml of Con A for 48-96 hr of culture and the levels of proliferation 
determine by 3H_ TdR incorporation. 
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Dose Response of Spleen Cells Stimulated With Con A 
[Con AJ 
Single cell suspensions obtained from the spleens of a single WT mouse and a 
single D6 KO animal were cultured in medium ± 1, 2 or 5 ~g/ml of Con A for 
48-96 hr and levels of proliferation determined by 3H-TdR incorporation. 
106 
c 
0 
~ 
~ 
0 
... 
.: 
D: 
"0 
'7 
~ 
c 
o 
I 
... 
.5 
D: j 
A 
12000 
9000 
6000 
3000 
0 
c 
Figure 3.8 
Week 1 
med OVA 
Week 3 
NS 
NS 
CJWT 
_KO 
CJWT 
_KO 
c 
0 
~ 
~ 
0 
... 
.: 
D: 
~ 
~'I. 
c: 
o 
~ 
I 
~ 
:i: 
.. 
B 
Week 2 
o 
Week 6 
Priming of Antigen-Specific Proliferative Responses In D6 KO Mice 
CJWT 
_KO 
WT and D6 KO mice were immunised in the footpad with OV A/CF A and 1 (A), 
2 (B), 3 (C) and 6 (D) weeks later, draining popliteal lymph node cells were 
cultured in medium:t OVA (1 mg/ml) for 120 hours before assessment of 
3H-TdR incorporation. The results are from an individual experiment and are the 
means + I SD of 3-4 animals per group. 
** p < 0.00 I, NS = not significant 
107 
A 
_ 1800 
§ 
Cl 
E; 1200 
.z 
~ 
B 
2400 
_ 1800 
~ 
..2: 1200 
>-z 
u. 
- 600 
Figure 3.9 
** 
CJWT 
aKO 
t::JWT 
_KO 
Priming of Antigen-Specific IFNy production in D6 KO mice 
WT and D6 KO mice were immunised in the footpad with OV AlCF A, and 2 (A) 
and 3 (8) weeks later, draining popliteal lymph node cells were cultured in 
medium ± OVA (1 mglml) for 48 hr and levels ofIFNy in culture supernatants 
were determined by specific ELISA. Results are from an individual experiment 
and are the mean + 1 SD of 3-4 animals per group. 
* p< 0.05, ** P < 0.001 
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Figure 3.10 
Priming of antigen-specific DTH Responses in D6 KO Mice 
WT and D6 KO mice were immunised in the footpad with OV AlCF A and 
re-challenged 2 (A), 3 (B), and 6 (C) weeks later with heat-aggregated OVA. 
The mean increase in footpad thickness was measured 24h later. Results are 
from an individual experiment and are the mean + 1 SD of 3-4 animals per 
group. 
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Priming of antigen-specific antibody responses in D6 KO Mice 
-WT 
..... KO 
WT and D6 KO mice were immunised in the footpad with OV NeF A, and 2 CA, 
e, E) and 3 (B, D, F) weeks later, serum levels of OV A-specific IgG (A, B), IgG I 
(e, D), and IgG2a (E, F) antibodies were assessed by ELISA. The data represent 
the mean + 1 SD of 3-4 animals per group. 
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Priming of Antigen-Specific Proliferation and IFNy Production in D6 KO 
Mice 
c::::JWT 
IBIKO 
c:::JWT 
aKO 
WT and D6 KO mice were immunised in the footpad with OV A/CF A and I (A, B) 
and 2 (C, D) weeks later, draining popliteal lymph node cells were cultured in 
medium ± OVA (1 mg/ml) for 120 hours before assessment of 3H-TdR 
incorporation (A, C). Culture supernatants were harvested at 48h and the levels 
ofIFNy determined by ELISA (B, D). Results represent the mean + 1 SD of3-4 
animals per group. 
111 
E 
E 
A DTH B OVA-lgG 
2.6 
';; 0.3 
: 
-+-WT 
..... KO 
.li 
.!.! 
= ... 
I 
: 
e 
E 
.§ 1.5 
.., 
UI 
o 
o 
0.6 
~ CTRL 
~ O.O~L...I.,....,.--I"--
c ~ i' ~~ ~ ~ .~ ~~ ~~ ~~ ~ ~'ti ~ ... ro ~"J~ ~rT ~ ... ",'ti ... <:t-~ :: 
E 
c 
OVA-lgG1 
2.5 
E ~ 1.5 
8 
0.5 
Figure 3.13 
__ WT 
·· .. ·KO 
~ ClRL 
serum dilution 
o 
OVA-lgG2a 
1.2 
~ 0.8 
~ 
80.4 
o.o-4--";t--+-...;..-t::::lF~""" 
-+-WT 
..... KO 
~ CTRL 
Priming of antigen-specific DTH and Antibody Responses in D6 KO Mice 
WT and D6 KO mice were immunised in the footpad with OV AlCF A and challenged 
one week later with heat-aggregated OVA (HAD). The mean increase in footpad 
thickness was measured 24 hr later and serum levels of OV A -specific JgG, JgG 1 
and IgG2a antibodies were determined by ELISA. The control group represents 
unimmunised animals that were injected with HAO to calculate non-specific 
footpad swelling. Results shown are the means + 1 SD of 3-4 animals per group. 
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Priming of DTH and Antibody Responses in D6 KO Mice 
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WT and D6 KO mice were immunised in the footpad with OV AlCF A and challenged 
two weeks later with heat-aggregated OVA. The mean increase in footpad thickness 
was measured 24 hr later and serum levels of OVA-specific IgG, IgG 1 and IgG2a 
antibodies were determined by ELISA. The control group represents unimmunised 
animals that were injected with HAO to calculate non-specific footpad swelling. 
Results shown are the means + 1 SD of 3-4 animals per group. 
* p < 0.05, ** P < 0.01 
113 
A Proliferation B IFNy 
* 80000 ~ c: c::JWT .2 IIIIIIIIKO e 80000 8. I 8 40000 
.: % 0= 
~ 20000 !!: 
J: 
.... 
0 
med med 
c Proliferation D IFNy 
20000 * 
c c::::::JWT c::::::JWT 
0 
aKO _KO !15000 
-. 
~ E 
0 ~ u 
.E 2 0= 
" 
!!:: 
I-;" 
J: 
M 
med 
Figure 3.15 
Priming of Proliferation and IFNy Responses in DBA/2 D6 KO Mice 
WT and D6 KO animals on a DBN2 genetic background were immunised in the 
footpad with OV NCFA and 1 (A, B) and 2 (C, D) weeks later, draining popliteal 
lymph nodes cells were cultured in medium ± OVA (1 mg/ml) for 120 hours and the 
levels of proliferation determined by 3H_ TdR incorporation. Culture supernatants 
were harvested at 48h and IFNy levels were measured by ELISA. Results are the 
means + 1 SD of 3 mice per group. 
* p < 0.05 
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Priming DTH and Antibody Responses in DBA/2 D6 KO Mice 
__ WT 
. .... KO 
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WT and D6 KO mice on a DBAl2 genetic background were immunised in the 
footpad with OV A/CF A and challenged one week later with heat-aggregated OV A. 
The mean increase in footpad thickness was measured 24hr later (A) and serum 
levels of OVA-specific IgG (B), IgGl(C) and IgG2a (D) antibodies were assessed 
by ELISA. The control group represents unimmunised animals that were injected 
with HAO to calculate non-specific footpad swelling. Results are the mean + 1 SD 
of 4 mice per group. 
* p < 0.05, ** p< 0.001, *** P < 0.0001 
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Priming DTH and Antibody Responses in DBAl2 D6 KO Mice 
WT and D6 KO mice on a DBAl2 genetic background were immunised in the footpad 
with OV AlCF A and challenged two weeks later with heat-aggregated OV A. The mean 
increase in footpad thickness was measured 24hr later (A) and serum levels of 
OV A-specific IgG (B), IgG 1 (C) and IgG2a (D) antibodies were assessed by ELISA. 
The control group represents unimmunised animals that were injected with HAO to 
calculate non-specific footpad swelling. Results are the mean + 1 SD of 4 mice per 
group. 
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Day Post TPA-Treatment 
Lymph Node Cellularity in TPA-Treated D6 KO Mice 
Single cell suspensions were obtained from the inguinal lymph nodes of WT and D6 
KO mice that had received 3 topical applications of TPA (50f-tM solution in acetone) 
and from controls that were treated with acetone alone. The results represent the 
mean viable cell counts for 5 (TPA) or 2-3 animals per group (control) + 1 SD. 
* p < 0.05 
NS = not significant 
ND = not determined 
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Cellular Composition of Lympb Nodes of TPA-Treated D6 KO Mice 
WT and D6 KO mice received 3 topical applications of TP A and 48h later single 
cell suspensions were made from the draining inguinal lymph nodes. The 
proportions of CD4+, CD8+, B220+, CDllc+ and F4/80+ cells were determined 
by flow cytometry and the results represent the means + 1 SD for 5 mice per group. 
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Mitogen-Induced Proliferative Responses of Lymph Node Cells from 
TP A-Treated Mice 
WT and D6 KO mice received 3 topical applications ofTPA and at 4 (A) and 6 
(8) days later, draining inguinal lymph node cells were stimulated, in vitro, in 
medium ± 5~glml Con A or 1 ~glml LPS for 72 hr. The results respresent the 
mean incorporation or 3H-TdR for 4-5 animals per group (TPA) or 2-3 animals 
per group (acetone controls) + 1 SD. 
*** p < 0.001, NS = not significant 
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Chapter 4 
The Myeloid System of D6 KO Mice 
120 
Introduction 
My initial characterisation studies of the D6 KO mice revealed minor changes in the 
proportions ofF4/S0+ and CDllc+ cells in the spleen under steady state conditions and had 
also pointed to deviations in the numbers of F4/80+ cells in lymphoid organs draining the 
inflamed skin (See Chapter 3, Figure 3.3). These data suggested that D6 could playa role in 
the development, recruitment and/or functions of myeloid lineage cells. 
The peritoneal cavity houses a large macrophage population that is essential for 
maintaining the sterility of this compartment (307). D6 ligands have been shown to play 
critical roles in both the recruitment and activation of cells to this site during inflammation 
(47, 136, 137, 155, 308). Thus to further explore a role for D6 in myeloid responses, I 
decided to analyse the cellular composition of the peritoneum of D6 KO mice, both under 
normal conditions and during inflammation. 
4.1 Myeloid and Lymphoid Populations in Resting Peritoneum of D6 KOs 
Peritoneal cells were isolated from untreated WT and KO mice by lavage and assessed for 
the relative proportions of macrophages, dendritic cells, T cells, B cells and neutrophils 
using flow cytometry. As shown in Figure 4.1 A, comparable total cell yields were 
retrieved from WT and KO peritoneum and there were no differences between WT and D6 
KO PEC in the proportions of CD4+, CDS+, CDllc+ and B220+ cells (Fig. 4.1 B). 
However, higher proportions of F4/80+ cells were detected in the PEC of KO mice 
compared with WT controls (Fig. 4.1 B). Further analysis revealed that this was due to a 
specific increase in an F4/80hi subpopulation in D6 KO mice, while there were similar 
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numbers of cells expressing lower levels of F4/80 (Fig. 4.2). This alteration was similar to 
the increase in F4/80+ cells I observed in the spleen ofD6 KO mice (See Chapter 3). 
4.2 Inflammatory Infiltrates in Peritoneal Exudates 
Next, to explore the effect of D6 on myeloid cell responses in more detail, I employed a 
model of sterile peritonitis induced by thioglycollate injection. Following thioglycollate 
administration, monocytes are recruited in a CCR2-dependent fashion to the peritoneum, 
where they differentiate into macrophages. Roles for several other inflammatory CC-
chemokines have also been demonstrated in murine models of peritonitis (47, 136, 137, 
155, 308). Thus it seemed possible that altered levels of CC-chemokines, such as CCL2, 
resulting from absence of D6 scavenging function, could lead to abnormal recruitment of 
inflammatory cells to the KO peritoneum. 
Peritoneal administration of thioglycollate induced a large inflammatory infiltrate which 
peaked at 24hr and the total numbers of cells recruited were not significantly different 
between WT and KO mice at any of the time points analysed (Fig 4.3). As others have 
shown (309), thioglycollate injection induced a significant influx of neutrophils and F4/80+ 
monocytes/macrophages to the peritoneal cavities of WT and KO mice at 24h post 
challenge (Fig. 4.4 A). However, by later times (48h-96h) isolated PEC comprised 
primarily F4/80+ cells (Fig. 4.4 B-D). In contrast to the F4/80+ cells in resting PEC, which 
were mostly F4/80hi (Fig. 4.1), the vast majority of F4/80+ cells which appeared at later 
times in the inflamed peritoneum demonstrated low to intermediate expression of this 
surface antigen (Fig. 4.5). Although there was a slight increase in F4/80+ cells in the D6 
KO PEC harvested at 24-48 hours, this was not seen later and, overall, there were no 
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statistically significant differences in proportions of total F 4/80+ cells or neutrophils in WT 
and KO PEC at any of the time-points investigated, (Fig. 4.4). 
Compared with WT animals, D6 KO mice had an increased proportion ofCDllc+MHCn+ 
cells in the inflamed peritoneum at all time points after thioglycollate administration (Fig. 
4.4 and 4.6). Further analysis indicated that the majority of these CO 11 c +MHCn+ cells also 
expressed F4/80 (Fig. 4.7). Thus the absence of D6 appeared to alter myeloid cell sub-
populations during peritoneal inflammation, with 06 KO mice exhibiting an increase in 
F4/80+COIlc+ cells and an accompanying decrease in the numbers of F4/80+CDllc· cells, 
which was most obvious at 72 and 96h post-injection (Fig. 4.7). However, by 96h after 
thioglycollate challenge, there was also a small but significant increase in the 
COI1c~4/S0· population in the KO PEC compared with WT PEC (Fig 4.7 D). 
Closer examination of PEC indicated that at least five different cell populations could be 
defined in terms of their intensity of COlIc and F4/S0 expression (Figure 4.S). These were 
therefore divided PEC into F4/S0int COIle·, F4/S0int COlIcin., F4/80 in' COllchi, F4/80· 
CD II c + and F 4180· CD II c· subsets, all of which expressed CD 11 b. I therefore compared 
the relative proportions of each of these populations in WT and KO peritoneum following 
thioglycollate injection. 
As shown in figure (4.8 A), the proportion of F4/S0·COllc· cells present in both WT and 
KO PEe was greatest at 24h and this decreased sharply at each time point thereafter. 
Higher proportions ofF4/S0-CDllc· cells were found in WT PEC compared with KO PEC 
at 24 and 4Sh after thioglycollate challenge, but by later time-points the proportions of 
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F4/S0·CDllc· cells present in PEC were equivalent in the two strains. The F4/80 in' COllc in' 
population became gradually more prevalent in inflamed peritoneum, increasing steadily 
from 24h to 96h, but similar proportions of this cell type were detected in both WT and KO 
exudates (Figure 4.8 B). Thus the increase in F4/80+CDllc+ cells I had detected in the 
inflamed peritoneum from D6 KO mice appeared to be due to expansion of the F4/80 inl 
CDllchi subset (Figure 4.8 C). Although similar proportions of these F4/80in' CDIIchi cells 
were detected in WT PEC at all times analysed, this population continued to increase in KO 
PEC and became significantly higher in KO exudates from 4Sh onwards, being most 
marked at 96h. Conversely, as shown in Figure 4.S D, there were lower proportions of 
F4/80 int CDllc· cells in KO PEC at 72h and 96h post thioglycollate. There were no 
differences between WT and KO PEC in the frequency of this subset at 24h and 4Sh time-
points. The proportions of F4/S0· CD 11 c + cells in PEC (Figure 4.S E) were generally low 
«7%), but by 96h following thioglycollate challenge, a statistically significant increase in 
this population was noted in KO compared with WT PEC (6.44±0.2I KO vs. 4.09±.7I 
WT), suggesting that this subset might also contribute to the increased numbers of CD 11 c + 
cells found in KO exudates (Fig 4.8 E). 
Further analysis of the different F4/S0/CDIlc fractions revealed that the majority of the 
F4/80int CDIIcint and F4/S0int CDllchi subpopulations were large, granular cells (Fig 4.9). 
This was particularly the case for the F 4/S0int CD II Chi cells, but in both cases their forward 
scatter and side scatter properties were characteristic of macrophage or DC-like cells. The 
F4/S0int CDllc· cells were generally smaller and less granular cells, similar to lymphocytes 
or monocytes, but there was also a population of these cells which had forward and side 
scatter profiles indicative of eosinophils (310). The F4/80· CDllc+ and F4/S0· CDllc· 
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populations both consisted of small, fairly agranular cells, again, likely to be lymphocytes 
or monocytes (Figure 4.9). 
In light of the differences in myeloid cell subsets defined by COlIc and F4/S0 in inflamed 
06 KO and WT peritoneum, I went back and examined resting PEC for the same markers. 
Interestingly, the F4/80hi cells that were the predominant F4/80 subset in resting PEC did 
not co-express CO 11 c (Figure 4.10). Additionally, very few F 4/80lo/intco 11 c + cells were 
detected in resting PEC, and there were no significant differences in these populations 
between WT and KO mice (figure 4.10). Therefore the F4/80 int COl Icint and F4/S0int 
CO 11 Chi populations appeared to be a specific result of peritoneal inflammation. 
Overall, these data suggested that the absence of the D6 chemokine receptor could support 
increased recruitment and/or differentiation of a large, granular F4/80+COl1c + population 
in the inflamed peritoneum. 
4.3 Functional Comparison of WT and D6 KO PEe 
Next, I examined whether the phenotypic differences I had observed in PEC had any 
functional consequences. Classical macrophage activation is associated with high 
microbicidal activity and production of pro-inflammatory cytokines: I therefore compared 
the capacity of WT and KO inflammatory PEC to generate the free radical nitric oxide and 
various cytokines upon in vitro stimulation with LPS and IFNy (311). WT and KO PEC 
isolated at 6, 48 and 96 h produced NO following stimulation with LPS and IFNy, with the 
greatest generation of NO seen by 96h PEC (Figure 4.11). However, there were no 
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differences in NO-generation by WT and KO PEC isolated at either 6, 48h or 96 hours 
following thioglycollate administration (Fig 4.11). 
To compare the cytokine and chemokine production of WT and KO infiltrates, cells were 
isolated from the inflamed peritoneum at 96h following thioglycollate injection, as this was 
the time-point at which WT and KO PEC appeared to differ most. Cells were stimulated 
overnight with IFNy and LPS and the culture supernatants were assessed by Luminex 
technology, enabling simultaneous analysis of multiple cytokines and chemokines. 
Supernatants from LPS/IFNy-stimulated PEC contained substantial amounts of IL-12 
p40/p70 and IL-IO as well as low levels ofIL-4 and IL-2, but there were no quantitative 
differences in the amounts produced in WT and KO cultures (Figure 4.12 A - D). As shown 
in Figures 4.12 E - H, high levels of IL-I, IL-6 and TNF a were detected in stimulated 
culture supernatants and greater amounts of these cytokines were found in WT culture 
supernatants compared with KO cultures, with the increases in IL-Ia and TNFa levels 
being statistically significant. Substantial amounts of the inflammatory CC-chemokines, 
CCL2, CCL3, CCL4 and CCLS, all of which are ligands of 06, were found in culture 
supernatants, with lower levels of CCL4 being seen in KO cultures (Figure 4.13 0 - G). 
The levels of CCL3 and CCLS also appeared to be lower in KO cultures, although these 
differences did not reach statistical significance (Figures 4.13 E and G). There were also 
detectable levels of CXCL 1 and IFNy-inducible CXCL9 and CXCL 10, with significantly 
less CXCL lOin 06 KO cultures compared to WT. Overall, these data suggested that 06 
KO PEC were either less efficient than WT counterparts in the generation of pro-
inflammatory cytokines and chemokines following activation, or showed enhanced uptake 
or degradation of these cytokines and chemokines. 
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4.4 Assessment Of Chemokine Levels in Inflamed Peritoneal Fluid 
As 06 is proposed to be a decoy receptor for CCL2 and is vital in mediating macrophage 
recruitment to the inflamed peritoneum (47, 136, 137, 155,308), I decided to analyse levels 
of this particular 06 ligand in peritoneal fluid at different times after thioglycollate 
injection. As shown in figure 4.14, levels of CCL2 increased in peritoneal lavage fluid of 
WT mice from 24 to 96 hours after thioglycollate injection (61.3 ± 3.2 pg/ml at 24h and 
112.5 ± 17.2 pglml at 96h). However the levels of CCL2 in 06 KO lavage did not increase 
over time, so that by 96 hours, significantly increased levels of CCL2 were detected in WT 
peritoneal fluid. 
4.5 Chemokine Receptor Expression by WT and D6 KO PEC during Inflammation 
CCR2 and CCR5 are activatory receptors for inflammatory CC-chemokine ligands of 06 
(CCL2, CCL3, CCL5, CCL 7) and have been shown to be involved in monocyte trafficking 
to inflamed sites (47, ISS, 312). As such, it was possible that their expression could be 
affected by 06 function and so to further compare WT and KO peritoneal exudates, I 
examined the expression of the CCR2 and CCRS chemokine receptors on resident and 
inflammatory PEC of 06 KO and WT mice, analysing particularly the different subsets 
defined by COlle and F4/80 that I had identified in earlier experiments. 
In resident PEC, a higher proportion of KO F4/80+ cells expressed CCR2 and CCRS 
compared with WT F 4/80+ cells, although only CCR2 expression was significantly 
different (Figure 4.1S A). In contrast, resident KO F4/80+ PEC expressed higher levels of 
CCRS per cell than WT F4/80+ PEC, as shown by MFI (Figure 4.1S B). 
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Next, in order to compare chemokine receptor expression in the inflammatory response, I 
analysed the chemokine receptor profile of the various F4/80/CO 11 c subsets at 24 and 96 
hours after thioglycollate challenge to represent early and late time points. As shown in 
Figures 4.16 A and B, at 24h after thioglycollate injection, almost all (~9S%) 
F4/S0+COllc+ PEC from both WT and KO mice expressed CCR2 and CCRS, but the 
levels of expression of these receptors were higher on 06 KO F4/80+CO 11 c + PEC (Fig. 
4.l6 C and 0), although this was only statistically significant for CCR5. The vast majority 
(~90%) of F4/S0TOllc + cells at this time were also positive for both of these chemokine 
receptors, but levels of expression were similar between WT and KO cells (Fig 4.16 A - 0). 
Similar percentages of WT and KO F4/S0+COllc' cells expressed CCR2 (~75%) and 
CCR5 (~50%) (Fig. 4.16 A and B); however the F4/S0+CDllc' cells that were CCR2 or 
CCR5 positive in 06 KO PEC expressed significantly higher levels of these receptors 
compared with their WT counterparts (Fig. 4.16 C and 0). Only around 10% of F4/S0' 
COlle' cells from both WT and KO expressed CCR2 or CCR5, and there were no 
differences in levels of receptor expression between WT and 06 KO cells. 
At 96h post-thioglycollate, most (>90%) of the F4/S0+COllc+ subset expressed CCR2 and 
CCR5 (Figures 4.17 A and B). Similar to 24 PEC, 06 KO F4/80+COllc+ cells showed 
higher levels of CCR5 expression compared with WT F4/S0+CDllc + PEC (Fig. 4.17 D). 
However, at this time point levels of CCR2 expression were lower on the KO 
F4/S0+CDllc + cells (Fig. 4.17 C). Expression of CCR2 and CCR5 was comparable 
between WT and 06 KO F4/S0+COllc+ and F4/80TDllc+ subsets harvested at 96h (Fig. 
4.17 A - B). Although high proportions of24h F4/S0+COllc' cells were found to express 
CCR2 and CCR5, at 96h only around a quarter of this subset at most expressed either of 
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these receptors. In addition, although CCR5 expression levels were similar between WT 
and D6 KO F4/80+CDllc+ PEC at this time, compared with their WT counterparts, the 
expression ofCCR2 was lower on 96h F4/80+CDllc- KO PEC (Fig. 4.17 A and C). 
Taken together, these data demonstrated that myeloid populations retrieved from both 
resting and inflamed peritoneum of D6 KO mice differed from their WT counterparts in 
terms of CC-chemokine receptor expression. 
4.6 Investigation of DC Development In Bone Marrow Cultures from D6 KO and WT 
Mice 
The increased prevalence of CDllc+ cells in the inflamed D6 KO peritoneum suggested 
that absence of D6 either favoured the recruitment of DC to sites of inflammation, or that 
there was enhanced differentiation of myeloid precursors towards the DC lineage. To 
examine the latter idea in more detail, I compared the generation and function of dendritic 
cells derived from WT and KO bone marrow. 
Bone marrow cells isolated from femurs ofWT and KO mice were cultured in GM-CSF for 
seven days in order to generate BM-derived DC. At day 7, non-adherent cells were 
harvested and cultured overnight with or without LPS, before assessment of differentiation 
and activation markers. D6 KO BM incubated overnight with medium contained 
significantly greater proportions ofCDllc+ cells compared with WT controls (Fig 4.18 A). 
Moreover, the CDllc+ cells in KO cultures expressed higher levels of CDllc than WT 
CDllc+ cells (Fig 4.18 B). LPS had no effects on the numbers or levels of CDllc 
expression in either strain, but, as expected, led to increased levels of the activation markers 
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CD40, CD80, CD86, as well as some increase in class II MHC expression (Fig 4.19). WT 
and KO cells did not differ significantly in these responses to LPS (Fig 4.19). 
As these results suggested that there might be unusual differentiation of DC in GM-CSF 
stimulated 8M-cultures in D6 KO mice, I examined this in more detail by investigating 
CD 11 c + cell development in 8M cultures taken after days 4, 6, 8, 10 and 12 of culture with 
GM-CSF. As shown in Figure 4.20 A, the proportion of cells in 8M-cultures expressing 
CD 11 c gradually increased throughout the duration of culture. and by day 12, almost all 
cells in both WT and KO cultures were COl1c+. Greater proportions of CDllc+ cells were 
found in KO cultures at most times, although this was only statistically significant at days 4 
and 8 of culture. Additionally, COllc+ cells from 06 KO 8M-cultures expressed higher 
levels of CD 11 c than their WT counterparts at all times, as determined by increased MFI 
and was statistically significant on days 8 and 10 of culture (Fig 4.20 B). 
In my earlier experiments examining the cellular composition of exudates from inflamed 
peritoneum, I had been unable to determine the identity of the F4/S0+COllc+ subset that 
prevailed in the KO peritoneum. Therefore I next examined if 8M-generated DC expressed 
the F4/80 antigen and if this differed between 06 KO and WT DC. F4/80 expression could 
be detected on around 20% of BM cells by day 4 of culture, and the proportions of F4/80+ 
cells increased with the duration of culture, with around 60-70% of cells being F4/80+ by 
day 12 (Fig. 4.20 C). However, no significant differences in F4/80 expression were seen 
between WT and KO cells at any of the times analysed. 
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4.7 Chemokine Receptor Profile ofBM-derived DC 
My studies of the peritoneal exudates had revealed differences in chemokine receptor 
expression between WT and D6 KO cells. Therefore I decided to examine chemokine 
receptor expression by WT and KO BM-DC. 
Consistent with existing reports (163), the vast majority of CDllc+ cells in both WT and 
KO BM cultures expressed CCR2 and CCR5 on day 7 (Fig 4.21). However, in keeping 
with my previous studies, I found increased expression of both CCR2 and CCR5 by D6 KO 
CDllc+ cells, although this was statistically significant only for CCR5 (Fig 4.21). In 
contrast, CXCR4 expression was equivalent between WT and KO BM-DCs (Figure 4.21). 
I next assessed whether CCR2 and CCR5 showed similar downregulation in response to 
LPS. Following overnight culture with LPS, DC derived from both WT and KO mice 
showed significant down-regulation of CCR5, although there was little or no effect on 
CCR2 (Fig 4.22). There were no differences between WT and KO DC in terms of 
chemokine receptor down-regulation in response to LPS (Fig 4.22). 
4.8 Functional Activity of BM-derived DC 
To examine the functional properties of BM-derived DC from D6 KO and WT mice, I first 
compared their endocytic activity. BM DC were harvested after 4,6,8, 10 and 12 days of 
culture with GM-CSF and the uptake of FITC-dextran assessed by flow cytometry. In all 
cases, uptake of FITC-dextran increased with the time of culture with greatest uptake seen 
at 60 min, but no significant differences were observed between WT and KO endocytic 
responses regardless of the day at which these cells were harvested (Figure 4.23). 
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Next, I assessed the APC activity ofWT and KO DC by measuring their ability to stimulate 
allogeneic T cells in a mixed-leukocyte reaction (MLR). WT and D6 KO BM-derived DC, 
harvested at day 7 or 9, were treated with mitomycin C and co-cultured with BALB/c 
lymphocytes. Under these conditions, both DC sources stimulated allogeneic T cells, with 
maximal responses being obtained using DC:T ratios of 1 :2. As shown in Figure 4.24, D6 
KO DC generated lower MLR reactions than their WT counterparts and this difference was 
most apparent in cultures of DC harvested at day 9. 
Finally, I compared cytokine production by WT and KO DC. DC isolated on d7 of culture, 
were cultured overnight in medium or with LPS and the culture supernatants analysed by 
Luminex. Culture with LPS led to substantial production of IL-l, IL-6 and TNFa by WT 
and KO DC (Figures 4.25 A-D). While the levels ofIL-la, IL-l ~ and IL-6 did not differ 
between WT and KO LPS·treated DC cultures, significantly higher levels of TNFa were 
detected in the D6 KO cultures. IL-4 and IL·l 0 were detected when DC were cultured with 
medium alone and at higher levels in LPS cultures, but no differences were observed 
between WT and KO cultures (Figures 4.25 E and F). LPS-treatment induced significant 
IL-12 p40/p70 secretion (Figure 4.25 G), but again, the levels of IL-12 p40/p70 did not 
differ between WT and KO cultures. The angiogenic cytokine, VEGF, was present at high 
levels in cultures of both WT and KO DC in medium alone, and these were reduced in the 
presence of LPS (Figure 4.25 H). Increased levels of VEGF were found in KO DC cultures 
compared with WT, both in the presence and absence of LPS. LPS-stimulated DC produced 
marked amounts of the CXC-chemokines CXCLl, CXCL9 and CXCLIO, but there were no 
differences between WT and KO DC (Figures 4.26 A-C). The D6 ligands CCL2, CCL3, 
CCL4 and CCL5 were barely detectable when DC were cultured in medium alone, but were 
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found at high levels in LPS-treated DC cultures (Figure 4.26 D-G). The production of 
CCL2 was similar for both WT and KO DC, but KO DC produced higher levels of CCL3, 
CCL4 and CCL5 in response to LPS culture compared with WT DC (Figure 4.26 E-F). 
Overall, my data indicated that D6 KO BM-derived DC differ from WT DC in terms of 
CD 11 c, CCR2 and CCR5 expression. In spite of this altered surface phenotype, I failed to 
detect any functional differences in D6 KO DC in terms of costimulatory molecule 
upregulation or endocytosis of antigen. However, D6 KO DC generated poorer MLR 
responses compared to WT counterparts. In addition, higher levels of TNFa, VEGF and a 
variety of inflammatory CC-chemokines were found in culture supernatants from LPS-
stimulated D6 KO BM-DCs compared to their WT counterparts. Taken together, these data 
suggested that absence of D6 might result in both phenotypically and functionally altered 
BM-DC. 
Summary 
In this chapter I explored the myeloid cell compartment of D6 KO animals. I detected 
increased numbers of resident F4/80+ macrophages in the peritoneal cavity of resting D6 
KO mice and these cells showed higher expression of CCR2 and CCR5 compared with WT 
controls. Following injection of thioglycollate, D6 KO mice showed normal levels of total 
cell recruitment to the peritoneum, but there was preferential accumulation of an 
F4/S0+CDllc+ cell population. Inflammatory peritoneal exudates from D6 KO animals 
could not be distinguished from WI cells in terms of NO generation, but generated less 
pro-inflammatory cytokines following ex vivo stimulation. Generation of DC revealed that 
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D6 KO BM-derived DC were characterised by more rapid and higher expression of CD 11 c, 
as well as of the CC-chemokine receptors, CCR2 and CCR5. These differences did not alter 
the capacity of D6 KO BM-DC to upregulate costimulatory molecules in response to LPS-
activation, and KO DC were equally efficient at endocytosis compared with WT DC. 
However, D6 KO DC were poorer in their capacity to generate mixed leukocyte reactions 
compared with WT DC and KO DC also demonstrated higher production of TN Fa, VEGF 
and a number of inflammatory CC-chemokines in response to LPS. Overall, these data 
suggest that the D6 chemokine receptor may influence the development and function of 
myeloid lineage cells. 
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Cellular Composition of Resting D6 KO Peritoneum 
Cells were obtained from the peritoneal cavity of WT and D6 KO mice by 
lavage and the relative proportions ofCD11c+, F4/80+, CD4+, CD8+ and 
B220+ cells were determined by flow cytometry. Figure A represents the total 
number of cells retrieved from the peritoneum and figure B shows the relative 
proportions of the different cell populations in peritoneal exudates. The data 
are means + 1 SD for 3 animals per group. Similar results were obtained from 
three individual experiments. 
* p < 0.05 
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Cellular Composition of Resting D6 KO Peritoneum 
Figure A shows the relative proportions ofF4/80-lo and F4/80-high cell subsets 
in peritoneal exudate cells of WT and D6 KO mice, as determined by flow 
cytometry. Representative flow analyses from a WT (left) and D6 KO (right) 
mouse are shown in figure B. The data in (A) are the mean + 1 SD for 3 animals 
per group. Similar results were obtained from three individual experiments. 
* p < 0.05 
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Figure 4.3 
Induction of Peritoneal Inflammation by Injection of Thioglycollate 
The above figure represents the total number of cells retrieved from the peritoneal 
cavities ofWT and D6 KO mice at various times following intraperitoneal injection 
of 4% thioglycollate. The data represent the mean ± 1 SD for 3-4 animals per group. 
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Figure 4.4 
Induction of Peritoneal Inflammation by Thioglycollate Injection 
Cells were obtained from the peritoneal cavity ofWT and D6 KO mice by lavage at 
different times following injection ofthioglycollate and the relative proportions of 
F4/80+ cells, CDllc+ cells and Grl+ neutrophils determined by flow cytometry. 
Figures A, B, C and D show the composition of exudates obtained at 24, 48, 72 and 
96 hours, respectively. The data represent the mean + 1 SD for 3-4 animals per group 
and similar results were obtained from two or three individual experiments at each 
time point. 
* p < 0.05, ** p < 0.01, *** p < 0.001, NS = not significant 
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Figure 4.5 
Effects of Thioglycollate on F4/80 Expression by Peritoneal Exudate Cells 
Cells were obtained from the peritoneal cavity ofWT and D6 KO mice by lavage 
at different times after injection ofthioglycollate and the expression ofF4/80 
determined by flow cytometry. Figures A, B, C and D show the percentages of 
F4/80hi and F4/801o obtained at 24, 48, 72 and 96 hours, respectively. The data 
represent the mean + 1 SD for 3-4 animals per group and similar results were 
obtained from two or three individual experiments at each time point. 
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Figure 4.6 
Relative Proportions of CDllc+MHCII+ Cells in Peritoneum Following 
Injection of Thioglycollate 
Cells were obtained from the peritoneal cavity of WT and D6 KO mice by lavage 
at different times after injection ofthioglycollate and the relative proportions of 
CDllc+MHCll+ cells determined by flow cytometry. Figures A, B, C and D show 
the percentages ofCD11c+MHCII+ cells obtained at 24, 48, 72 and 96 hours, 
respectively. The data represent the mean + 1 SD for 3-4 animals per group and 
similar results were obtained from two or three individual experiments at each 
time point. 
* p<O.05, ** p<O.OI 
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Figure 4.7 
Subsets of CDllc+ and F4/80+ Cells in Exudates From Thioglycollate 
Challenged Peritoneum 
Cells were obtained from the peritoneal cavity ofthioglycollate-injected WT 
and D6 KO mice by lavage and the relative proportions of F4/80+CD II c-, 
F4/80+CDllc+, F4/S0-CDllc+ and F4/S0-CDllc- cells determined by 
flow cytometry. Figures A, B, C and D show the proportions of each subset 
retrieved at 24,48. 72 and 96 hours. respectively, following thioglycollate 
injection. The data represent the mean + 1 SD of 3-4 animals per group. Also 
shown are representative F ACS plots from a thioglycollate-challenged WT 
mouse (centre) and D6 KO mouse (right) at each time point. Similar results 
were obtained from two or three individual experiments at each time point. 
* p < 0.05, ** P < 0.01, *** P < 0.001, NS = not significant 
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Figure 4.8 
Phenotypic Characterisation ofCDllc+ and F4/80+ Cells in 
Thioglycollate Induced Peritoneal Exudates 
Cells were obtained from the peritoneal cavity of thioglycollate-injected 
WT and 06 KO mice by lavage and the relative proportions of 
COlI c-F4/80-, F4/80int COlIcin" F4/80int COli chi, F4/80int CD II c- and 
F4/80-CDllc+ subsets determined by flow cytometry. (A) Representation 
of the different subsets in one WT animal (left) and one 06 KO animal 
(right) 96h post thioglycollate injection. Figures B. C, D. E and F show the 
proportions ofCOllc-F4/80-, F4/80intCOllcint, F4/80intCDllchi, F4/80int 
COllc- and F4/80-C01Ic+, respectively, at 24, 48, 72 and 96 hours 
following thioglycollate injection. The data represent 3-4 animals per group 
and are presented as the means + SO. Similar results were obtained from at 
least two individual experiments at each time point. 
• p < 0.05, .. p < 0.01, ... p < 0.001 
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Morphological Features of F4/80+ and CDllc+ Subsets Obtained from 
Thioglycollate Inflamed Peritoneum 
The F ACS plots above show the Forward Scatter and Side Scatter properties of the 
F4/S0-CDllc subsets identified in Fig. 4.8 in the peritoneum of a thioglycollate 
challenged D6 KO animal at 96h post injection. 
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(A) The proportions of resting F4/S0int-CDllc-, F4/S0int-CDllc+ and 
F4/S0-CDllc+ subsets were determined in the resting peritoneum ofunmanipulated 
WT and D6 KO animals. The data are the mean + 1 SD of 3 mice per group. (B) 
Representative F ACS plots from an unchallenged WI (left) and KO mouse (right). 
146 
1 
-
"0 
i 
s 
·c 
-Z 
Figure 4.11 
t:::lWT 
_KO 
Nitric Oxide Production By Thioglycollate-Induced Peritoneal Exudate Cells 
Cells were obtained from the peritoneal cavity of thioglycollate-injected WT and D6 
KO mice by lavage at 6h, 48h and 96h and stimulated with 1 !-lglml LPS and 25 Vlml 
IFNy for 48h. NO generation was assessed by measuring nitrite levels in culture 
supernatants using the Griess reaction. The data represent the mean + 1 SD for 3-4 
animals per group. 
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Figure 4.12 
Cytokine Production By Thioglycollate-Induced Peritoneal Exudate Cells 
Cells were obtained from the peritoneal cavity ofthioglycollate-injected WT and 
D6 KO mice by lavage at 96h and stimulated with 1 fAg/ml LPS and 2SU/mi IFNy 
in complete medium for 24h. The levels of (A) IL-2, (B) IL-4, (C) IL-l O,(D) 
IL-12 p401 p70, (E) IL-Ia, (F) IL-lP, (0) IL-6 and (H) TNFa were determined 
by Luminex analysis. The data represent the mean + 1 SD of 3 animals per group. 
* p < 0.05, ** p < 0.01 
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Figure 4.13 
Chemokine Production By Thioglycollate-Induced Peritoneal Exudate Cells 
Cells were obtained from the peritoneal cavity ofthioglycollate-injected WT and 
D6 KO mice by lavage at 96h and stimulated with 1 ~glml LPS and 2SU/mi IFNy 
for 24h. The levels of (A) CXCLI, (B) CXCL9, (C) CXCLIO,(D) CCL2, (E) 
CCL3, (F) CCL4 and (G) CCLS were determined by Luminex analysis. The data 
represent the mean + 1 SD of 3 animals per group. 
* p < 0.05 
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Peritoneal Levels of CCL2 Following Thioglycollate Challenge 
Peritoneal lavage fluid was obtained from WT and D6 KO animals at 24, 48, 72 
and 96h after injection of thioglycollate and CCL2 levels assayed by luminex. 
The data represent 3 animals per group and are presented as the mean ± SD. 
* p < 0.05 (96h WT vs KO) 
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Figure 4.15 
Expression of CCR2 and CCR5 by Resident F4/80+ Cells in Peritoneum 
Cells were obtained from the peritoneal cavity of unmanipulated WT and D6 
KO mice by lavage and the expression ofCCR2 and CCRS on F4/80+ cells was 
assessed. (A) The proportions ofF4/S0+ cells postive for chemokine receptor 
expression and (B) the MFI of CCR2 and CCRS on F4/S0+CCR2+ cells and 
F4/S0+CCRS+ cells are shown. The data represent the mean + 1 SD for 3 
animals per group. 
* p < 0.05 
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Figure 4.16 
Chemokine Receptor Expression By Thioglycollate-Induced Peritoneal 
Exudate Cells 
F4/80+ and CDllc+ cells obtained from the peritoneal cavity ofWT and D6 
KO mice at 24h post thioglycollate-injection were assessed by flow cytometry 
for the expression of (A, C) CCR2 or (8, D) CCR5. Figures A and 8 show the 
proportion of each subset positive for CCR2 or CCR5 expression, and figures C 
and D represent the MFI of the CCR2 or CCR5 positive cells. The data are the 
mean + 1 SD for 3 mice per group. 
* p < 0.05, ** p < 0.01 
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Figure 4.17 
Cbemokine Receptor Expression By Tbioglycollate-Induced Peritoneal 
Exudate Cells 
F4/80+ and CDllc+ cells obtained from the peritoneal cavity ofWT and D6 
KO mice at 96h post thioglycollate-injection were assessed by flow cytometry 
for the expression of (A, C) CCR2 or (B, D) CCR5. Figures A and B show the 
total percent of each subset positive for CCR2 or CCR5 expression, and figures 
C and D represent the MFI of the CCR2 or CCR5 positive cells. The data are the 
mean + 1 SD for 3 mice per group. 
* p < 0.05 
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Development of BM Derived DC in D6 KO and WT Mice 
BM cells from WT and D6 KO mice were cultured in GM-CSF for 7 days and 
harvested and cultured overnight in medium alone or in medium containing 1 ~g/ml 
of LPS and the expression of CD 11 c was determined by flow cytometry. The 
proportion (A) and MFI (B) ofCDllc+ cells is presented as the mean + 1 SD for 3 
animals per group. 
* p < 0.05 , ** p < 0.01 
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Activation of BM Derived D6 KO and WT DC by LPS 
coso 
MHCII 
BM cells from WT and D6 KO mice were cultured in GM-CSF for 7 days and 
harvested and cultured overnight in medium alone or in medium containing I I-tglml 
LPS. The expression of (A) CD40, (B) CD80, (C) CD86 and CD) class II MHC on 
CDllc+ cells was determined by flow cytometry. The data represent the mean MFI 
+ 1 SD of 3 animals per group. 
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Time Course of Development of 8M Derived DC in D6 KO and WT Mice 
BM cells from WT and D6 KO mice cultured in GM-eSF were harvested at 
days 4,6,8, 10 and 12 of culture and the expression ofeDIIc and F4/80 was 
determined by flow cytometry. The results shown are the mean proportion (A) 
and MFI (B) ofCDllc expression and the proportion ofF4/80 expression (e) 
+ 1 SD for 3 animals per group. 
* p < 0.05 
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Chemokine Receptor Expression By BM Derived DC From D6 KO and WT Mice 
BM cells from WT and D6 KO mice were cultured in GM-CSF for 7 days and the 
expression of CCR2, CCR5 and CXCR4 determined by flow cytometry. The results 
shown are the proportions of positive CD 11 c+ cells and are the means + 1 SD for 3 
animals per group. 
* p < 0.05 
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Chemokine Receptor Expression on BM Derived DC from D6 KO and WT Mice 
BM-derived DC from WT and 06 KO mice harvested after 7 days of culture in 
GM-CSF were cultured overnight in medium or medium containing 1 ""glml LPS and 
the expression of (A) CCR2 and (B) CCR5 determined by flow cytometry. The results 
shown are the mean proportions of chemokine receptor positive cells in the COl1c+ 
population + 1 SO for 3 animals per group. 
* p < 0.05 (med vs LPS), 
* * p < 0.005 (med vs LPS) 
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Endocytic Activity of BM Derived Dendritic Cells 
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Day 10 
BM cells from WT and D6 KO mice were cultured in GM-CSF for 4, 6, 8, 10 and 
12 days, and then harvested and cultured with 1 mg/ml FITC-dextran at 37°C for 20 -
60 minutes. The specific uptake of FITC-dextran (~MFI) was calculated by 
subtracting the MFI of controls cultured with FITC-dextran at 4°C from the MFI 
readings obtained from the 37°C FITC-dextran cultures. The data are the means + 1 
SD for 3 animals per group. 
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Antigen Presenting Cell Activity of BM Derived DC in MLR 
BM-derived DC from B6/129 WT and D6 KO mice were harvested after 7 (A, B) 
and 9 (C, D) days of culture in GM-CSF, pre-treated with mitomycin C and then 
cultured for 48h (A, C) or 72h (B, D) with BALB/c responder lymphocytes (T) at 
the ratios indicated. 3H_ TdR was added for the last 20 hours of culture and the 
results shown are the mean for 2 animals per group. 
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Cytokine Production by D6 KO and WT BM Derived DC 
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BM-derived DC from WT and D6 KO mice harvested after 7 days of culture in 
OM-CSF were cultured overnight in medium or mediwn containing 1 ~g/ml LPS. 
Levels of (A) IL-lu, (B) IL-lf3, (C) IL-6, (D) TNFu, (E) IL-4, (F) IL-IO, (0) IL-12 
p40/p70 and (H) VEOF in culture supernatants were determined by Luminex analysis. 
The data are the means + 1 SD for 3 animals per group. 
* p < 0.05 
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BM-derived DC from WT and D6 KO mice harvested after 7 days of culture in 
GM-CSF were cultured overnight in medium or medium containing 1 ~g/ml LPS. 
Levels of (A) CXCLl, (B) CXCL9, (C) CXCLlO, (D) CCL2, (E) CCL3, (F) CCL4 and 
(G) CCLS in culture supernatants were determined by Luminex analysis. The data are 
the means + 1 SD for 3 animals per group. 
* p < 0.05 
162 
Chapter 5 
The Intestinal Immune System of D6 KO Mice 
163 
Introduction 
It is possible that excessive chemokine accumulation in the intestine may drive chronic 
immunopathology. Increased levels of inflammatory-type CC-chemokines have been 
detected in the colonic mucosa of ulcerative colitis and Crohn's patients (313-315). 
Moreover, mice with deletion of CCR2 or CCR5 are protected from experimental colitis 
(301). Conversely, these receptors have also been reported to be essential for development 
oftolerance following antigen feeding (19,20,297). Therefore proper regulation of the CC-
chemokine family seems likely to be essential for homeostasis in intestinal tissue. 
Although 06 is expressed abundantly by human intestinal lymphatics (287), the functional 
consequence of this remained unexplored. I thus set out to determine a role for 06 in the 
control of intestinal immunity, by comparing both tolerogenic and inflammatory responses 
in the intestines of WT and 06 KO animals. To achieve these aims, I utilised a high dose 
model of oral tolerance and attempted to induce intestinal inflammation by treating mice 
with indomethacin or dextran sulphate sodium (OSS). 
5.1 Expression of D6 and D6 Ligands in the Murine Intestine 
Initially, it was important to establish the sites of 06 expression in murine intestine. RNA 
was isolated from stomach, small intestine, mesenteric lymph nodes and Peyer's patches of 
WT mice and assessed for presence of 06 mRNA using RT-PCR. As shown in Figure 5.1, 
06 mRNA was detected in stomach, jejunum, ileum, colon, MLN and PP, but not in 
duodenum. These data, whilst not quantitative, confirmed the presence of D6 in the mouse 
intestine. 
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5.2 Assessment of Oral Tolerance in D6 KO Mice 
CCR2 and CCR5 have been reported to be essential for high dose oral tolerance (19, 20, 
316), and since these receptors recognise several D6 ligands, I decided to examine whether 
the D6 chemokine receptor could influence this phenomenon. D6-deficient mice and 
control animals were fed either a single high dose of OV A (25mg) or saline, and seven days 
later, animals were challenged in the footpad with OVA /CF A. Tolerance induction was 
assessed by measurement of in vitro proliferation responses and cytokine production after 
restimulation of draining lymph node cells with OVA, and by examining the ability of 
animals to mount delayed-type hypersensitivity responses to OVA in vivo. Proliferation and 
in vivo responses were determined at two and three weeks following footpad challenge. 
respectively. 
As shown in Figure 5.2, both WT and KO animals fed OVA prior to OV AlCF A challenge 
showed reduced OVA-specific proliferation and IFNy production compared with saline 
controls. Responses of OVA-fed KO animals were comparable to those of the OVA-fed 
WT mice and there were also no differences between the control responses of both WT and 
KO mice (Figure 5.2). 
In both WT and KO groups, DTH responses were reduced in animals fed OVA when 
compared with saline-fed controls (Figure 5.3 A). OVA-fed mice also had reduced levels of 
circulating OVA-specific IgG antibody, of both IgG 1 and IgG2a classes. (Figures 5.3 B-O). 
Again, no differences were noted between the OTH and antibody responses in either saline 
or OVA fed KO and WT mice. Overall, these data indicated that the induction of oral 
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tolerance was normal in both D6 KO and WT animals, suggesting that oral tolerance 
induction is not dependent on the presence of the D6 chemokine receptor. 
Investigation of Intestinal Inflammation in D6 KO Mice 
Increased chemokine expression correlates with disease activity in IBD patients and a 
number of 06 ligands have been detected in the inflamed mucosa of mouse and man (302, 
317, 318). By modulating CC-chemokine availability, D6 may play a role in regulating 
intestinal inflammatory responses. To explore this idea, I attempted to induce intestinal 
inflammation in D6 KO mice by administration of indomethacin or dextran sulphate 
sodium (OSS). 
5.3 Indomethacin-Induced Enteritis 
Indomethacin is a non-steroidal anti-inflammatory drug (NSAIO) that can damage the GI 
tract of humans and rodents, leading to mucosal erosions and ulceration secondary to 
inhibition of the normally protective effect of prostaglandins on the epithelial barrier (319-
324). WT and D6 KO mice received daily i.p. injections of indomethacin for two weeks, 
following which, sections of duodenum, jejunum, ileum and colon were assessed by 
microdissection for villus length, crypt length and mitotic activity. Control samples from 
PBS-challenged mice were also included. 
As shown in Figure SA, there were no significant differences between WT and KO control 
mice in any of the parameters of intestinal morphology in any part of the intestine. These 
results suggested that no overt abnormalities in intestinal architecture arise as a result of 
D6-deficiency. Unfortunately, administration of indomethacin mice did not induce any 
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signs of damage in any part of the intestine, with villus lengths, crypt lengths and mitotic 
activity being similar to those in the same parts of the intestine in appropriate controls 
groups (Fig 5.4). There were also no differences between WT and KO mice given 
indomethacin. Thus WT and KO mice on the 129/86 background were not susceptible to 
this particular model of intestinal inflammation. 
5.4 Induction of OSS Colitis in 06 KO Mice 
As neither WT nor KO mice showed susceptibility to indomethacin-induced injury, I next 
adopted a model of chemically induced colitis to explore the role of D6 in intestinal 
inflammation in these animals. Administration of the sulphated polysaccharide dextran 
sulphate sodium (DSS) to mice in drinking water results in the development of severe 
colonic inflammation with some of the characteristics of human ulcerative colitis (303). 
Increased levels of several CC-chemokines have been detected in colonic tissue of patients 
with inflammatory bowel disease (180) and animals deficient for CCR2 or CCR5 are 
reportedly resistant to OSS-mediated colitis ((325),(313 ),(318),(301)). I therefore predicted 
that 06 KO animals might show increased susceptibility to colitis following addition of 
DSS to their drinking water. 
As anticipated, wild type mice given 2% DSS in the drinking water developed colitis, with 
most mice displaying clinical symptoms of diarrhoea and rectal bleeding (Figures 5.5 and 
5.7 A). Moreover, OSS-treated WT mice demonstrated marked weight loss and most mice 
were moribund by day 7 (Figure 5.6 A). When these mice were sacrificed on day 8, they 
had significantly shorter colons than controls. (Fig 5.7 B) 
167 
Unexpectedly, the D6 KO recipients of DSS appeared to be less susceptible to the 
development of colitis compared with their WT counterparts (Figures 5.6 and 5.7). 
Diarrhoea and rectal bleeding became evident later and the clinical scores were 
significantly lower in D6 KO mice at all times (Figure 5.7 A). 06 KO animals also had 
significantly less weight loss than WT mice and more KO mice survived the duration of the 
experiment (Figures 5.6 A and B). Additionally, there was significantly less colonic 
shortening in D6 KO animals (Fig 5.7 B). Histological examination confirmed these results, 
as although both groups demonstrated colonic pathology and inflammation, pathology was 
significantly reduced in D6 KO mice, as determined by scoring of mucosal damage and 
inflammation (Figures 5.7 e and 5.8). Throughout the course of the experiment, water 
consumption was equivalent in both WT and KO groups, indicating that the reduced 
disease observed in the 06 KO mice was not a result of decreased DSS intake (Fig 5.6 C). 
Repeated experiments, using either 2% or 2.5% gave similar results, although in some cases 
the differences observed between WT and D6 KO mice were less marked (Figures 5.6, 5.13 
and 5.19). Taken together however, my data demonstrated that the absence of D6 appeared 
to ameliorate disease in this model of colitis. 
5.5 Characterisation of Lamina Propria Infiltrates In Colitic Mice 
The increased resistance of eeR2 and eCR5 KO mice to colitis development is associated 
with an altered mucosal infiltrate (301). I therefore set out to determine if differential cell 
recruitment, possibly resulting from an altered chemokine environment, might account for 
the reduced severity of colitis in D6 KO animals. Lamina propria cells were obtained from 
control and inflamed colons of both WT and KO mice by collagenase digestion, and the 
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relative proportions of CD4 T cells, CD8 T cells, B cells, neutrophils, macrophages and 
dendritic cells detennined by flow cytometric analysis. 
As shown in Figure 5.9 A, the total number of leukocytes retrieved from the colons of 
colitic mice increased markedly between days 2 and 7 after induction of disease. However, 
there were no significant differences between the total number of cells isolated from WT 
and KO mice at either time point following DSS administration (Fig 5.9 A). Phenotypic 
analysis of WT and KO LP cells from colitic mice revealed that, in both cases, F4/80+ 
macrophages were the predominant cell type, with dramatic increases between days 2 and 7 
of disease (Fig 5.9 B). There were also significantly increased numbers of Ly6G+ 
neutrophils, T-cells and B-cells in the inflamed colon compared with controls (Fig 5.9 B). 
There were no statistically significant differences between the numbers of any of these 
populations in the lamina propria of WT and D6 KO mice at either day 2 or day 7. 
5.6 Chemokine Receptor Expression by Lamina Propria Infiltrate Cells 
I next assessed whether the inflammatory infiltrates of WT and KO mice might differ in 
tenns of chemokine receptor expression, by analysing the expression of two functional 
receptors for D6 ligands, CCR2 and CCRS. As shown in Figure 5.10, the infiltrates of d7 
colitic mice contained higher proportions of CCR2+ and CCR5+ cells compared with day 2 
infiltrates. There were increases in the proportions of F4/80-negative CCR5+ cells in KO 
infiltrates compared with WT infiltrates, at both day 2 (4.5% ± 3.3 WT vs. 8.5% ± 4.2 KO, 
mean ± SD) and day 7 (10.2% ± 6.6 WT vs. 39.3 ± 24.9 KO), although these were not 
statistically significant. 
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To identify the particular cell subset responsible for the increased CCR5 positivity in KO 
cells, I next compared expression of CCR2 and CCR5 by CD4+, CD8+, B220+, F4/80+, 
COlle and Ly6G+ cells from day 7 colitic mice. As shown in Figure 5.11 A, around half 
of all CD4+ cells from WT and KO colons expressed CCR2 or CCR5. Most CD8+ cells 
from both WT and KO colitic colons expressed CCR2 and CCR5 (Figure 5.11 B), and there 
were slightly higher proportions of CCR2+ and CCR5+ cells among the CD8+ cells from 
KO mice compared with WT (74.6 ± 6.7 vs. 64.4 ± 8.5) and (92.4 ± 3.6 vs. 82.4 ± 5.1), 
respectively, although the differences were not statistically significant. 
Conversely, analysis of F4/80+, COllc+, and Ly6G+ populations revealed higher 
expression of CCR2 and CCRS by WT cells compared with KO cells (Figures 5.11 C-E). 
As seen in Figure S.ll C, many F4/80+ cells from WT and 06 KO colons stained positive 
for CCR2, but significantly fewer KO F4/80+ cells were CCR2+ compared with WT 
F4/80+ cells (80.5% ± 7.9 vs. 62.6% ± 2.3). Less than half as many 06 KO F4/80+ cells 
expressed CCR5 compared with WT F4/80+ cells (56.9% ± 29.6 vs. 22.2% ± 5.8), although 
this difference was not statistically significant (Figure 5.11 A). Similarly, a consistently 
reduced proportion of CO 11 c+ lamina propria cells from colitic KO mice expressed CCR2 
and CCRS compared with their WT counterparts, although only the differences in CCR2 
expression were statistically significant. Most Ly6G+ neutrophils from colitic mice were 
found to express CCR2, but again, fewer KO Ly6G+ cells were positive for this receptor, 
as well as for CCRS compared with the WT Ly6G+ fraction, although these differences 
were not significant. 
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As shown in Figures 5.l2A and B, almost all B220+ cells, from both WT and KO colon, 
expressed CCR2 (95.2% :t: 0.5 cf. 95.8% :t: 1.5, respectively). However, analysis of CCRS 
expression by B220+ cells revealed a dramatic and significant increase in the expression of 
this receptor by KO B cells compared with WT B cells (Figure 5.12 A and C). Whilst less 
than half of B220+ cells from the colons of colitic WT mice expressed CCRS, almost all 
B220+ cells from KO animals were CCRS positive. Analysis of LP cells from resting 
colons revealed that this phenotype was not specific to colitis, as B220+ cells isolated from 
untreated KO animals also showed increased expression of CCRS compared with WT 
controls. These findings are explored in more depth in Chapter 6. 
In summary, although WT and KO mice appeared to have similar overall proportions of T 
cells, B cells, macrophages and neutrophils in the DSS-subjected colon, the populations 
appeared to differ in tenns of chemokine receptor expression, suggesting existence of more 
subtle differences between WI and KO colitic infiltrates. 
5.7 Analysis of Cytokine Response to DSS 
My studies so far had revealed altered chemokine receptor profiles of WT and D6 KO 
lamina propria cells retrieved from colitic mice. I next set out to determine whether the 
milder disease in D6 KO mice was associated with a different pattern of inflammatory 
cytokine production. Using Luminex technology, I measured the levels of multiple 
cytokines and chemokines in supernatants of colon explants taken from control and colitic 
mice. This was done at days 3 and 6 following DSS administration, when the experiment 
had to be terminated due to severe disease in the WT mice (Figure 5.13). 
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Consistent with previous studies (326), I found that the colons of colitic mice released 
significant quantities of the pro-inflammatory cytokines IL-Ia, IL-Ij3, IL-6 and TNFa. 
These cytokines were not released, or released only in very low quantities by control 
colons, but were detectable after 3 days of DSS treatment and were present at high levels in 
d6 DSS colon cultures (Figure 5.14). Supernatants from the colons of DSS-treated mice 
also contained increased levels ofIL-2, IL-12 (p40/p70), IL-13, IL-17 and IFNy (Figure 
5.15) as well as of the chemokines CXCL I, CXCL9, CCL2, CCL3, CCL4 and CCL5 
(Figure 5.16) and the growth factors GM-CSF, FGF and VEG-F (Figure 5.17). 
There were significantly elevated levels of TNFa, IFNy and IL-17 in day 6 DSS KO 
cultures compared with WT cultures (Figures 5.14 0, 5.15 0 and 5.15 E, respectively) and 
the higher levels of IFNy and IL-17 correlated with reduced weight loss (Figure 5.18 A and 
B). A similar trend was seen for TNFa and weight loss although this was not statistically 
significant (Figure 5.18 C). These results suggested that the increased resistance to DSS-
induced colitis in 06 KO mice was associated with higher production of the pro-
inflammatory cytokines IFNy, TNFa and IL-17. No statistically significant differences 
were seen in the levels of the other mediators between WT and KO supernatants in either 
baseline, day 3 DSS or day 6 DSS cultures (Figures 5.14, 5.15, 5.17). 
As IL-23 has been reported to drive the development of IL-17 producing effector T cells 
(327), I examined the levels oflL-23 in WT and KO colon cultures by ELISA. As shown in 
Figure 5.15 F, substantial quantities of IL-23 were detected in supernatants of control 
colons from untreated WT and KO mice as well as in d3 DSS colons. However, the levels 
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of IL-23 then fell markedly on d6 of colitis and there were no differences between WT and 
KO colon cultures in terms ofIL-23 production. 
Following these initial findings, I carried out a repeat experiment to attempt to confirm the 
different pattern of cytokine production. On this occasion, I included an additional group 
that were given DSS for 3 days and then returned to water for 8 days, as I wished to 
compare the recovery response ofD6 WT and KO animals. Under these conditions, 06 KO 
mice were again generally less susceptible than WT mice to colitis (Figure 5.19 A), 
although this effect was not as great as had previously been observed (Figures 5.6 and 
5.13). 
The 3 days DSS/ 8 days water group suggested some differences between WT and KO 
mice in their ability to recover from DSS-mediated intestinal damage (Figure 5.19 B). Out 
of 6 WT mice subjected to this protocol, one mouse died on day 6 and the other WT mice 
demonstrated maximum weight loss at days 6 and 7. However, by days 7 and 8, these mice 
began to recover weight and by the end of the experiment had virtually all returned to their 
original body weight. 
In the D6 KO group, 3 out of 6 mice demonstrated no significant weight loss throughout 
the duration of the experiment. One mouse showed signs of weight loss by day 5 but 
recovered weight thereafter to reach its original body weight by the end of the experiment. 
The remaining two KO mice showed signs of weight loss by day 5 and unlike their WT 
counterparts, these animals continued to lose weight until the end of the experiment on day 
11. Whilst the group sizes were relatively small, these data suggested that although 06 KO 
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mice may be less susceptible to induction of DSS-colitis, once ill, these animals might 
show poorer recovery from DSS-mediated damage compared with their WT counterparts. 
Supernatants were collected from d3 and d7 colon cultures (normal DSS protocol) and from 
dll (DSS recovery protocol) colon cultures and, as before, analysed by Luminex for 
cytokine and chemokine levels. In agreement with my initial findings, DSS treatment led to 
high levels ofIL-l a, IL-l~, IL-6 and TNFa in d7 DSS colon cultures, as well as IL-2, IL-
12 (p40/p70), IL-l3, IL-I7, IFNy, CXCLl, CXCL9, CCL2, CCL3, CCL4, CCLS and the 
growth factors GM-CSF, FGF and VEG-F (Figures 5.20 - 5.23). The levels of cytokines 
and chemokines were comparable in the two experiments. 
However, in contrast to my earlier analysis, there were no significant differences in the 
levels of any of the mediators secreted from the colon explants by WT and KO mice on day 
7. Specifically, although I had previously detected significantly higher IFNy, IL-17 and 
TNFa levels in D6 KO colon cultures taken on d6 compared with WT, the levels of all 
these cytokines were comparable in WT and KO cultures in this second experiment 
(Figures 5.21 E and F and 5.20 D). 
It was possible that the failure to detect differences in these colon cultures was due to the 
greater variability between disease in WT and KO mice in this particular DSS experiment. 
In the initial cytokine analysis experiment all WT mice had developed severe disease and 
extensive weight loss in response to DSS, while KO animals showed only minimal weight 
loss and few clinical symptoms. On the other hand, in my repeat experiment some of the 
WT mice remained relatively healthy following DSS treatment, while some of the D6 KO 
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mice developed more severe colitis (Fig. 5.19). Therefore I decided to pool the luminex 
results from all colitic mice and compare cytokine production with disease activity, using 
body weight as an indicator ofthe latter. 
These analyses revealed statistically significant inverse correlations between the levels of 
IL-17, IFNy and IL-12 (p40/p70) in colon cultures and weight loss, with the highest levels 
of these cytokines being present in the mice that showed the least weight loss following 
DSS administration (Figures 5.24 A - C). A similar trend was seen with TNF production, 
although this did not achieve statistical significance (Figure 5.25 D). On the other hand, the 
levels of GM-CSF showed a significant positive correlation with weight loss, as did IL-6 
production, although again this was not statistically significant (Figure 5.24 D). There was 
no association between weight loss and IL-llevels in colon cultures (Figure 5.25 A and B), 
or with weight loss and the levels oflL-2, IL-13, IL-23, FGF and VEGF (data not shown). 
When chemokine levels were analysed in this way, higher CXCLI correlated significantly 
with weight loss (Figure 5.26 A) and similar but non-significant trends were found between 
the CC-chemokines CCL2. CCL3. CCL4 and CCL5and weight loss (Figures 5.26 C - F). 
There was no correlation between CXCL9leveis and weight loss (Figure 5.26 B). 
In summary. my data from the cytokine analysis revealed that higher secretion of the pro-
inflammatory cytokines IL-17, IFNy and IL-12 (p40/p70) was associated with less weight 
loss in response to acute DSS-colitis and provided some preliminary evidence that the 
increased resistance demonstrated by D6 KO animals might be associated with an increased 
ability to generate these cytokines. 
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5.8 Intracellular Cytokine Analysis of LP Infiltrate 
To extend these findings regarding IFNy and IL-17 levels in colon cultures, I next 
attempted to analyse intracellular production of these cytokines by colonic LP cells. Cells 
isolated from the lamina propria of day 7 colitic WT and KO mice were cultured with 
ionomycin, PMA and Brefeldin A, and following permeabilisation and staining with 
fluorescently-conjugated antibodies, they were assessed by flow cytometry for presence of 
intracellular IFNy or IL-17. As shown in Figure 5.27, only a small percentage of colonic LP 
cells stained positively for intracellular IL-17 and no difference was found between WT 
and KO samples. A higher proportion of LP cells were found to stain positive for IFNy 
expression, but again there were no differences between WT and KO samples. 
5.9 Assessment of Colonic Epithelial Cell Turnover 
My cytokine analyses had demonstrated a trend for increased production of certain 
inflammatory type cytokines, most notably IL-17 and IFNy, in the colons of mice which 
were relatively resistant to DSS colitis. However, it was still unclear if or why this altered 
cytokine environment reduced susceptibility to DSS. Although the exact mechanism by 
which DSS invokes experimental colitis has not been defined, it is thought to be directly 
toxic to intestinal epithelial cells, with the inflammatory response developing secondary to 
a loss of barrier function (304, 305). Therefore, one possible explanation for my findings 
could be that the epithelium ofD6 KO mice was inherently less susceptible to DSS-induced 
damage, or repaired more efficiently. I therefore compared epithelial cell turnover in WT 
and D6 KO mice by analysing the incorporation of bromodeoxyuridine (BrdU) over a 
period of 24 hours. This was assessed in untreated mice, mice that had received DSS for 3 
days, mice that had received DSS for 5 days followed by water for 2 days, and mice that 
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had received OSS for 3 days and water for 8 days. The latter group was included to 
examine the recovery phase from colitis. 
As previously reported (328-330), OSS administration for 3 days resulted in a marked 
reduction of dividing cells in the colonic crypts of WT mice (Figures 5.28 and 5.29). 
Recovery was evident, although variable, in WT animals by day 7 and the rates of BrdU 
incorporation had returned to normal by day 11 despite evidence of continuing severe 
architectural damage. 06 KO mice showed significantly lower epithelial cell turnover than 
WT mice under resting conditions and only a small further reduction on day 3, which was 
not statistically significant. Rates of epithelial turnover remained low in 06 KO animals at 
day 7, but higher epithelial proliferation, comparable to that observed in WT controls, was 
evident in KO colons by day 11. 
Overall, these data suggest that the absence of 06 can lead to aberrant epithelial turnover in 
the large intestine. Since OSS can be directly toxic to dividing epithelium, a reduced 
baseline rate of epithelial proliferation might lessen the negative impact of OSS 
administration (331). Therefore lower turnover of the epithelium in the resting 06 KO 
colon might account for the reduced susceptibility of these animals to OSS-induced 
damage. 
Summary 
In this chapter, I explored the function of the 06-chemokine receptor in both tolerogenic 
and inflammatory intestinal responses. 06 and at least 7 of its ligands were expressed in the 
normal murine intestine, but the absence of D6 did not affect the induction of oral 
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tolerance. Somewhat unexpectedly, 06 KO mice demonstrated increased resistance to acute 
colitis induction following oral administration of OSS. Whilst no differences were detected 
between WT and 06 KO mice in the recruitment of various leukocyte populations to the 
inflamed colon, cellular infiltrates of WT and KO animals were found to differ in terms of 
CC-chemokine receptor expression. Reduced susceptibility to acute-OSS colitis was found 
to correlate with increased ex vivo secretion of several inflammatory cytokines, most 
notably IL-I7 and IFNy, by cultured explanted colons. Additionally, there were significant 
differences between the proliferation of epithelial cells in resting colonic tissue of D6 KO 
mice compared to WI mice. If confirmed, these data suggest that alterations in 
inflammatory-cytokine production and innate barrier function may account for the 
increased resistance of 06 KO animals to DSS-induced colitis. 
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Figure 5.1 
D6 mRNA Expression In Intestinal Tract 
RNA was isolated from stomach, colon, ileum, jejunum, duodenum, MLN and PP 
of 129/B6 WT mice and the presence of 06 mRNA determined by RT-PCR in the 
presence (+) or absence (-) of reverse transcriptase(RT). Mouse genomic DNA 
(gDNA) was also analysed by RT -PCR as a positive control. 
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Figure 5.2 
Induction of Oral Tolerance in D6 KO and WT Mice 
WT and 06 KO mice were fed 25mg OV A or saline alone and seven days later 
were immunised in the footpad with OV AfCFA. Two weeks later, the popliteal 
lymph nodes draining the site of immunisation were harvested and 2 x 105 LN 
cells stimulated with 1 mglml OVA in complete medium for 120 hours. 
Antigen-specific proliferation responses were determined after 120 hr by 
3H_ Tdr incorporation (A) and the levels of IFNy in culture supernatants were 
measured by ELISA after 48h (B). The data represent the means + 1 SO for 
3-4 mice per group. 
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Figure 5.3 
Assessment of Oral Tolerante Indudion in D6 KOs 
WT and D6 KO mice were fed 25mg OV A or saline alone and seven days later 
were immunised in the footpad with OV AlCF A. Two weeks later, mice were 
challenged in the opposite footpad with heat-aggregated OVA and their ability to 
mount DTH responses assessed by the increase in footpad thickness 24 hr later 
(A). The levels of OVA-specific IgG (B), IgG 1 (C) and IgG2a (D) antibodies were 
assessed in serum by ELISA. The data are the means + 1 SD for 5 animals per 
group. 
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Intestinal Architecture in Indomethacin Treated Mice 
WT and D6 KO mice received daily i.p. injections of2.5 mglkg indomethacin for 
14 days and sections of duodenum, jejunum, ileum and colon were assessed by 
microdissection for (A) villus length, (B) crypt length and (C) mitotic activity. 
The data shown are the means + 1 SD for 3 animals per group (indomethacin 
treated). Control samples from 1 PBS fed WT and KO are also shown. 
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Figure 5.5 
Clinical Disease In DSS Colitis 
WT mice that received 2% DSS in their drinking water typically showed 
clinical symptoms of colitis, namely diarrhoea (A) and rectal bleeding (B), 
by day 4. The development of clinical symptoms of colitis was delayed in 
DSS-treated D6 KO mice and, overall, diarrhoea and rectal bleeding were 
less pronounced in D6 KO mice compared to their WT counterparts. 
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Induction of DSS Colitis in D6 KO and WT Mice 
H~---.~ 
WT and D6 KO mice received 2% DSS in their drinking water for 5 days and normal 
water thereafter. Body weight (A), survival (B) and water intake (C) were assessed 
daily. The data in (A) are the means ± 1 SEM for 13 animals per group. The data in 
(B) and (C) represent the means for 13 mice per group . 
*** p < 0.001 
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Figure 5.7 
Induction of DSS Colitis in D6 KO and WT Mice 
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WT and D6 KO mice received 2% DSS in their drinking water for 5 days and normal 
water thereafter. Clinical disease (A) was assessed daily by monitoring diarrhoea 
(score of 0-2) rectal bleeding (score of 0-2) and general appearance (score of 0-2) . 
After 8 days, colons were excised, their lengths were recorded (B) and the tissues 
were fixed in 10% formalin, embedded in paraffin and stained with haemtoxylin and 
eosin for histological scoring (C). Scoring was performed in a blinded fashion using 
a combined score of inflammatory cell inflltration (0-5) and tissue pathology (0-5) 
The data are the mean + 1 SD for 13 animals per group (A,B) and for 4-8 animals per 
group (C). 
* p < 0.05, *** P < 0.001 
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Figure 5.8 
Histology of Colons from DSS-treated WT and D6 KO Mice 
WT and D6 KO mice received 2% DSS in their drinking water for 5 days 
and normal water thereafter (see Fig. 5.7). Control mice received water 
alone. At day 8, excised colons were fixed in 10% fonnalin, embedded in 
paraffin and stained with haematoxylin and eosin for histological analysis . 
Shown above are representative histology from WT and D6 KO control 
mice (A and B) and from DSS-treated WT and D6 KO mice (C and D). 
The epithelium of the DSS-treated WT mouse (C) is characterised by 
complete ulceration and crypt loss. By contrast, the pathology observed in 
the D6 KO colonic epithelium (D) is less severe, although crypt 
hyperplasia, goblet cell loss and inflammatory cell infiltration are evident 
and indicate DSS-induced damage. Magnification x 200. 
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Lamina Propria Infiltrates During DSS Colitis in D6 KO and WT Mice 
WI and D6 KO mice received 2% DSS in their drinking water for 5 days and normal 
water thereafter. At days 2 and 7, lamina propria cells were isolated, total cell 
counts determined (A) and the proportions ofF4/80+, CDllc+, CD4+, CD8+, 
B220+ and Ly6G+ cells assessed by flow cytometry (B). The results are the means 
+ 1 SD for 3 mice per group. 
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Chemokine Receptor Expression By Lamina Propria Cells in DSS Colitis 
WI and D6 KO mice received 2% DSS in the drinking water for 5 days and 
normal water thereafter. At days 2 and 7 (A and B, respectively) lamina propria 
cells were isolated and the expression ofF4/80, CCR2 and CCR5 assessed by 
flow cytometry. The data are the means + 1 SD for 3 mice per group. 
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Figure 5.11 
Chemokine Receptor Expression By Colonic Lamina Propria Infiltrates of 
DSS Colitic Mice 
WT and D6 KO mice received 2% DSS in their drinking water for 5 days and normal 
water thereafter. Colonic lamina propria cells were isolated on day 7 and the 
expression ofCCR2 and CCR5 by (A) CD4+, (B) CD8+, (C) F4/80+, (D) CDl1c+ 
and (E) Ly6G+ cell populations was assessed by flow cytometry. Data are presented 
as means + 1 SD for 3 mice per group. 
* p < 0.005, ** P < 0.001 
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Figure 5.12 
Chemokine Receptor Expression By Colonic Lamina Propria B cells during 
DSS Colitis 
WT and D6 KO mice received 2% DSS in their drinking water for 5 days and normal 
water thereafter. Colonic lamina propria cells were isolated on day 7 and the 
expression of CCR2 and CCR5 on B220+ B cells was assessed by flow cytometry . 
(A) The mean proportions + 1 SD of chemokine receptor expressing B ceUs for 3 
mice per group. (B, C) Representative FACS plots ofCCR2 (B) and CCR5 (C) 
expression by WT (left) and KO (right) B220+ lamina propria B cells. 
*** p < 0.0001 
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Figure 5.13 
Induction of DSS Colitis in D6 KO Mice 
WT and D6 KO mice (n = 10) received 2% DSS in their drinking water for 5 days 
and normal water thereafter. Body weight (A) and clinical disease (B) were 
monitored daily and are presented as the means ± 1 SEM (A) and as the means + 1 
SD (B) for 5-10 mice. On days 3 and 6, five mice from each group were culled and 
whole colon lengths measured (C) . 
** p < 0.01 , *** p< 0.001 
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Figure 5.14 
Production of Cytokines by Colon Explants from D6 KO and WT Mice with 
DSS Colitis 
WT and D6 KO mice received 2% DSS in the drinking water for 5 days and normal 
water thereafter. Control mice received normal drinking water for the duration of 
the experiment. At days 3 and 7, individual explants of colon were cultured for 24 
hours and the levels of (A) IL-la, (B) IL-l~, (C) IL-6 and (D) TNFa in culture 
supernatants were determined by Luminex analysis. 
* p < 0.05 
192 
A IL-2 B IL-12p40/p70 
a 
• • • 
• • • • • • 
i 4 -L.. ..-- • • • 
•• 
--2 
•• • •• • 
--
• 
•• -;e 0 
WTctrt KO ctrI WTdS KOdS WTdt KOdt WTctrt KO ctrt WTdS KOdS WTdt KOdt 
C IL-13 0 IL-17 
** 13 
• 
10 I i 7 • i • -.--
• 4 
• • • .-... 
• • 
-.- 0 
WTctrt KOctrl WTdS KOdl WTdt KOdt WTctrt KOctrt WTdS KOdS WTd' KOdi 
E F 
IFNy 
*** 
IL-23 
80 800 
• ~ 40 4- 800 • I i • 
---• .!a.... ... 20 300 • • • -.- • • 
• • ~ • ~ 
WTctrt KOctrt WTdS KOdS WTdt KOdt WTolI1 KOoll1 d3 KOd3 WTd. KOdi 
Figure 5.15 
Production of Cytokines by Colon Explants from D6 KO and WT Mice with 
DSS Colitis 
WI and D6 KO mice received 2% DSS in the drinking water for 5 days and 
normal water thereafter. Control mice received normal drinking water for the 
duration of the experiment. At days 3 and 7, explants of colon were cultured for 
24 hours and the levels of (A) IL-2, (8) IL-12, (C) IL-13, (D) IL-17 and (E) IFNy 
in culture supernatants were determined by Luminex analysis. Levels of IL-23 (F) 
were assessed by ELISA. 
** p < 0.01, .. p < 0.001 
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Figure 5.16 
Production of Chemokines by Colon Explants from D6 KO and WT Mice 
with DSS Colitis 
WT and 06 KO mice received 2% OSS in the drinking water for 5 days and 
normal water thereafter. Control mice received normal drinking water for the 
duration of the experiment. At days 3 and 7. explants of colon were cultured for 
24 hours and the levels of (A) CXCLI. (B) CXCL9, (C) CCL2, (D) CCL3, (E) 
CCL4 and (F) CCL5 in culture supernatants were determined by Luminex 
analysis. 
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Figure 5.17 
Production of Cytokines by Colon Explants from D6 KO and WT Mice with 
DSS Colitis 
WT and D6 KO mice received 2% DSS in the drinking water for 5 days and 
normal water thereafter. Control mice received normal drinking water for the 
duration of the experiment. At days 3 and 7, explants of colon were cultured for 
24 hours and the levels of (A) FGF, (B) GM-CSF and (C) VEGF in culture 
supernatants were determined by Luminex analysis. 
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Figure 5.18 
Correlation Between Colonic Cytokine Production and Weight Loss in Mice 
with DSS Colitis 
Linear regression analysis of weight loss and IFNy (A), IL-17 (B) and TNFa (C) 
production by day 7 colon explants from individual D6 KO and WT mice with DSS 
colitis (see Figure 5.14). 
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Figure 5.19 
Induction of Acute DSS Colitis and Recovery From DSS-Induced Injury in 
WT and D6 KO Mice 
WT and D6 KO mice received (A) 2% DS S in the drinking water for 5 days and 
normal water thereafter or (B) 2% DSS in the drinking water for 3 days only 
followed by normal water for 7 days to monitor recovery from DSS-induced injury. 
The data shown in A are the mean body weights + 1 SD for 9-10 animals per group . 
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Figure S.20 
Cytokine Release In Colon Cultures Of Colitic Mice 
WT and D6 KO mice received 2% DSS in the drinking water for 5 days and normal 
water thereafter (d3, d7) or 2% DSS in drinking water for 3 days only followed by 
normal water for 7 days to monitor recovery from DSS-induced injury (dll). 
Control mice received normal drinking water for the duration of the experiment. At 
days 3, 7 and 11 the levels of (A) IL-Ia, (B) IL-I~, (C) IL-6 and (D) TNFa in culture 
supernatants from colon explants were determined by Luminex analysis. 
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Figure 5.21 
Cytokine Release In Colon Cultures Of Colitic Mice 
WT and D6 KO mice received 2% DSS in their drinking water for 5 days and 
normal water thereafter (d3, d7) or 2% DSS in their drinking water for 3 days only 
followed by normal water for 7 days to monitor recovery from DSS-induced 
injury (dll). Control mice received normal drinking water for the duration of the 
experiment. At days 3, 7 and 11 the levels of (A) IL-2, (B) IL-I0, (C) IL-12 
p40/p70, (D) IL-13, (E) IL-17 and (F) IFNy in the culture supernatants were 
determined by Luminex analysis. 
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Figure 5.22 
Chemokine Release In Colon Cultures Of Colitic Mice 
WT and D6 KO mice received 2% DSS in drinking water for 5 days and 
normal water thereafter (d3, d7) or 2% DSS in drinking water for 3 days only 
followed by normal water for 7 days to monitor recovery from DSS-induced 
injury (dll). Control mice received normal drinking water for the duration of 
the experiment. At days 3, 7 and 11 the levels of (A) CXCL 1, (B) CXCL9, (C) 
CCL2, (D) CCL3, (E) CCL4 and (F) CeLS in culture supernatants were 
determined by Luminex analysis. 
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Figure 5.23 
Production of Cytokines by Colon Explants from D6 KO and WT Mice with 
DSS Colitis 
WT and D6 KO mice received 2% DSS in drinking water for 5 days and nonnal 
water thereafter (d3, d7) or 2% DSS in drinking water for 3 days only followed by 
normal water for 7 days to monitor recovery from DSS-induced injury (d}I). 
Control mice received nonnal drinking water for the duration of the experiment. At 
days 3, 7 and 11 the levels of (A) FGF, (8) GM-CSF, and (C) VEGF in culture 
supernatants from colon explants were detennined by Luminex analysis. 
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Figure 5.24 
Correlation Between Colonic Cytokine production and Weight Loss in Mice 
with DSS Colitis 
Linear regression analysis of weight loss and IL-17 (A), IFNg (B), IL-12 p40/p70 
(C), and GM-CSF CD) production by day 6 or 7 colon explants from all individual 
D6 KO and WT mice with DSS colitis examined in two separate experiments. 
* p< 0.05, .. P < 0.005, .. * p< 0.0005 
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Correlation Between Colonic Cytokine Production and Weight Loss in Mice 
with DSS Colitis 
Linear regression analysis of weight loss and IL-In (A), IL-Ij3 (B), IL-6 (C), and 
TNFn (D) production by day 6 or 7 colon explants from all individual D6 KO and 
WT mice with DSS colitis examined in two separate experiments. 
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Figure 5.26 
Correlation Between Colonic Chemokine Production and Weight Loss in 
Mice with DSS Colitis 
Linear regression analysis of weight loss and eXeLl (A), eXeL9 (B), eeL2 (e), 
eeL3 (D), eeL4 (E) and eeLS (F) production by day 6 or 7 colon explants from all 
individual D6 KO and WT mice with DSS colitis examined in two separate 
experiments. 
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Figure 5.27 
Intracellular Cytokine Production by Colonic Lamina Propria Cells 
WT and D6 KO mice received 2% DSS in the drinking water for 5 days and normal 
water therafter. On day 7, colonic lamina propria cells were isolated and cultured 
with ionomycin, PMA and Brefeldin A for 4-5 hr. The cells were then 
permeabilised and the presence of intracellular IFNy (A) and IL-17 (B) within cells 
lying in a lymphocyte gate were assessed by flow cytometry. Specific staining was 
calculated by subtracting isotype control values. 
205 
.. 
CD 
D. 
.!! 
Ci) 
0 
+ ;:) 
'E 
m 
** 
I 
*** 
I 
II 
Figure 5.28 
Proliferative Activity Of Colonic Epithelial Cells in D6 KO and WT Mice 
with Colitis 
WT and D6 KO mice received 2% DSS in the drinking water for 5 days and normal 
water thereafter, or 2% DSS in the drinking water for 3 days only followed by 
normal water for 7 days to monitor recovery from DSS-induced injury. Control mice 
received normal drinking water for the duration of the experiment. On days 3, 7 and 
11, mice that had been administered BrdU solution (50mglkg) by intraperitoneal 
injection 24h previously, were sacrificed, sections of colons were snap-frozen and 
the number of BrdU+ cells assessed by immunohistochemistry. The results shown 
are the mean numbers of BrdU+ cells per crypt + 1 SD for 3 animals per group (ctrl, 
d3 and d7) and the means of2 animals per group (dll). 
** p< 0.005, *** p< 0.0001 
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Figure 5.29 
Proliferative Activity Of Colonic Epithelial Cells in D6 KO and 
WT Mice with Colitis 
WT and D6 KO mice received 2% DSS in the drinking water for 5 days 
and normal water thereafter, or 2% DSS in the drinking water for 3 davs 
only followed by normal water for 7 days to monitor recovery from . 
DSS-induced injury. Control mice received normal drinking water for the 
duration of the experiment. On days 3, 7 and II, mice that had been 
administered BrdU solution (50mglkg) by intraperitoneal injection 24h 
previously, were sacrificed, sections of colons were snap-frozen and the 
number of BrdU+ cells assessed by immunohistochemistry. 
Representative images from WT and D6 KO mice taken at the various 
time-points indicated are shown. Magnification x 400. 
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Chapter 6 
Chemokine Receptor Profile of D6 KO Leukocytes 
208 
Introduction 
Several of the experiments described in previous chapters suggested that there were 
differences in chemokine receptor expression between WT and D6 KO leukocytes. 
Thioglycollate-induced peritoneal macrophages, bone marrow DC and colonic lamina 
propria cells from colitic 06 KO animals all displayed altered chemokine receptor profiles 
relative to WT counterparts. In light of these findings, I decided to conduct a more 
thorough examination of chemokine receptor expression by 06 KO leukocytes from 
unmanipulated D6 KO mice. 
6.1 Chemokine Receptor Profile Of Colonic Leukocytes 
Analysis of lamina propria cells from mice with DSS colitis had revealed higher 
proportions of CCRS+ leukocytes in the inflamed colonic lamina propria of 06 KO mice 
compared with WT mice with colitis (Chapter S). This appeared to be mainly due to greater 
numbers of CCRS+ B220+ cells in the KO lamina propria and to explore this in more detail, 
I first assessed chemokine receptor expression by cells isolated from the colon of untreated 
WT and KO mice. 
Lamina propria cells from the colons of three WT and three KO mice were pooled and 
assessed for expression of CCR2 and CCRS, two of the CC-chemokine receptors that are 
activated by a number ofD6ligands. As a control, I also examined expression ofCXCR4, a 
CXC-receptor family member not activated by ligands of D6. As shown in Figure 6.1, 
similar proportions of WT and KO lamina propria cells expressed CCR2 and CXCR4, with 
around 70% of isolated cells positive for these receptors in both cases. However, while only 
20% of WT lamina propria cells expressed CCRS, this chemokine receptor was found on 
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56% of KO LP cells (Figure 6.1). This was similar to what I had found in colitic mice and 
in further agreement with these previous findings, the increase in CCR5+ cells in 06 KO 
colonic tissue was due to a large increase in the proportion of CCRS+ 8 cells. While only 
19.2% of WT 8220+ cells expressed CCRS, 77.6% of KO 8 cells were CCRS-positive 
(Figure 6.2 A). On the other hand, CCR2 and CXCR4 expression did not differ between 
WT and KO 8 cells. 
WT and KO CD8+ cells demonstrated a similar chemokine receptor profile, with CCR2, 
CCR5 and CXCR4 being found on approximately 40%, 80% and 70% of each population 
of CD8+ cells, respectively (Figure 6.2 C). CXCR4 expression was also equivalent on the 
WT and KO CD4+ populations, but only around half as many D6 KO CD4+ cells expressed 
CCR2 and CCR5 compared with WT CD4+ cells (19% vs. 48% and 22% vs. 42%, 
respectively, Figure 6.2 8). In contrast to my findings with colitic mice, more F4/80+ 
lamina propria cells from untreated D6 KO mice expressed CCR2 and CCRS compared 
with their WT counterparts (90% vs. 77% and 40% vs. 16%, respectively, Figure 6.2 0). 
There were also slightly increased numbers of F4/80+CXCR4+ cells in KO lamina propria 
isolates compared with WT (63% CXCR4+ WT vs. 72% KO). These data suggested that the 
differential chemokine receptor profiles of WT and KO lamina propria isolates was not 
disease related, as differences in CCR2 and CCRS expression by B220+, C04+, CD8+ and 
F4/80+ populations were seen in both normal and colitic colon. In both cases, the most 
striking difference was an increased proportion of CCRS+ B cells in D6 KO colon. 
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6.2 Chemokine Receptor Profile of D6 KO Leukocytes 
Previously, I had found no differences between the overall numbers of leukocytes in WT 
and KO lymphoid organs (Chapter 3). However, having detected altered chemokine 
receptor profiles of normal D6 KO colonic leukocytes, I went on to determine if there were 
similar alterations in organised lymphoid tissues of D6 KO mice. 
Cells isolated from peripheral lymph nodes, mesenteric lymph nodes and spleen of WT and 
D6 KO mice were examined for the expression of CCR2, CCRS, CCR9, CXCR4 and 
CXCRS. There were similar proportions of total CCR2, CCR9, CXCR4 and CXCRS 
positive cells in WT and KO PLN (Figure 6.3) and in spleen (Figure 6.4). However, 
significantly increased percentages of KO PLN cells and KO splenocytes expressed CCRS 
compared with their WT counterparts. Greater proportions of CCRS+ cells were also 
detected in the MLN of D6 KO mice (Figure 6.S). Interestingly, while there were no 
differences in CCR2, CXCR4 and CXCRS expression by WT and KO MLN cells, there 
was a small but significant increase in the numbers of CCR9+ cells in the 06 KO MLN 
(Figure 6.5). 
In contrast to my findings in the colon, higher proportions of CD3+ T cells were found to be 
CCRS+ from all lymphoid tissues (Figure 6.6) of D6 KO animals (Figures 6.7 A - C). 
However, in accordance with my earlier results, the most dramatic differences between WT 
and KO lymphoid tissues were seen with 8220+ cells, which showed much higher 
expression of CCRS in PLN, spleen and MLN. Additionally, in each of the three KO 
tissues> 85% of KO 8 cells were CCR5+ compared with < 25% of WT. 
211 
In all three tissues, almost all B220+ B cells were found to be CCR2+, while fairly low 
numbers of CD3+ T cells expressed this chemokine receptor and there were no differences 
between WT and KO expression (Figures 6.8 A - C). However, there was an increase in the 
proportion of CD3-B220- cells, most likely representing non-lymphoid populations, 
expressing CCR2 in KO PLN compared with WT PLN (Figure 6.8 A). 
There were no differences in CCR9 expression by any of these T and B cell subsets in WT 
and KO PLN (Figure 6.9 A), but analysis of MLN cells revealed increased proportions of 
CCR9+ cells in the CD3+ and B220+ populations ofKO mice (Figure 6.9 B). Additionally, 
CD3+ T cells and CD3-B220- cells in the KO spleen showed increased expression of CCR9 
compared with WT cells (Figure 6.9 C). There were no differences in the expression of 
CXCR4 and CXCR5 by the various B220/C03 subsets from PLN, MLN and spleen of WT 
and 06 KO mice (Figures 6.10 A - C and 6.11 A - C). 
Finally, I examined chemokine receptor expression by T- and 8- lymphocytes from the 
peritoneal cavity, as a representative extra-lymphoid site. As shown in Figures 6.12 A and 
B, the expression of CCR2, CCR5, CCR9 and CXCR4 was similar on WT and D6 KO 
peritoneal C04+ and C08+ T cells. Additionally, similar proportions of WT and KO 
peritoneal B220+ B cells expressed CCR2, CCR9 and CXCR4 (Figure 6.12 C). However, in 
agreement with my findings from the colon and secondary lymphoid tissues, more 06 KO 
peritoneal B cells expressed CCR5 compared with WT control B cells (Figure 6.12 C). 
Taken together, these data demonstrate that increased expression of CCR5 is not specific to 
colonic lamina propria B cells of 06 KO animals, but also characterises B cells from PLN, 
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MLN, spleen and peritoneum of D6 KO mice. Moreover, differential chemokine receptor 
expression was also apparent in some other D6 KO leukocytes. 
6.3 Increased CCR5 Transcription in D6 KO Cells 
To confirm whether the increased levels of CCR5 surface expression reflected increased 
levels of CCR5 transcripts, I next examined CCR5 mRNA levels. In collaboration with Dr. 
Clive McKimmie, levels of transcripts for CCR5 were compared between purified B cells 
from WT and KO spleen by real-time PCR. As shown in Figure 6.13, around a three-fold 
increase in expression of CCR5 mRNA was detected in purified D6 KO B cells compared 
with WT controls. Thus the increased level of CCR5 protein expression by D6 KO B cells 
correlated with increased CCR5 transcription. Increased expression of CCR5 mRNA was 
also found in purified T cell, neutrophil and macrophage populations from D6 KO animals, 
although these differences were less dramatic than with the B cells. Altogether, these 
experiments revealed that absence of D6 affected transcription of CCR5 and not merely 
surface protein expression. 
6.4 Chemokine Responsiveness of D6 KO B Cells 
To determine the functional consequences of the increased CCR5 expression by D6 KO B 
cells, I compared the chemotaxis responses of WT and D6 KO B cells to CCL4 in a 
Transwell assay. Splenocytes from WT and KO mice were added to the top chamber of 
Transwell plates and the migration of B220+ cells towards CCL4 in the lower chamber was 
assessed by flow cytometry. As shown in Figure 6.14, D6 KO B cells showed greater 
specific migration to CCL4 compared with WI B cells, with optimal migration of D6 KO 
B cells occurring in response to 10 ng/ml of CCL4. 
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6.S Chemokine Receptor Profile of Developing B Cells 
As there were increased numbers of CCR5+ B cells in all D6 KO tissues, I decided to 
examine at what stage of B cell differentiation this phenotype arose. Early B cell 
development occurs in bone marrow, where sequential interactions between lymphoid 
progenitors and the surrounding stroma culminate in the export of functional B-cells to the 
periphery (333-335). Various chemokines and adhesion molecules have been implicated in 
this process (102, 333-335) and I therefore compared chemokine receptor expression by 
WT and D6 KO bone marrow B cells. 
As shown in Figure 6.15, around 20-30% of BM cells in WT and D6 KO mice expressed 
the B220 antigen. Mature CD3+ T cells were rare. Based on the level of B220 expression, 
two distinct populations could be discerned: a larger population which was B220int (-15-
20% of BM cells) and a minor B220hi subset «5%). B220 is one of the earliest identifiable 
markers to appear on B-lineage cells, and is present throughout B-cell development, with 
the highest expression evident on mature B cells (333, 336-338). Thus the B220int and 
B220hi populations most likely comprised developing progenitor subsets and mature B 
cells, respectively. Interestingly, the B220int subset appeared somewhat reduced in D6 KO 
mice (15.1% total BM cells:t 1.8) compared with WT (22.8:t 6.8), although this difference 
was not statistically significant. 
Consistent with its essential role in B cell development (102), virtually all B220+ cells in 
both strains expressed CXCR4 (Figure 6.16 A). In keeping with my previous findings in 
secondary lymphoid organs, highly statistical differences in CCR5 expression were noted 
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between WT and KO 8220+ cells. While less than a fifth of WT 8220+ 8M cells were 
CCR5-positive, around half of all 8220+ KO cells expressed this chemokine receptor. The 
vast majority of 8220+ cells were also CCR2+, but this was more so for 06 KO 8220+ cells 
compared with WT (85.9% vs. 71.5%, respectively). Expression of CCR9 by WT 8220+ 
8M cells was low (-9%) and this was increased in 06 KO BM B220+ cells, although the 
difference was not statistically significant. Few B220+ cells were found to express CXCR5 
« 2%). 
Next, I compared chemokine receptor expression by the 8220int and 8220hi subsets of WT 
and 06 KO mice. 80th these subsets expressed CXCR4 at high levels in both strains 
(Figure 6.16 E), while the few CXCR5+ cells identified were found to reside in the 8220hi 
subset (6.16F). CCR5 was expressed at higher levels on the B220hi subset compared with 
B220int cells, but this was increased on both subsets from 06 KO BM compared with the 
WT subsets (Figure 6.16 0). Interestingly, virtually all 8220hi cells expressed CCR2 
(Figure 6.l6B), revealing that the increased CCR2-positivity of KO B220+ cells was 
accounted for by the B220int subset (66.5% ± WT vs. 80.6% ± 7.8 KO). Although 
comparable percentages of WT B22010 and 8220hi cells expressed CCR9, more CCR9-
postive cells were found in both equivalent KO subsets, with the most dramatic increase 
witnessed in the B220hi subset (Figure 6.16 C). 
In addition to comparing the overall proportions of cells positive for the various chemokine 
receptors, I also determined the MFI of the positive cells in order to evaluate the levels of 
receptor expression. While all B220+ cells expressed CXCR4, greater levels of expression 
were found on B220hi BM subsets of both WT and D6 KO animals (Figure 6.17). CCR2 
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expression levels were also higher in B220hi subsets and 06 KO B220+ cells from both 
subsets had higher surface levels of CCR2 than WT counterparts (Figure 6.18). As shown 
in Figure 6.19, CCRS+B220hi KO cells demonstrated slightly higher levels of CCRS 
expression compared with WT counterparts. Strikingly, although I had found less CCRS+ 
cells in the WT B220int subsets compared with KOs, WT B220intCCRS+ cells demonstrated 
significantly higher levels of CCR5 expression compared with their KO counterparts 
(Figure 6.19). Similar trends were seen with respect to CCR9 expression (Figure 6.20). 
Thus, although there were more CCR5+ and CCR9+ cells in 06 KO B220int populations, 
individually, the CCR5+B220int and CCR9+B220int cells of WT mice demonstrated higher 
receptor expression than their KO counterparts (Figure 6.19 and 6.20). Taken together, 
these data indicated that in the absence of 06, aberrant chemokine receptor expression 
occurs during B-Iymphopoiesis. 
6.6 Analysis of B Cell Function in D6 KO Mice 
My studies had revealed dramatically enhanced CCRS expression by 06 KO B cells both at 
mRNA and protein levels, and this appeared to be from an early stage of development. 
Therefore I decided to examine if these abnormalities had any functional consequences. To 
address this point, I first compared the levels of total immunoglobulins in the sera of WT 
and D6 KO mice. As shown in Figure 6.21 A, serum IgM levels were comparable in WT 
and KO mice but there appeared to be somewhat lower total IgG levels in the D6 KO 
animals, although this was only significant at one serum dilution (Figure 6.21 B). 
Next, I compared the functional and phenotypic responses of WT and KO B cells following 
stimulation with mitogenic factors in vitro. Purified splenic B cells were cultured for 48h in 
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medium alone, or medium supplemented with uCD40 ± uIgM, DSS or LPS. The 
expression of costimulatory molecules and chemokine receptors, cytokine production, and 
proliferation responses were then examined. 
B cells from both WT and KO mice showed significant proliferation above background in 
response to anti-CD40/anti-IgM or DSS, and even greater proliferation was seen in cultures 
stimulated with LPS (Figure 6.22). WT and KO B cells showed similar levels of 
proliferation in all culture conditions examined. 
B cells stimulated with DSS or LPS showed some upregulation of CD80, whereas anti-
CD40 had no effect (Figure 6.23 A). On the other hand, cultured B cells upregulated CD86 
in response to all mitogens, most notably LPS (Figure 6.23 B). Again, no differences were 
detected between WT and KO cells in any of the culture conditions. 
Confirming my results with B cells from lymphoid tissues, higher proportions of D6 KO B 
cells expressed CCR5 when cultured in medium for 2 days and similar differences were 
seen when B cells were stimulated with DSS or LPS (Figure 6.24 C). KO B cells also 
expressed higher levels of CCR5 in all treatment conditions (Figure 6.24 D). LPS-treatment 
increased CCR5 expression levels in both WT and D6 KO cultures (Figure 6.24 D). 
Conversely, culture with DSS appeared to have no effect on CCR5 expression by WT cells 
and, interestingly, DSS treatment reduced CCR5 expression levels of purified KO B cells 
(Figures 6.24 C and D). 
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As shown in Figure 6.24 A, the vast majority of B220+ cells were CCR2 positive (>90%) 
after culture, irrespective of the stimulus. D6 KO B cells cultured in medium alone had 
higher levels of CCR2 expression compared with WT B220+ cells (Figure 6.24 B), but the 
intensity of CCR2 expression was comparable on WT and KO B cells stimulated with OSS 
or LPS cultures. Due to the use of a polyclonal anti-rat IgO in the staining procedure, I was 
unable to examine CCR2 and CCR5 expression by WT and KO B cells cultured with anti-
CD40 and anti-IgM. 
In conjunction with the above analyses, I also determined chemokine levels in WT and KO 
B cell culture supernatants. As shown in Figures 6.25 A - C, B cells cultured in medium 
alone produced little or none of the D6 ligands CCL3, CCL4 and CCLS, but higher levels 
of these chemokines were detected after stimulation with DSS and, notably, with LPS. No 
differences were seen between the levels of chemokines produced by WT or 06 KO B cells 
in medium alone or in response to DSS, and although LPS stimulated KO B cells produced 
generally lower levels of these CC-chemokines than WT B cells, these differences did not 
reach statistical significance. There was no production of the non-D6 ligand CXCL 10 by 
WT or KO B cells cultures in medium or with DSS, but stimulation with LPS induced some 
production ofCXCLlO, which was equivalent in the two strains (Figure 6.250). 
Summary 
In this chapter, I examined chemokine receptor expression by D6 KO leukocytes, and I 
found that various D6 KO populations displayed differential chemokine receptor profiles 
compared with their WT counterparts. Most strikingly, 06 KO B cells from all tissues 
examined, demonstrated increased CCR5 expression. Despite this altered chemokine 
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receptor expression, serum immunoglobulin levels and in vitro mitogen-induced responses 
were comparable between WT and D6 KO B cells. However, presumably as a result of 
increased CCR5 expression, KO B cells demonstrated increased migration to CCL4 in 
chemotaxis assays. Altogether, these data suggest a role for D6 in the proper development 
of leukocytes populations, with absence of this atypical receptor resulting in deregulated 
expression of other chemokine receptors. 
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Chemokine Receptor Profile of Colonic Lamina Propria Cells From D6 
KO Mice 
Lamina propria cells pooled from the colons of 3 WT and 3 D6 KO mice were 
analysed by flow cytometry for expression of CCR2, CCR5 and CXCR4. 
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Chemokine Receptor Profile of Colonic Lamina Propria Cells From D6 KO 
Mice 
Lamina propria cell populations pooled from the colons of 3 WT and 3 D6 KO 
mice were analysed by flow cytometry for expression of CCR2, CCR5 and CXCR4. 
Figures A, B, C and D show the chemokine receptor profiles ofB220+, CD4+, 
CD8+ and F4/80+ lamina propria cells, respectively. 
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Figure 6.3 
Chemokine Receptor Profile of Peripheral Lymph Node Cells From D6 
KO Mice 
Cells isolated from peripheral lymph nodes of WT and D6 KO mice were 
analysed by flow cytometry for the expression ofCCR2, CCR5, CCR9, CXCR4 
and CXCR5. Data are presented as mean + SD of 3 animals per group. 
** p < 0.01 
222 
'-
£ 
c. 
Q) 
(.) 
Q) 
0:: 
C) 
c 
en 
en 
2! 
c. 
>< 
W 
~ 20 
Q) 
o 
'#. 
Figure 6.4 
*** 
Chemokine Receptor Profile of SpJenocytes From D6 KO Mice 
CJWT 
BIIKO 
Cells isolated from peripberallymph nodes of WT and D6 KO mice were analysed 
by flow cytometry for the expression ofCCR2, CCRS, CCR9, CXCR4 and CXCR5. 
Data are presented as mean + SD of 3 animals per group. 
*** p < 0.001 
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Figure 6.S 
Chemokine Receptor Profile of Mesenteric Lymph Node Cells Of D6 KO 
Mice 
Cells isolated from mesenteric lymph nodes of WT and D6 KO mice were analysed 
by flow cytometry for the expression ofCCR2, CCR5, CCR9, CXCR4 and CXCR5. 
Data are presented as mean + SD of 3 animals per group. 
** p < 0.01 
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Cellular Composition of Lymphoid Tissues in D6 KO Mice 
Cells isolated from (A) peripheral lymph nodes, (B) spleen and (C) mesenteric 
lymph nodes ofWT and D6 KO mice were assessed by flow cytometry for the 
proportions of CD3+ and B220+ cells. Data are presented as mean + SD of 3 
animals per group. 
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Figure 6.7 
CCR5 Expression By CD3+ and B220+ Cell Subsets From D6 KO Mice 
Cells were isolated from (A) PLN, (B) MLN and (C) spleens ofWT and D6 
KO mice and the expression of CCR5 by CD31B220 subsets assessed by flow 
cytometry. Data are presented as the mean + SD of 3 animals per group. 
*** p < 0.001 
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Figure 6.8 
CCR2 Expression By CD3+ and B220+ Cell Subsets From D6 KO Mice 
Cells were isolated from (A) PLN, (B) MLN and (C) spleens ofWT and D6 
KO mice and the expression of CCR2 by CD31B220 subsets was assessed by 
flow cytometry. Data are presented as mean + SD for 3 animals per group. 
* p < 0.05 
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Figure 6.9 
CCR9 Expression By CD3+ and B220+ Cell Subsets From D6 KO Mice 
Cells were isolated from (A) PLN, (B) MLN and (C) spleens ofWT and D6 
KO mice and the expression ofCCR9 by CD31B220 subsets was assessed by 
flow cytometry. Data are presented as mean + SD for 3 animals per group. 
* p < 0.05, ** p < 0.01 
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Figure 6.10 
CXCR4 Expression By CD3+ and B220+ Cell Subsets From D6 KO Mice 
Cells were isolated from (A) PLN, (B) MLN and (C) spleens of WT and 06 KO 
mice and the expression of CXCR4 by C031B220 subsets was assessed by flow 
cytometry. Data are presented as mean + SO for 3 animals per group. 
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Figure 6.11 
CXCR5 Expression By CD3+ and 8220+ Cell Subsets From D6 KO Mice 
Cells were isolated from (A) PLN, (B) MLN and (C) spleens ofWT and D6 
KO mice and the expression of CXCR5 by CD3/B220 subsets was assessed 
by flow cytometry. Data are presented as mean + SD for 3 animals per group. 
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Chemokine Receptor Profile of Peritoneal Exudate Cells From Resting D6 KO 
Mice 
Cells were isolated from the peritoneum of 3 WT and 3 D6 KO mice, pooled and the 
expression ofCCR2, CCR5, CCR9 and CXCR4 by (A) CD4+, (B) CD8+ and (C) 
B220+ cells determined by flow cytometry" 
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Figure 6.13 
Quantification of CCR5 mRNA From D6 KO Cell Populations 
RNA was extracted from purified T and 8 cells, bone marrow neutrophils, 
and M-CSF 8M-derived macrophages. Levels of CCR5 mRNA were 
determined by real time PCR and normalised to the housekeeping gene, 
GAPDH. The data represent the means of three mice ± SEM. Dotted line 
represents the limit of sensitivity. The data appears courtesy of Dr Clive 
McKimmie. 
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Figure 6.14 
Chemotactic Responses Of D6 KO B Cells to CCL4 
Splenocytes (1 x 105) from WT and D6 KO mice were added to the top chamber 
of Transwell plates containing 0, 1, 10 or 100 ng/m I of CCL4 in the lower 
chamber. Plates were cultured at 37°C for 3 hrs and then cells were collected 
from the lower wells. The index of migration was calculated by dividing the 
number of CD 19+ cells found in the lower chamber by the original number of 
CD19+ cells added to the top chamber. The data are representative of2 individual 
experiments. 
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B220 and CD3 Expression by Bone Marrow Cells in D6 KO Mice 
3.58 
Bone marrow cells were retrieved from the femurs of WT and D6 KO mice and the 
proportions ofB22010, B220hi and CD3+ cells determined by flow cytometry. Data 
are presented as mean + SD and represent 3 animals per group. Below are shown 
representative B220-FACS profiles ofWT(left) and D6 KO (right) mice. 
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Chemokine Receptor Profile of B220+ BM Cells in D6 KO Mice 
Bone marrow cells were retrieved from the femurs of WT and D6 KO mice and 
the expression of CCR2, CCR5, CCR9, CXCR4 and CXCR5 by 8220+ cells 
determined by flow cytometry (A). The expression of (B) CCR2, (C) CCR5, (D) 
CCR9, (E) CXCR4 and (F) CXCR5 by B220int (left) and B220hi (right) was also 
assessed. Data are the mean + SD of 3 animals per group. 
** p < 0.01 , *** p < 0.001 
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Chemokine Receptor Profile of D6 KO B Cells 
Shown above are representative flow cytometry plots of chemokine 
receptor-stained B cells from PLN of WT and D6 KO mice. 
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Figure 6.17 
CXCR4 Profile of B220+ BM Subsets in D6 KO Mice 
16 4 
: '0' 
0011 
Bone marrow cells were retrieved from femurs ofWT and D6 KO mice and the 
expression of CXCR4 by B220-int and B220-hi subsets determined by flow 
cytometry. Data are the mean + SD for 3 animals per group. Representative FACS 
plots from WT (left) and D6 KO (right) mice are shown below. 
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CCR2 Profile of B220+ BM Subsets in D6 KO Mice 
Bone marrow cells were retrieved from femurs of WT and D6 KO mice and the 
expression of CCR2 by B220int and B220hi subsets determined by flow cytometry . 
Data are the mean + SD for 3 animals per group . Representative FACS plots from 
WT (left) and D6 KO (right) mice are shown below. 
* p < 0.05 
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Figure 6.19 
CCR5 Profile of B220+ BM Subsets in D6 KO Mice 
Bone marrow cells were retrieved from femurs of WT and D6 KO mice and the 
expression of CCR5 by B220int and B220hi subsets was determined by flow 
cytometry. Data are the mean + SD for 3 animals per group. Representative FACS 
plots from WT (left) and D6 KO (right) mice are shown below. 
** p < 0.01 , *** P < 0.001 
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Figure 6.20 
CCR9 Profile of B220+ BM Subsets in D6 KO Mice 
Bone marrow cells were retrieved from femurs of WT and D6 KO mice and the 
expression of CCR5 by B220int and B220hi subsets determined by flow cytometry . 
Data are the mean + SD for 3 animals per group. Representative FACS plots from 
WT (left) and D6 KO (right) mice are shown below. 
* p < 0.05 
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Figure 6.21 
Serum IgM and IgG Levels in D6 KO Mice 
Total levels of (A) IgM and (B) IgG were measured in sera of WT and D6 KO mice 
by ELISA. Data are the mean + SD of3 animals per group . 
... p < 0.05 
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Proliferative Responses of D6 KO B Cells to Mitogenic Stimulation 
B cells purified from spleens of WT and D6 KO mice were cultured in complete 
medium alone, or complete medium containing aCD40 + algM (1 O~g/ml), DSS 
(50~g/ml) or LPS (l~g/ml) for 48 hours. 3H-Tdr was added for the last 20 hours 
of culture and levels of proliferation determined by 3H_ Tdr incorporation. Data 
are the means + 1 SD for 3 mice per group. 
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Figure 6.23 
Costirnulatory Molecule Expression By D6 KO B Cells in Response to 
Mitogenic Stirn uli 
B cells purified from spleens ofWT and D6 KO mice were cultured in complete 
medium alone, or complete medium containing aCD40 + aIg (1 O""g/ml), DSS 
(50""g/ml) or LPS (l""g/ml). Cells were harvested after 48h and the expression of 
(A) CD80 and (B) CD86 determined by flow cytometry. Data are the means + 1 SD 
for 3 mice per group. 
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Figure 6.24 
Chemokine Receptor Expression By D6 KO B Cells in Response to Mitogenic 
Stimulation 
B cells purified from spleens of WT and D6 KO mice were cultured in complete 
medium alone, or complete medium containing DSS (50~g/ml) or LPS (1 ~g/ml) . 
Cells were harvested after 48h and expression of CCR2 (A + B) and CCR5 (C + D) 
determined by flow cytometry. Percentage ofB220+ cells positive (A + C) and MF] 
of B220+ cells (B + D) are both shown. Data are the means + 1 SD for 3 animals per 
group. 
* p < 0.05 , ** p < 0.01 
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Chemokine Production By D6 KO B Cells in Response to Mitogenic 
Stimulation 
B cells purified from spleens of WT and D6 KO mice were cultured in complete 
medium alone, or complete medium containing (50f-tglml) DSS or LPS (If-tglml). 
Culture supernatants were harvested at 48h and assessed for levels of CCL2, 
CCL3, CCL5 and CXCLIO by Luminex. Data are presented as mean + SD and 
represent 3 animals per group. 
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Chapter 7 
Discussion 
245 
The immune system faces the daunting task of protecting the organism against pathogens 
while simultaneously preserving host integrity. Therefore multiple regulatory mechanisms 
exist to fine-tune inflammatory responses, enabling protection against foreign microbes to 
develop in the absence of overt immunopathology. More than two decades ago, the study of 
the IL-I type II receptor (IL-I RII) suggested a novel biological function for this molecule 
as a "decoy receptor" (339). The decoy paradigm describes a receptor that is capable of 
binding its ligand with high affinity, but lacks the capacity to transduce a productive signal 
following ligand recognition (265). Decoy receptors have been described for members of 
the IL-l, TNF and IL-l 0 cytokine families, and it is has been proposed that these molecules 
enable tight regulation of cytokine networks (265). 
Recently, it has become apparent that decoy receptors may also playa role in chemokine 
biology. First described by Nibbs and colleagues in 1997, D6 is homologous to members of 
the CC-chemokine receptor family and shows high affinity for an unusually large number 
of inflammatory-type CC-chemokines (270, 271). However, unlike conventional CC-
chemokines receptors, D6 expressed in cell lines does not induce any detectable signal or 
chemotaxis in response to ligand binding (270). Also atypically, D6 constitutively recycles 
to and from the cell surface independently of ligand, but is extremely efficient at 
intemalising any ligand detected at the cell surface and targeting it for intracellular 
degradation (285, 286, 288). Due to this ability to scavenge ligands in the absence of any 
detectable functional response, it has been proposed that D6 may serve as a decoy receptor 
for inflammatory CC-chemokines (264, 274, 275). 
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When I started this thesis, all of the work previously published to support the "06 decoy" 
hypothesis had been performed in vitro. However, others in the Division had recently 
generated D6-deficient mice and, strikingly, found that these animals developed excessive 
and prolonged cutaneous inflammatory responses when subjected to topical application of 
phorbol ester (292). These studies therefore represented the first evidence that 06 might 
normally have an anti-inflammatory function in vivo. Despite this, our understanding of the 
in vivo function of D6 remained limited at the time I started. Thus the aims of my thesis 
were to conduct a more thorough characterisation of the immune system of 06-deficient 
animals, in an attempt to understand the true biological significance of this molecule. I 
sought to investigate the role of D6 in lymphoid and extra-cutaneous tissues of both normal 
and immunologically challenged animals. In particular, due to the high levels of D6 
expression that had been reported in intestinal tissue, I aimed to explore the function of 06 
at this particular site. The studies described in this thesis have generated a number of novel 
observations with regard to the 06-deficient animals. 
The Role of D6 in Steady State Leukocyte Trafficking 
My initial experiments, described in Chapter 3, examined the cellular composition of 
various lymphoid tissues from D6-deficient animals under resting conditions. Although the 
ligands of D6 are traditionally associated with inflammation, CC-chemokines also 
influence haematopoiesis and govern leukocyte recruitment to non-inflamed sites (115, 
121, 125, 135, 340). Moreover, immunohistochemical studies have shown 06 to be 
expressed at high levels by lymphatic endothelial cells. Therefore I wished to examine if 
D6-deficient mice would demonstrate altered leukocyte trafficking to lymphoid tissues in 
the steady state. 
247 
Compared to their WT counterparts, D6 KG mice did not show any aberrations in any 
lymphocyte populations of the thymus, spleen or lymph nodes. However, I detected a 
marginal increase in the proportions of F4/80+ and CD 11 c + cells in the D6 KO spleen. 
These early experiments suggested that the absence of D6 does not affect the gross 
population of lymphoid tissues by T cells and B cells. On the other hand, my data do not 
exclude the possibility that different functional leukocyte populations, for example altered 
effector T cell subsets, are present in the D6 KG nodes. This could be addressed in future 
experiments by comparing cytokine production by WT and D6 KG T cells. Indeed, I 
observed that lymph node cells and splenocytes from D6 KO mice showed higher levels of 
proliferation in response to Con A stimulation, in vitro, compared with WT controls and 
this could reflect differences in leukocyte sub-populations in D6 KG lymphoid tissue. 
Alternatively, as CCL2 and CCL3 have been shown to enhance Con A induced activation, 
another explanation for my findings is that in the absence of D6 scavenging, increased 
levels of CC-chemokines amplified the mitogenic effects of Con A (89). Comparing levels 
of CC-chemokines in WT and KG cultures would be necessary to address this point. It 
would also be interesting in future to investigate whether Con A induced responses of WT 
mice can be heightened by addition of exogenous CC-chemokines, or if the Con A 
responses of D6 KG animals can be reduced by addition of antibodies targeted against 
various CC-chemokine ligands of D6. 
A further explanation for these findings could be that greater numbers of antigen-presenting 
cells, which are needed to sustain Con-A induced responses of T cells, were present in the 
D6 KG cultures (341). As already stated, I found that the spleen of D6 KG mice contained 
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slightly increased proportions of F4/80+ and CD 11 c + cells, taken to be macrophages and 
dendritic cells, respectively. Although I did not detect similar increases in CD II c + and 
F4/80+ cells in other lymphoid tissues of D6 KO mice, the extremely low numbers of 
CDllc+ or F4/80+ cells obtained from these sites may have complicated these analyses. 
Other experimental approaches, for example, quantification of CDllc+ cells in situ by 
laser-scanning cytometry, may enable better comparison of DC and macrophage 
populations in WT and D6 KO lymph nodes. On the other hand, as distinct mechanisms 
control the myeloid cell recruitment and maintenance at different tissues (342), it is 
possible that a lack of chemokine regulation by D6 might only affect myeloid populations 
in the spleen. An increase in splenic CDllc+ and F4/80+ populations in D6 KO mice could 
have arisen from higher levels of monocyte-attracting CC-chemokines in the absence of D6 
scavenging. Also, as the maintenance of DC and macrophage populations in spleen has 
been proposed to be controlled by in situ proliferation and to be independent of monocyte 
input (343, 344), CC-chemokine-driven proliferation or survival may have caused the 
phenotype observed in the KO mice (122, 345). This could be investigated by comparing 
the rates of cell division and apoptosis in spleens from WT and KO animals, using BrdU 
labelling or TUNEL analysis, respectively. In addition, comparison of CC-chemokine 
levels in spleen homogenates of WT and D6 KO animals would be necessary to determine 
if lack of D6 scavenging leads to higher chemokine levels at this site. 
Investigating the Myeloid Compartment of D6 KO Mice 
These early data suggested minor deviations in the myeloid compartment of the D6 KO 
mice. However, as it was difficult to obtain sufficient cells of this kind in other organs, I 
decided to investigate the cellular composition of the peritoneum under resting and 
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inflamed conditions (Chapter 4). The peritoneal cavity houses a large resident macrophage 
population that can be easily retrieved by lavage and thus represents an excellent source of 
these cells. Analysis of peritoneal exudate cells (PEC) from resting WT and D6 KO mice 
revealed comparable numbers of C04+ T cells, COS+ T cells, B220+ cells and COllc+ 
cells. However, I found that increased proportions of F4/80+ cells were present in the non-
inflamed peritoneum of 06 KO mice compared with WT controls. Therefore altered 
myeloid population was not restricted to the spleen of the 06 KO animals. The F4/S0+ cells 
could be divided into two subsets, namely F4/S0hi and F4/S0(O, based on their expression 
levels of this surface antigen. The augmented F4/80+ compartment in 06 KO mice was 
found to result from a specific increase in F4/S0hi cells, while both WT and KO mice had 
similar proportions of F4/801o cells. Further analysis also revealed that F4/S0+ cells isolated 
from the normal peritoneum of 06 KO mice showed higher expression of CCR2 and CCR5 
compared with their WT counterparts. 
This expansion of the F4/80hi subset in 06 KO mice suggested an increase in resident tissue 
macrophages, which are characterised by high levels of F4/80 expression (346-348). 
Ligands of 06 have been demonstrated to playa role in monocyte emigration from bone 
marrow and trafficking of eosinophils to tissues in the absence of inflammation (125, 127). 
It is possible therefore, that 06 ligands in non-inflamed sites mediate the constitutive 
recruitment of resident macrophages and that a lack of 06 function enables greater baseline 
macrophage recruitment. On the other hand, 06 has been found, at least in humans, to be 
expressed predominantly by lymphatic endothelium and does not appear to be expressed by 
vascular endothelial cells (287). This, as well as the fact that equal numbers of cells were 
found in the inflamed peritoneum of both WT and 06 KO mice following thioglycollate 
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challenge, suggests that D6 may not regulate the recruitment of cells to the peritoneum. An 
alternative explanation is that the increased prevalence of F4/80+ cells in the KO peritoneal 
cavity may have been due to greater in situ proliferation, or prolonged persistence of 
resident macrophages in the D6 KO peritoneum. To address these points, BrdU labelling 
experiments could be used to compare the turnover rates of peritoneal macrophages in WT 
and D6 KO mice. CCRS has been shown to deliver anti-apoptotic signals to both human 
and murine macrophages (82), and as already mentioned, I found that resident macrophages 
from the peritoneal cavity of D6 KO mice demonstrated enhanced CCR2 and CCR5 
expression. Therefore D6 KO resident macrophages may be recruited normally to the 
resting peritoneum, but might have a longer tissue lifespan there, perhaps as a result of 
increased CCR5 expression. In this regard, it would be interesting to examine if 
antagonising CCR5, for instance through administration of Met-RANTES, could reduce 
levels of peritoneal macrophages (349, 350). As in other aspects of understanding the 
biology of D6, a concern is the lack of information regarding the sites of D6 expression. 
Work by others in our group has revealed that various murine leukocyte populations, 
including macrophages and DC, express D6, at least at the mRNA level (351). Therefore it 
is possible that the absence of D6 has an autonomous effect on tissue macrophages. It will 
be important to determine if the altered CCR2 and CCR5 expression arises within the 
peritoneum or if circulating monocytes in D6 KO mice have aberrant chemokine receptor 
expreSSIOn. 
Examination of Cell Populations in the Inflamed Peritoneum of D6 KOs 
To further investigate the role of D6 in myeloid cell responses, I employed a model of 
sterile peritonitis induced by thioglycollate injection. Administration of thioglycollate 
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results in the recruitment of inflammatory monocytes to the peritoneum in a CCR2-
dependent fashion (47, 48, 136, 137, 308). It was therefore envisaged that absence of 06 
activity might lead to higher levels of CCR2 ligands and result in increased influx of 
monocytes to the 06 KO peritoneal cavity. Despite these predictions, WT and KO mice 
recruited similar numbers of F4/S0+ cells to the inflamed peritoneum at all times from 24-
96h after thioglycollate challenge. As discussed above, this finding may reflect the absence 
of 06 activity at vascular endothelium. Although I found no differences in the total number 
of isolated PEC, F4/80+ PEC from 06 KO mice co-expressed higher levels of CD 11 c than 
their WT counterparts. This phenotype became more distinct at later time-points following 
thioglycollate injection. I considered the possibility that some of these F4/80+ PEC may 
have been eosinophils, which have been described previously as F4/80lo expressing cells 
with distinct high side-scatter properties (310, 352, 353). However cells with such 
characteristics appeared to be present in equal numbers in WT and KO mice. Moreover, the 
F4/S0+CDl1c+ cells were also found to co-express class II MHC and these were more 
likely a monocyte-derived population. 
Similar to my findings with resident F4/80+ PEC, I detected differences in the levels of 
expression of CCR2 and CCR5 by WT and KO inflammatory F4/S0/CDllc subsets. 
Virtually all of the F4/S0+CD11c+ cells in both WT and KO PEC expressed CCR5, but the 
levels ofCCR5 expression were greater in 06 KO PEC. On the other hand, F4/S0+CDllc+ 
PEC harvested from KO mice at 24h expressed CCR2 at comparable levels to WT PEC, 
and showed reduced levels of CCR2 expression by 96h. Chemokine receptor expression 
also differed between F4/80-single positive cells in inflammatory exudates of WT and 06 
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KO mice, with enhanced CCR2 and CCRS expression seen by 06 KO PEC at 24h post-
thioglycollate injection, although by 96h this difference was no longer apparent. 
These phenotypic differences between WT and KO inflammatory PEC suggested that 
aberrant trafficking or differentiation of inflammatory monocytes may have been occurring 
in the absence of 06 function. Since the F4/S0+CDllc+ subset also expressed high levels of 
class II MHC, it is possible that greater numbers of DC were appearing in the inflamed 
peritoneal cavity of the D6 KO mice. Circulating blood monocytes are a highly 
heterogeneous population, which can give rise to both macrophages and DCs in peripheral 
tissues. Recently, Geissmann et al. described the existence of two distinct murine monocyte 
subsets, which can be distinguished based on differential chemokine receptor profiles (124, 
354). The major monocyte subset to infiltrate the inflamed peritoneum is the 
"inflammatory" CCR2+CX3CRl l°Grl hi monocyte, but "constitutive" CCR2TX3CRI hiGrllo 
monocytes are also recruited in response to thioglycollate administration (124). Although 
both monocyte subsets have been reported to be capable of differentiating into antigen-
presenting DC (124), it has been suggested that the CCR2-CX3CR 1 hiGrl lo monocyte 
population may be more predisposed to DC-development, as adjudged by an increased 
propensity to upregulate COlle (312). Interestingly, in ApoE KO mice, this subset is 
characterised by higher expression of CCR5, a phenotype reminiscent to that demonstrated 
by D6 KO PEC (312). Therefore one explanation for my observations could be that D6 KO 
mice were preferentially recruiting monocytes of the Grl lo subset, thus giving rise to more 
DC in the peritoneum. However, against this hypothesis, the increased tendency for the 
CCR2TX3CRI hiGrl10 monocytes to differentiate into DC-like cells has been observed only 
in ApoE-deficient KO mice. Tacke and coworkers reported CCR5 mRNA expression to be 
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similar between both monocyte subsets in WT mice, while Sunderkotter and colleagues 
suggested that in WT animals CCR5 is in fact expressed at greater levels by Gr I hi 
"inflammatory" monocytes compared to the Grl 10 subset (312, 354). Lang et al. 
additionally reported that the appearance ofF4/S0+CDllc+ cells in the ApoE KO model of 
atherosclerosis is dependent on CCR2, suggesting that inflammatory monocytes are the 
precursors of the F4/S0+CDllc+ cells. Indeed, I found PEC isolated from both WT and KO 
thioglycollate-subjected animals to demonstrate high CCR2-positivity, arguing that the vast 
majority of recruited cells in response to thioglycollate administration were "inflammatory" 
monocytes. 
An alternative explanation for my findings could therefore be that inflammatory monocytes 
recruited to the 06 KO peritoneum following thioglycollate injection are more prone to 
give rise to DC. CC-chemokines have been shown to upregulate CD 11 c expression by 
monocytes (355) and so it is possible that they may promote monocyte differentiation into 
DC. In support of this, although macrophages generated from BM by M-CSF and IL-6 
show poor APC function, addition of CCR5 ligands during maturation increases their 
ability to stimulate T cell proliferation (356). It may therefore be the case that the increased 
levels of CCR5 expressed by freshly recruited 06 KO monocytes results in greater DC-
differentiation. This would be consistent with the findings by Tacke and colleagues that the 
subset of monocytes expressing highest levels of CCR5 demonstrated greater expression of 
COlle (312). Notably, thioglycollate-induced F4/S0+CDllc+ cells from both WT and KO 
mice demonstrated higher levels ofCCR5 expression than all other F4/S0/CDlic subsets. 
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On the other hand, certain macrophages, including lung and splenic marginal zone 
populations, have also been reported to express CD II c and I was unable to rule out the 
possibility that the F 4/80+ CD II c + cells represented a macrophage subset that was expanded 
in the D6 KO peritoneum (357,358). As there are few, if any, reliable markers which can 
differentiate DC from macrophages absolutely (359), I next attempted to use functional 
assays to try and distinguish the subsets of PEC in WT and KO mice. I compared the 
capacity of WT and KO inflammatory PEC to induce the free radical nitric oxide and 
examined inflammatory cytokine production by both popUlations. Neither population 
differed in terms of nitric-oxide generation, but PEC taken from D6 KO mice after 
thioglycollate injection were characterised by lower production of the pro-inflammatory 
cytokines IL-I a and TNF a. The maturation of monocytes into inflammatory macrophages 
is associated with a switch from IL-I~ production to IL-Ia (360). In addition, TNFa is 
predominantly produced by activated macrophages. Therefore the lower levels of IL-I a 
and TNFa in D6 KO PEC cultures could support my conclusions that the increased 
F4/80+CDllc+ cells in D6 KO mice were not mature macrophages. 
However, it remains possible that these cells represent a distinctive macrophage, such as 
the "alternatively activated" subset. Macrophages demonstrate great heterogeneity, but it 
has been proposed that these cells can be roughly categorised as "classically" or 
"alternatively" activated populations. Classically activated macrophages "CAM" are 
associated with the production of pro-inflammatory 1 T HI-type cytokines and chemokines, 
such as IL-I, TNFa, IL-12, IL-23, CXCLI0 and CCL3 (361, 362). Alternatively activated 
macrophages (AAM) populations produce high levels of anti-inflammatory/TH2-type 
cytokines, such as IL-I0, CCL 17 and CCL22, and negatively regulate T HI and CAM 
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generation (361-363). In response to stimulation with LPS and IFNy, D6 KO PEC produced 
lower levels of CCL3, CXCL 1 0, IL-l, TNF and IL-6 compared with WT PEC. 
Interestingly, the population of AAM recruited to the peritoneal cavity during helminth 
infection have also been shown to express higher levels of CCRS similar to my findings in 
D6 KO mice (364). Therefore it is possible that AAM, rather than DC, were the cellular 
type which was expanded in the inflamed peritoneum of the D6 KO mice. As CCR4 and its 
ligands have been implicated in the generation of AAM, it is possible that deregulated 
chemokine networks in the D6 KO animals may have led to alternative macrophage 
activation (363, 365). Comparison of the levels of CCR4 ligands in peritoneal lavages of 
WT and KO mice would be necessary to determine this. 
With the exception of CCL2, I was not able to detect CC-chemokines in peritoneal lavage 
fluid from WT and 06 KO animals. This may have reflected the absence of other ligands of 
06 or may indicate that the volumes I used to retrieve the lavage fluids were too great, 
leading to dilution of chemokines below the levels of detection. Measurement of CCL2 
levels in peritoneal lavage fluid provided no evidence that D6 scavenging activity occurred 
in normal peritoneum and, in fact, at late-time points (72-96h post thioglycollate), lower 
levels of CCL2 were found in D6 KO lavages. This may indicate that 06 is not expressed 
in the peritoneal cavity, or is expressed at insufficient levels to function as a decoy for 
inflammatory chemokines generated at this site. As a recent study examining the role of D6 
in pulmonary inflammation by Whitehead and coworkers reported the scavenging ability of 
D6 to be concentration dependent, another explanation for these findings is that the levels 
of CCL2 did not fall within those concentration ranges susceptible to D6 regulation. 
Absence of D6 scavenging in the peritoneum does not account for my findings that levels 
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of CCL2 were actually higher in D6 KO lavages at later time-points. However, monocyte 
recruitment to inflamed lung has been shown to lead to a reduction in CCL2 levels as a 
result of CCR2-mediated uptake (140). Therefore the heightened expression of CCR2 
observed in the early D6 KO PEC may have led to greater consumption of CCL2 in KO 
lavages. 
Characterisation of BM-DC from D6 KO Mice 
As I was unable to be sure if the expanded CDIIc+ subsets in the KO peritoneum were DC 
or macrophages, I decided to compare the generation of DC from precursor cells in WT and 
KO bone marrow cultures. Compared with identically treated WT BM cultures, GM-CSF-
expanded BM cultures from D6 KO mice generated greater numbers of CD 11 c + cells. In 
addition, CD II c positive cells in KO cultures expressed CD II c at higher levels than 
CDllc+ cells in WT cultures, as assessed by measuring MFI. This was consistent with my 
findings from the myeloid cells in the peritoneal cavity and suggested that monocytes may 
be more predisposed to DC development in D6 KO mice. Interestingly, many BM CD 11 c + 
cells from both WT and KO cultures also expressed the F4/S0 antigen, supporting my idea 
that the CDIlc+F4/S0+ cells I found in the inflamed peritoneum could be DC rather than a 
macrophage subset. It has been suggested that the DC generated from monocyte/GM-CSF 
cultures reflect inflammatory type DC, as opposed to the steady-state, circulating DC that 
can be expanded by Flt-3 ligand (366). Therefore dual F4/80/ CDllc expression may be a 
characteristic of DC populations recruited during inflammation. Similar to my findings 
with thioglycollate-induced PEC, 06 KO BM DC also showed increased expression of 
CCR5 when compared with WT BM-DC. The levels of CCR2 also seemed marginally 
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higher on D6 KO DC, but this did not reach statistical significance. On the other hand, both 
WT and KO DC expressed CXCR4 at comparable levels. 
CC-chemokines are not only involved in the trafficking of DC, but have also been shown to 
affect cytokine production, costimulatory molecule expression and antigen presentation by 
DC (77, 367-369). Therefore I next compared the functional responses of WT and D6 KO 
BM-DC. Although higher yields of DC could be obtained from D6 KO cultures, the KO 
DC did not differ from WT counterparts in terms of costimulatory molecule expression, 
with comparable expression of CD40, CD80 and CD86 in WT and KO DC both at baseline 
and after LPS-stimulation. In addition, both WT and KO DC demonstrated comparable 
endocytosis of FITC-dextran and similar downregulation of CCR5 in response to LPS 
treatment. However, D6 KO DC were less efficient at inducing MLR responses than WT 
DC and, compared to their WT counterparts, LPS-treated D6 KO DC also produced greater 
levels of TNFa, CCL3, CCL4, CCL5, and VEGF. D6 KO DC produced greater levels of 
VEGF even in the absence of LPS-treatment, although no differences were found between 
levels of any other cytokine or chemokine under these conditions. The increased levels of 
CC-chemokines detected in the D6 KO cultures may have reflected lack of scavenging of 
these ligands by DC-expressed D6 (351). This in turn may have led to greater generation of 
TNFa by D6 KO DC, as it has previously been shown that CCL5 can induce TNFa 
production by murine BM-DC (367). Increased levels of CC-chemokines may also have 
accounted for the increased levels of VEGF detected in the D6 KO cultures, as G-protein 
signalling and ligands of D6 have been shown to lead to VEGF production (370-372). 
Furthermore, as VEGF has been demonstrated to decrease the stimulatory activity of BM-
derived DC, this may explain the reduced MLR generated by D6 KO DC (373-376). 
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Overall, these studies support the idea that D6 can affect the differentiation and function of 
myeloid cells. 
Adaptive Immune Responses in D6-deficient Mice 
Although others in our group had found a role for D6 in the down-regulation of cutaneous 
inflammation, the role of D6 in the generation of antigen-specific immune responses 
remained unexplored (292). Therefore, as described in Chapter 3, WT and D6 KO animals 
were immunised in the footpad with OV AlCF A to address this point. Chemokines enhance 
the development of adaptive immune responses by promoting the recruitment, activation 
and interaction of leukocyte populations (33, 158). Ligands of D6 have also been shown to 
have direct stimulatory effects on T proliferation and cytokine production, and more 
recently, Castellino and coworkers reported a role for CCL3 and CCL4 in promoting the 
generation of CD8+ T cell memory by enhancing T cell and DC clustering (173, 175-177) 
It was therefore possible that heightened levels of CC-chemokines in D6 KO mice might 
lead to amplified adaptive immune responses in these animals. 
In my initial experiments, performed on WT and D6 KO mice that had been maintained on 
a mixed 1291B6 background, in vitro antigen specific responses of D6 KO mice appeared 
reduced at weeks 1 and 6 following immunisation but increased at weeks 2 and 3, although 
only the differences seen at week 2 were statistically significant. On the other hand, DTH 
responses were comparable in WI and D6 KO mice at each time point. In a repeat set of 
experiments on this strain, I did not find any significant differences in the generation of 
antigen-specific immune responses between WT and D6 KO mice. However, in a similar 
set of experiments conducted on WI and D6 KO mice on a DBA/2 background, D6 KO 
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mice showed reduced antigen-specific proliferative responses one week after priming with 
OV A/CF A, but then demonstrated enhanced proliferative responses by two weeks 
following immunisation. Levels of OVA-specific antibodies were also lower in the sera of 
immunised D6 KO DBAl2 mice at week one, with the levels of OV A-IgG2a antibodies 
being particularly diminished. By week 2 however, similar levels of specific antibody were 
detected in the sera of WT and D6 KO DBA/2 mice. No significant differences in DTH 
responses were noted at either time-point. 
While these data were somewhat variable, the first set of experiments with the 129/B6 mice 
and those conducted on the DBA/2 background suggested there might be a reduced 
antigen-specific immune response in D6 KO mice at early times after priming with 
OV AlCF A, followed by increased responses later on. This suggests that D6 might be 
important in controlling the kinetics of the developing primary immune response after 
immunisation with antigen in adjuvant. However, by themselves, these data are 
inconclusive and repeat analysis of antigen-specific responses, preferably using a wider 
range of time-points following immunisation would be necessary to confirm the 
differences. It would also be useful to employ an adoptive transfer system, using TCR 
transgenic T cells, in order to compare antigen-specific T cell expansion directly in WT and 
D6 KO animals. Unfortunately, D6 KO mice were not available on the correct genetic 
background to allow such experiments during my project. Of note, a recently published 
study reported reduced antigen-specific priming of D6 KO T cells in D6 KO mice subjected 
to experimental autoimmune encephalitis (EAE) (377). This defective T cell behaviour was 
sufficient to confer protection from disease in these animals. These findings, along with my 
own observations, suggest that D6 may be involved in the generation of adaptive immune 
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responses and point to a more complex function for 06 than simply as a negative regulator 
of inflammation, as was originally suggested. 
As DC are key players in the initiation of adaptive immunity, aberrant DC responses in the 
absence of D6 might explain these altered Ag-specific responses observed in D6 KO mice 
(377). Reduced T cell priming could result from a lower stimulatory capacity of D6 KO 
DC, and in support of this, I found D6 KO BM DC to be less effective than WT DC in 
stimulating a MLR. Further experiments, such as examination of OV A-specific transgenic 
T cell priming by OVA-pulsed WT and 06 KO DC would enable a better assessment of 
APC capacity. On the other hand, D6 KO OC showed similar upregulation of costimulatory 
molecules and high production of inflammatory cytokines following LPS stimulation, 
which would be inconsistent with defective function. In addition, I found that the responses 
of D6 KO mice were equivalent or greater to those of WT animals at later times following 
immunisation. An alternative explanation therefore could be that altered DC trafficking in 
the absence of D6 leads to kinetic differences in adaptive immune responses. The 
magnitude of the CD4+ T cell response generated during immunisation has been reported 
to be proportional to the number of antigen-loaded DC that traffic to the node, and 
decreased DC recruitment to LN could have resulted in reduced T cell priming (129). One 
explanation for this could be that the higher expression of CCR5 by 06 KO DC retains 
these cells in inflamed tissues for a longer period of time, resulting in delayed T cell 
priming. Supporting this argument, several independent studies of D6 KO mice, have 
reported increased accumulation of CD 11 c + cells at the site of tissue inflammation (377, 
378). Although I did not examine this directly, this would also be consistent with my 
findings of higher numbers of COllc+ cells in the inflamed peritoneum of 06 KO mice, 
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which could reflect enhanced retention of DC. This could result in a delay of DC trafficking 
to lymphoid tissues draining the site of inflammation and so might account for the initial 
decrease, but subsequent increase in antigen-specific responses that appeared to occur in 
the D6 KO mice. In future, it would be interesting to address these points by using FITC 
skin painting experiments to compare the rates of WT and D6 KO DC trafficking to 
draining lymph nodes. 
Exploring the Role of D6 in Intestinal Immune Responses 
06 is expressed at high levels in the small and large intestine of both humans and mice, yet 
the function of 06 at these sites is not known. The intestinal immune system must be 
capable of responding to invasive pathogens but remain tolerant to foodstuffs and 
commensal organisms. As chemokines are involved in both tolerogenic and inflammatory 
intestinal immune responses, regulation of intestinal chemokine networks by D6 may be 
important for the maintenance of homeostasis at this site. Oral tolerance is the process by 
which the immune system becomes systemically tolerant to fed antigens, and is thought to 
be a physiologically important phenomenon for preventing aberrant responses to dietary 
proteins (379). The induction of high dose oral tolerance is reported to be dependent on 
signalling via CCR2 and eCR5 (19, 20, 297) and as D6 is expressed at high levels in 
human and murine intestine, I wished to explore if regulation of these ligands by D6 might 
playa role in maintaining intestinal homeostasis (19, 20, 270, 271, 287, 297). However, I 
found the induction of tolerance in response to a single high feed of OVA to be normal in 
D6 KO animals, with comparable suppression of all systemic antigen-specific responses in 
both WT and KO mice. These data suggest that 06 is not essential for the induction of oral 
tolerance, at least in response to a high dose of antigen. Different mechanisms are thought 
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to be responsible for the development of systemic tolerance following different feeding 
regimes. Specifically, it has been suggested that low-dose oral tolerance may involve 
induction of regulatory T-cell populations, while high dose feeding reputedly leads to 
deletion or anergy of antigen-specific T cells. My findings indicate that high dose oral 
tolerance is not impaired in the absence of 06. However, I did not explore low dose oral 
tolerance in the 06 KO mice, and these may be interesting experiments to conduct in 
future. 
The Role of D6 in Intestinal Immunity 
Another possible function for D6 at the intestinal mucosa might be to dampen inflammation 
at this site and prevent the development of immunopathological responses. Increased levels 
of CC-chemokines are found in the inflamed tissues of inflammatory bowel disease (IBO) 
patients and CC-chemokine receptor deletion or blockade has been reported to have 
beneficial effects in murine models of colitis (301, 302, 313, 317, 318). It was therefore 
predicted that, due to increased levels of CC-chemokines, D6 KO animals might display 
greater susceptibility to the induction of intestinal inflammation. As detailed in Chapter 5, 
my initial attempts to explore intestinal inflammation in 06 KO mice involved 
administration of indomethacin. This drug has previously been shown to damage the GI 
tract by preventing the synthesis of prostaglandins, which are important for maintaining 
homeostasis of the intestinal epithelium (319-324). However, I found no evidence of 
intestinal pathology in either WT or D6 KO mice following indomethacin treatment and I 
thus abandoned this model. 
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Instead, I adopted a model of colitis caused by oral administration of dextran sulphate 
sodium (DSS). DSS is thought to induce colitis by impairing barrier function, possibly due 
to the direct toxicity of DSS to intestinal epithelial cells, and the subsequent invasion of 
local bacteria, as well as direct activation of macrophages by DSS, may drive the ensuing 
inflammatory response (304, 328, 380, 381). Consistent with previous studies in this model, 
I found that administration of DSS to mice induced a colitis characterised by bloody 
diarrhoea, weight loss and colonic shortening (303). Histological analysis revealed 
extensive cellular infiltration and epithelial damage, including ulceration and crypt 
abscesses with crypt necrosis and fibrosis. Surprisingly, compared with their WT 
counterparts, D6 KO mice showed fewer clinical symptoms, reduced weight loss and had 
increased survival over the course of the colitis studies. This pattern was found 
consistently, although there was some variability in the susceptibility of individual animals 
to DSS and the time-course of development of clinical symptoms also varied between 
different colitis experiments. This variability may have been due to differences in intestinal 
bacterial colonisation in the mice used in different conditions, as the microflora play a 
major role in influencing the course of disease in all experimental colitides (382). However, 
despite this variability of colitis development, overall, D6 KO mice consistently showed 
reduced susceptibility to DSS. These findings were unexpected. given that previous work 
had proposed an anti-inflammatory role for D6. and could suggest that D6 may function in 
a different manner in intestinal tissue. 
Due to the importance of chemokines in cell recruitment, I decided to examine whether the 
different course of disease observed in the D6 KO mice might have been due to altered 
leukocyte infiltration to the inflamed colonic tissue. As expected, DSS administration led to 
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a marked increase in lamina propria leukocytes in the colon. However, similar proportions 
of C04+ and C08+ T cells, B cells, monocytes/macrophages and neutrophils were retrieved 
from the inflamed colons of WT and 06 KO mice. Interestingly though, I detected higher 
proportions of CCR2 and CCR5 positive cells in the colonic lamina propria (CLP) of 06 
KO mice compared to WT controls. Initially, I thought this might reflect higher CCR2 and 
CCR5 expression by infiltrating macrophages but, surprisingly, it was due mainly to 
increased expression ofCCR5 by 06 KO B cells. In fact, F4/80+ and COllc+ myeloid cells 
from 06 KO colons expressed lower levels of CCR2 and CCR5, perhaps suggesting that 
although similar overall proportions ofF4/80+ and COllc+ cells were detected in CLP from 
WT and KO mice, different myeloid subsets might be present in the two strains. CCR5 
expression was also found to be higher on C08+ T cells in 06 KO isolates, although this 
difference did not reach statistical significance. Subsequent experiments showed the same 
phenotype of higher CCR5 expression in LP B cells from non-colitic 06 KO mice, and as 
discussed in more detail below, I found increased CCR5 expression to be a striking and 
universal feature of 06 KO B cells. 
As CCR5 ligands have been shown to affect B cell expression of costimulatory molecules 
and antibody generation (383), it is possible that the altered B-cell compartment of the 06 
KO animals might have contributed to the ameliorated disease in 06 KO mice. In favour of 
this hypothesis. B cells have been shown to have a protective impact in a number of murine 
colitis models. Mizoguchi and coworkers showed that IL-IO producing B cells reduced 
spontaneous intestinal inflammation in TCRn KO mice (384, 385) while B cells were 
reported by Wei and coworkers to have a protective role in the Gai-deficient and 
CD4+C045RBhi ~ SCID transfer models of colitis, due to an effect on the expansion of 
265 
regulatory T cell populations (386). Homologous IgG has also been shown to have a 
suppressive effect on OSS-induced inflammation (387). Generation of intestinal antibody 
may protect mice from disease by preventing microbes permeating the epithelial barrier, by 
enhancing the clearance of apoptotic epithelial cells, or by triggering anti-inflammatory Fc 
receptors, such as FcyRIIB (388, 389). Therefore enhanced B cell function of any of these 
kinds may be responsible for the reduced colitis in 06 KO mice. However, I detected no 
differences in the levels of IL-l 0 produced by colon cultures from WT and D6 KO animals 
and my subsequent experiments in Chapter 6 did not uncover any differences in the 
function of WT and 06 KO B cells after activation. On the other hand, these latter 
functional studies used splenic B cells, which are likely to differ markedly from the B cell 
populations present in the colonic lamina propria, and I did not assess local B cell function. 
Therefore a role for mucosal B cells in protecting 06 KO animals from colitis development 
cannot be completely excluded. To address this issue, it would be important to compare 
mucosal antibody levels between WT and 06 KO mice and to examine the numbers of 
antibody-secreting plasma cells in the colonic lamina propria. Additionally, it would be 
interesting to compare functional responses of MLN and lamina propria B cells from WT 
and 06 KO mice. Of note, it has been shown that the behaviour of mucosal B cells is 
influenced by the dose of OSS used to induce colitis. Stevceva and coworkers reported that 
high doses of OSS (5%) reduced the number of colonic B cells while lower doses «2.5%) 
resulted in increased numbers of lamina propria B cells (390). Therefore one way to test the 
importance of B cells in the relative protection from colitis observed in the D6 KO animals, 
might be to compare colitis development in WT and KO mice in response to high and low 
doses of OSS. If B cells protect 06 KO animals, it would be predicted that greater 
resistance of 06 KO animals would be seen following administration of lower doses of 
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DSS, while at B-cell depleting high doses, both WT and KO animals would show similar 
susceptibility to DSS. 
Inflammatory Cytokine Production in Mucosa of Colitic D6 KO Mice 
Inflammatory bowel diseases are thought to arise partly from dysregulated cytokine 
networks, with pro-inflammatory cytokines overcoming regulatory mediators to drive 
immunopathological responses (296, 391). Accordingly, a number of inflammatory 
cytokines and chemokines have been associated with the colitic response that develops in 
response to DSS administration (301,326,391-400). Although I did not detect significant 
differences in the cell types found in the inflamed colon of WT and 06 KO mice, it was 
possible that the lack of D6 function might have led to an altered cytokine or chemokine 
response that allowed protection against DSS-induced disease. To examine this idea I 
collected supernatants from colon cultures of WT and KO mice at various times after 
administration of OSS and analysed a broad array of cytokines and chemokines by 
Luminex technology. I found no significant differences in the levels of IL-l a, IL-l~, IL-2, 
IL-6, IL-12 (p40/p70), IL-13, GM-CSF, FGF and VEGF in WT and KO culture 
supernatants. The levels of all chemokines analysed (CXCL 1, CXCL9, CCL2, CCL3, 
CCL4 and CCLS) were also comparable in WT and KO cultures. However, I detected 
significantly increased levels of IL-17, TNFa and IFNy in the colon cultures of colitic 06 
KO mice compared with WT cultures. Moreover, linear regression analysis revealed that 
higher levels of IL-17 and IFNy in colon cultures correlated significantly with increased 
resistance to OSS-induced weight loss. 
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Initially it seemed somewhat counter-intuitive that increased production of inflammatory 
cytokines might be associated with reduced colitis susceptibility, especially given the 
considerable evidence that most models of IBD are associated with exaggerated production 
of pro-inflammatory cytokines (296, 382, 401-403). However, a new concept emerging 
from the study of both human and experimental colitis is that IBO may reflect a 
dysregulated immune response, as opposed simply to an exaggerated one (404, 405). This 
reflects the delicate balancing act the intestinal immune response must perform, ensuring 
that proper pro-inflammatory mechanism to protect against infection are complemented 
with anti-inflammatory measures to prevent immunopathology. In particular, failure to 
mount an effective inflammatory response may allow persistence of bacteria that then 
trigger the development of adaptive immune responses. Defective expression of defensins 
is associated with Crohn's disease (406, 407) and it has been proposed that a diminished 
ability to generate defensins explains the association of NOD2 mutations with CD (408-
410). In addition, several studies have reported a protective role for TLR-2 and TLR-4 in 
DSS colitis (331,411, 412). TLR signalling can trigger the production of pro-inflammatory 
cytokines, which may contribute to these protective effects by recruiting inflammatory 
neutrophils and macrophages that engulf and destroy bacteria, so preventing penetration of 
the epithelial barrier (413, 414). Although I did not find any differences in neutrophil or 
macrophage recruitment to the inflamed D6 KO colon, the increased levels of inflammatory 
cytokines may have promoted the anti-bacterial functions of any cells which had arrived, 
thus mediating protection in D6 KO mice. 
An alternative possibility is that the increased inflammatory response in D6 KO animals 
may have protected the epithelial barrier directly against DSS-mediated damage. The 
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protective effect of TLR ligands in colitis has been attributed to the induction of factors that 
promote the protection and repair of mucosal epithelium. These include IL-6, TNF, KGF, 
VEGF, TGFj3 and COX-2 (331,411,412,415-419). Interestingly, one of the most striking 
differences I detected in the Luminex analyses of colon cultures, was heightened IL-17 
levels in D6 KO colons. IL-17 has attracted great interest recently, as it has become 
apparent that this cytokine, rather than IFNy, may be the main CUlprit in several models of 
autoimmune disease (420). However, IL-17 is also important for driving acute anti-
microbial responses, by inducing chemokine release and recruiting neutrophils to inflamed 
sites, and this could be important for promoting a rapid response upon breach of mucosal 
barriers (327, 421). In addition, it has been shown that IL-17 can directly protect the 
integrity of intestinal epithelium, either secondary to upregulation of claudin expression, 
which promotes tight-junction formation, or through the induction of COX-2 expression, 
which generates epithelial-protective prostaglandins (422-424). Importantly, anti-IL-17 
treatment has been demonstrated to exacerbate DSS colitis, supporting the argument that 
the increased levels of this cytokine in the KO colons may have mediated protection from 
disease (425). Unfortunately, I was unable to identify the cells responsible for producing 
IL-17 and this would be an important point to address in future experiments. Mutually 
exclusive subsets of CD4+ T cells are believed to be responsible for producing IL-17 and 
IFNy, but I found both these cytokines were increased in KO colon cultures. However, a 
recent study reported the presence of high frequencies of IFNy-secreting cells in the 
inflamed colons of colitic rodents, despite high levels of IL-17 (426), suggesting that IFNy 
and IL-I 7 responses can coexist in this condition. 
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As signalling via CC-chemokine receptors can enhance the generation of pro-inflammatory 
cytokines, greater bioavailability of CC-chemokines in the absence of D6 scavenging, 
could have explained the higher production of pro-inflammatory cytokines in D6-deficient 
animals (49, 87, 367, 427-429). However, I did not detect increased chemokine levels in 
colon cultures from D6 KO mice. This may indicate that D6 does not serve as a chemokine 
scavenger at this site, or that chemokines did not fall within a range susceptible to D6 
activity (378). On the other hand, my inability to detect increased CC-chemokines in the 
KO cultures could have been due to the increased CCR-expression by cells infiltrating the 
D6 KO colon leading to greater ligand consumption and so reducing the levels of ligand 
available for measurement. In addition, increased signalling via these chemokine receptors 
may have downregulated further chemokine generation (140, 430). IL-17 has also been 
shown to have a negative impact on CC-chemokine production, and so the elevated levels 
of this cytokine in inflamed D6 KO colons may have prevented further chemokine 
generation (423, 431, 432). Therefore to address these issues and gain a better 
understanding of the dynamic interplay of chemokine and cytokine networks, it would be 
useful to measure their levels at a greater range of time points during the course of DSS-
induced disease. 
An important caveat to these conclusions is that although my initial findings suggested a 
greater inflammatory response in D6 KO animals, a separate Luminex experiment found 
similar levels of all cytokines in WT and KO colon cultures. Interestingly, in this latter 
experiment, although D6 KO mice still showed decreased susceptibility to DSS colitis, the 
absence of a stronger inflammatory response in these KO mice was associated with lesser 
protection from colitis. This could support the idea that increased levels of pro-
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inflammatory cytokines such as IL-17 and other factors may be involved in protection of 
the D6-deficient animals. However, further work, for example antibody-mediated 
neutralisation of IL-17 in vivo, will be necessary to establish whether any of these cytokines 
are involved in protecting D6 KO mice from DSS-induced disease. 
A Role For D6 in Controlling Intestinal Turnover 
The colonic epithelial barrier is a single layer of non-dividing, terminally differentiated 
cells, which is continuously and rapidly renewed by proliferating colonic epithelial 
precursors located at the base of colonic crypts (433). The colonic epithelial precursors 
migrate upwards toward the luminal surface, differentiating into enterocytes as they 
progress. It is essential that this process in properly regulated, as impairment of epithelial 
integrity has been suggested to be a causative factor in the development of inflammatory 
bowel diseases (405). In support of this, a number of murine models of intestinal 
inflammation result from defects in epithelial barrier function (382). 
I therefore wished to assess if altered barrier function was associated with the increased 
resistance to DSS colitis observed in 06 KO animals. Measurement of steady-state 
epithelial turnover by BrdU incorporation revealed apparently decreased rates of 
proliferating cells in the normal colon of D6 KO mice compared with their WT 
counterparts. Consistent with previous reports, few BrdU+ cells were detected in the 
colonic crypts of WT and D6 KO mice immediately after DSS administration, presumably 
reflecting toxicity, while removal of DSS from the drinking water led to markedly 
increased rates of epithelial cell proliferation (328-330). It is known that higher baseline 
rates of epithelial cell proliferation increase susceptibility to intestinal damage (434). In 
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addition, a number of studies have shown that animals with intrinsically increased rates of 
baseline epithelial turnover have increased susceptibility to OSS colitis (331, 435, 436). 
Thus the altered epithelial turnover observed in the 06 KO mice could help explain the 
reduced colitis development in these animals. 
Time constraints meant that I was unable to address the mechanism behind the altered 
epithelial turnover observed in the KO mice. However, colonic epithelial cells 
constitutively express an array of chemokine receptors, including those for ligands of D6 
and there is evidence that 06 itself is expressed by intestinal epithelium (287, 437). As 
ligands of 06 are expressed constitutively in the murine colon under normal housing 
conditions, it is possible that D6 is involved in epithelial homeostasis (125, 438). 
Chemokine signalling could influence epithelial turnover in a number of ways, for instance, 
by driving the expression of growth and survival factors involved in barrier maintenance 
(93). In addition, D6 ligands could help drive movement of epithelial precursors upwards 
from colonic crypts. Upregulation of integrins, another known function of chemokines, can 
inhibit enterocyte migration, offering a further possible mechanism for chemokine-control 
of the epithelial escalator (439). Chemokines also activate molecules, such as the small 
GTPases Rae, Rho, and Cdc42, which are involved in actin cytoskeletal reorganization and 
can regulate tight junction formation (440), and CC-chemokines may promote 
differentiation of colonic epithelial cells (441). Interestingly. it has been reported that a 
eCL3 analogue reduces the number of mitotic cells in intestinal crypts and can protect mice 
from radiation-induced intestinal damage (442, 443). 
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In summary, my studies of intestinal inflammation revealed that the absence of D6 offers 
some protection against the disease induced by oral DSS, and suggest that this may be due 
to differences in epithelial homeostasis and/or an altered local inflammatory response. As 
development of DSS colitis is highly strain dependent it will be important to characterise 
the development of colitis in D6 KO mice on other genetic backgrounds (444, 445). In 
addition, it will be important to substantiate my findings by exploring other models of 
intestinal inflammation in D6 KO animals. For example, induction of TNBS-colitis or 
transfer of CD25+ -depleted T cell populations into RAG KO mice would enable exploration 
of the importance of D6 in T-cell mediated colitis (382). Moreover, as pro-inflammatory 
cytokines such as IL-17 have been reported to exacerbate disease in such models, they 
could allow direct determination of the link between IL-I7 and protection from colitis (446, 
447). 
Altered Chemokine Receptor Expression by D6 KO Leukocytes 
The altered CCR5 expression by intestinal LP cells of D6 KO mice was an unexpected 
finding that caused me to undertake a more extensive analysis of chemokine receptor 
expression by leukocytes in these mice (Chapter 6). These studies revealed increased CCR5 
expression by T cell and B cell populations isolated from the PLN, MLN and spleen of D6 
KO animals under resting conditions. The most dramatic effects were evident with B cells: 
in all lymphoid tissues analysed, WT B cells showed fairly low levels of CCR5 expression, 
whereas B cells from D6 KO animals were almost universally CCR5-positive. Expression 
of CCR2, CXCR4 and CXCR5 did not appear to be altered between WT and D6 KO 
lymphocytes. However, while CCR9 expression was comparable between WT and KO 
spleen and PLN cells, slightly increased levels of CCR9 were detected on D6 KO 
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leukocytes isolated from the MLN. Further analysis revealed that the aberrant expression of 
CCRS and CCR9 in D6 KO B cells was already apparent in bone marrow B cell 
populations, indicating that absence of 06 was affecting chemokine receptor expression 
during B lymphopoiesis. 
The expression of a chemokine receptor does not always predict responsiveness to ligands 
and it has been demonstrated that chemokine receptors can be uncoupled from their 
signalling components (266, 448, 449). However, I found that D6 KO B cells demonstrated 
greater chemotactic responses to CCL4 in vitro, suggesting that CCRS was functional on 
these cells. The specificity ofCCL4 for CCRS ruled out the possibility that other functional 
CC-chemokine receptors accounted for the increased chemotactic response of the D6 KO B 
cells (11). On the other hand, one caveat of these experiments could be that expression of 
06 by WT B cells may have competed with CCRS for binding to CCL4, diminishing their 
chemotaxis responses to this chemokine. 
To examine ifWT and D6 KO B cells differed functionally, I compared their responses to a 
number of mitogenic stimuli. However, I did not detect any differences between WT and 
D6 KO B in terms of their ability to proliferate or upregulate costimulatory molecules 
following culture with LPS, DSS or anti-C040+anti-lgM. Analysis of chemokine levels in 
these cultures also revealed no differences, except lower levels of CCL3 and CCLS in 06 
KO LPS supernatants compared with WT LPS supernatants. It is possible that this reflected 
higher uptake of these chemokines by KO B cells as a consequence of their increased 
CCRS expression. Levels of total serum IgM antibodies were comparable between WT and 
KO mice, and although D6 KO mice appeared to have slightly reduced levels of total serum 
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IgO, this difference was not statistically significant. Taken together, my data suggested that 
WT and D6 KO B cells were functionally similar, at least in terms of the parameters I 
measured. On the other hand, I only measured B cell activation in vitro, and it could be 
argued that aberrant chemokine receptor expression would be more likely to affect the 
development of B cell responses in vivo, for example, by altering the trafficking and 
positioning of these cells during development of immune responses. Indeed, some of the 
differences in specific antibody generation that I observed in 06 WT and KO following 
footpad immunisation may have been attributable to dysregulated B cell localisation. It 
would be interesting to examine if the positioning ofD6 KO B cells, for example within the 
follicles of the lymph node, is affected both during resting state and following 
immunisation. 
The increased expression of CCR5 by 06 KO B cells pointed to a potentially novel 
function of D6 in controlling levels of chemokine receptor expression in an autocrine 
manner. Although I did not explore this idea in a mechanistic way, it is possible that 06 
and CCR5 compete for anchorage sites at the cell surface, and the absence of 06 may lead 
to more space for CCR5. However, the fact that the levels of CCR5 mRNA were also 
higher in D6 KO leukocytes, argued against this idea, and it is therefore possible that D6 
and CCR5 are in transcriptional competition. In favour of this hypothesis, others in our 
laboratory have found that WT B cells express higher levels of 06 mRNA than other 
leukocyte populations (Dr Clive McKimmie, unpublished data). Therefore the absence of 
D6 may lead to inherently greater levels of transcription of CCR5 by this population. 
Recent findings show that LPS decreases D6 mRNA expression by B cells (205), whereas I 
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found that LPS had the opposite effect on CCR5 protein expression, supporting the idea 
that CCR5 and D6 expression may be mutually inhibitory. 
Another possible explanation is that lack of D6 decoy function results in dysregulatcd 
bioavailability of CC-chemokines, leading to changes in cellular chemokine receptor 
expression. Therefore, D6 may playa role in maintaining levels of CC-chemokines, and in 
its absence, decreased levels of CCR5 ligands would lead to upregulation of CCR5. It 
would be interesting to explore this idea by examining the effects of increasing or 
decreasing levels of its ligands on CCR5 expression. On the other hand, this would not 
seem to explain why the B cell compartment was most affected by the altered eCR5 
expression. It will be important in future to define whether defects in CCR5 expression are 
due to cell autonomous defects in D6 expression, or due to the lack of regulation of 
chemokines in the external milieu by other D6-positive cells. 
It is important to note that I did not determine any definitive link between dysregulated 
CCR5 expression and the other abnormalities I observed in the D6 KO mice. However, 
aberrant CCR5 expression has been associated with disease states in both mouse and man 
(450-454). Therefore it will be interesting to explore if altered CCR5 expression by D6 KO 
is responsible for some of the phenotypical changes that occur in these animals (291, 292, 
377, 378). In addition, targeting of this receptor represents a major pharmacological goal, 
both for treatment of immune pathologies and prevention of HIV infection. Deciphering the 
mechanisms regulating CCR5 expression will be important for effective drug development, 
and further study of how D6 affects B cell expression of CCR5 may add to our 
understanding of this subject. 
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CONCLUDING REMARKS: 
In summary, the studies in this thesis have revealed a number of novel phenotypical 
changes in D6-deficient animals. Importantly, my studies suggest previously unappreciated 
roles for D6 and its CC-chemokines in influencing monocyte differentiation and colonic 
epithelial turnover. Whether D6 shapes both of these biological processes through 
regulation of CCR5 expression remains to be determined. My results and the recently 
reported work of others also suggests that D6 may have a role over and above that of a 
simple chemokine scavenger (377, 378). Due to the extreme promiscuity of 06, and the 
hugely diverse roles of its many ligands, it is perhaps not surprising that both pro- and anti-
inflammatory functions are emerging for this receptor. The specific consequences of 06-
deficiency are almost certain to differ from tissue to tissue, depending on the particular 
chemokine networks present. 
The data from the thioglycollate peritonitis experiments suggested that the 06 KO mice 
were recruiting different myeloid cell populations to the inflamed peritoneum, or that the 
differentiation of recruited monocytes was skewed, possibly towards a DC-like phenotype. 
Despite evidence for the existence of a common macrophage/ dendritic cell precursor, the 
mechanisms that control the particular developmental pathway undertaken by tissue-
recruited monocytes remain unknown. Does a key role therefore exist for CC-chemokines 
in monocyte differentiation as well as in their recruitment? 
My studies represent the first investigation of D6 function in the context of intestinal 
biology, and suggest significant functions for D6 in both resting and inflamed colon. The 
role for D6 in promoting susceptibility to DSS colitis was an unexpected finding, giving its 
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proposed anti-inflammatory nature in other circumstances. It was also intriguing that this 
might be related to a protective effect of inflammatory mediators, such as IL-17, in 
maintaining epithelial barrier integrity. It will now be important to determine the link 
between CC-chemokines and IL-17 generation. In addition, the altered epithelial 
proliferation noted in the uninflamed D6 KO colon points to as yet unappreciated roles tor 
D6 and its ligands in epithelial homeostasis. 
Aberrations in monocyte differentiation, increased IL-17 generation or altered epithelial 
proliferation occurring in 06-deficient mice could account for many of the other 
phenotypes that are beginning to emerge from the study of these animals. However, many 
key questions remain unanswered. The exact locations and the regulation of 06 expression 
under different conditions remain unknown and the generation of a reliable antibody, as 
well as study of recently generated lacZ-06-reporter mice will hopefully help address these 
Issues. 
The challenge now is to define the exact mechanisms of 06 function in vivo. Such 
investigations will hopefully set a precedent for future study of CCX-CKR and any other 
atypical receptors that may emerge. A better appreciation of the true physiological role of 
these molecules will assist our understanding of the chemokine system and, hopefully, 
provide a framework for effectively targeting chemokine networks for therapeutic 
purposes. 
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